id	sid	tid	token	lemma	pos
njb-93	1	1	nepal	nepal	ADJ
njb-93	1	2	journal	journal	NOUN
njb-93	1	3	of	of	ADP
njb-93	1	4	biotechnology	biotechnology	NOUN
njb-93	1	5	.	.	PUNCT
njb-93	2	1	d	d	X
njb-93	2	2	e	e	PROPN
njb-93	2	3	c	c	PROPN
njb-93	2	4	.	.	PUNCT
njb-93	3	1	2	2	NUM
njb-93	3	2	0	0	NUM
njb-93	3	3	1	1	NUM
njb-93	3	4	7	7	NUM
njb-93	3	5	vol	vol	NOUN
njb-93	3	6	.	.	PROPN
njb-93	4	1	5	5	NUM
njb-93	4	2	,	,	PUNCT
njb-93	4	3	no	no	NOUN
njb-93	4	4	.	.	NOUN
njb-93	4	5	1	1	NUM
njb-93	4	6	:	:	SYM
njb-93	4	7	32	32	NUM
njb-93	4	8	-	-	SYM
njb-93	4	9	38	38	NUM
njb-93	4	10	issn	issn	PROPN
njb-93	4	11	2091	2091	NUM
njb-93	4	12	-	-	SYM
njb-93	4	13	1130(print)/issn	1130(print)/issn	NUM
njb-93	4	14	2467	2467	NUM
njb-93	4	15	-	-	SYM
njb-93	4	16	9319	9319	NUM
njb-93	4	17	(	(	PUNCT
njb-93	4	18	online	online	ADJ
njb-93	4	19	)	)	PUNCT
njb-93	4	20	original	original	ADJ
njb-93	4	21	research	research	NOUN
njb-93	4	22	article	article	NOUN
njb-93	4	23	©	©	PROPN
njb-93	4	24	njb	njb	PROPN
njb-93	4	25	,	,	PUNCT
njb-93	4	26	biotechnology	biotechnology	NOUN
njb-93	4	27	society	society	NOUN
njb-93	4	28	of	of	ADP
njb-93	4	29	nepal	nepal	ADJ
njb-93	4	30	32	32	NUM
njb-93	4	31	nepjol.info/index.php/njb	nepjol.info/index.php/njb	ADJ
njb-93	4	32	prevalence	prevalence	NOUN
njb-93	4	33	of	of	ADP
njb-93	4	34	extended	extend	VERB
njb-93	4	35	spectrum	spectrum	NOUN
njb-93	4	36	beta	beta	NOUN
njb-93	4	37	-	-	PUNCT
njb-93	4	38	lactamase	lactamase	NOUN
njb-93	4	39	producing	produce	VERB
njb-93	4	40	escherichia	escherichia	NOUN
njb-93	4	41	coli	coli	NOUN
njb-93	4	42	and	and	CCONJ
njb-93	4	43	klebsiella	klebsiella	PROPN
njb-93	4	44	species	species	PROPN
njb-93	4	45	from	from	ADP
njb-93	4	46	urinary	urinary	ADJ
njb-93	4	47	specimens	specimen	NOUN
njb-93	4	48	of	of	ADP
njb-93	4	49	children	child	NOUN
njb-93	4	50	attending	attend	VERB
njb-93	4	51	friendship	friendship	NOUN
njb-93	4	52	international	international	ADJ
njb-93	4	53	children	child	NOUN
njb-93	4	54	’s	’s	PART
njb-93	4	55	hospital	hospital	NOUN
njb-93	4	56	ujjwal	ujjwal	NOUN
njb-93	5	1	rimal1	rimal1	PROPN
njb-93	5	2	,	,	PUNCT
njb-93	5	3	shovana	shovana	PROPN
njb-93	5	4	thapa2	thapa2	PROPN
njb-93	5	5	,	,	PUNCT
njb-93	5	6	roshani	roshani	PROPN
njb-93	5	7	maharjan1	maharjan1	PROPN
njb-93	5	8	*	*	PROPN
njb-93	5	9	1department	1department	NUM
njb-93	5	10	of	of	ADP
njb-93	5	11	microbiology	microbiology	NOUN
njb-93	5	12	,	,	PUNCT
njb-93	5	13	trichandra	trichandra	VERB
njb-93	5	14	multiple	multiple	ADJ
njb-93	5	15	college	college	NOUN
njb-93	5	16	,	,	PUNCT
njb-93	5	17	ghantaghar	ghantaghar	ADJ
njb-93	5	18	,	,	PUNCT
njb-93	5	19	kathmandu	kathmandu	NOUN
njb-93	5	20	,	,	PUNCT
njb-93	5	21	nepal	nepal	ADJ
njb-93	5	22	.	.	PUNCT
njb-93	6	1	2department	2department	NUM
njb-93	6	2	of	of	ADP
njb-93	6	3	microbiology	microbiology	NOUN
njb-93	6	4	,	,	PUNCT
njb-93	6	5	international	international	ADJ
njb-93	6	6	friendship	friendship	NOUN
njb-93	6	7	children	child	NOUN
njb-93	6	8	’s	’s	PART
njb-93	6	9	hospital	hospital	NOUN
njb-93	6	10	,	,	PUNCT
njb-93	6	11	maharajgunj	maharajgunj	PROPN
njb-93	6	12	,	,	PUNCT
njb-93	6	13	kathmandu	kathmandu	NOUN
njb-93	6	14	,	,	PUNCT
njb-93	6	15	nepal	nepal	ADJ
njb-93	6	16	abstract	abstract	ADJ
njb-93	6	17	extended	extend	VERB
njb-93	6	18	-	-	PUNCT
njb-93	6	19	spectrum	spectrum	NOUN
njb-93	6	20	β	β	NOUN
njb-93	6	21	-	-	PUNCT
njb-93	6	22	lactamase	lactamase	NOUN
njb-93	6	23	producing	produce	VERB
njb-93	6	24	e.	e.	PROPN
njb-93	6	25	coli	coli	NOUN
njb-93	6	26	and	and	CCONJ
njb-93	6	27	k.	k.	NOUN
njb-93	6	28	pneumoniae	pneumoniae	NOUN
njb-93	6	29	is	be	AUX
njb-93	6	30	a	a	DET
njb-93	6	31	serious	serious	ADJ
njb-93	6	32	threat	threat	NOUN
njb-93	6	33	to	to	ADP
njb-93	6	34	the	the	DET
njb-93	6	35	patients	patient	NOUN
njb-93	6	36	.	.	PUNCT
njb-93	7	1	these	these	DET
njb-93	7	2	organisms	organism	NOUN
njb-93	7	3	are	be	AUX
njb-93	7	4	major	major	ADJ
njb-93	7	5	extended	extend	VERB
njb-93	7	6	spectrum	spectrum	NOUN
njb-93	7	7	beta	beta	NOUN
njb-93	7	8	lactamase	lactamase	NOUN
njb-93	7	9	(	(	PUNCT
njb-93	7	10	esbl	esbl	PROPN
njb-93	7	11	)	)	PUNCT
njb-93	7	12	producers	producer	NOUN
njb-93	7	13	.	.	PUNCT
njb-93	8	1	the	the	DET
njb-93	8	2	objective	objective	NOUN
njb-93	8	3	of	of	ADP
njb-93	8	4	this	this	DET
njb-93	8	5	study	study	NOUN
njb-93	8	6	was	be	AUX
njb-93	8	7	to	to	PART
njb-93	8	8	determine	determine	VERB
njb-93	8	9	the	the	DET
njb-93	8	10	prevalence	prevalence	NOUN
njb-93	8	11	of	of	ADP
njb-93	8	12	extended	extend	VERB
njb-93	8	13	spectrum	spectrum	NOUN
njb-93	8	14	βlactamase	βlactamase	NOUN
njb-93	8	15	producing	produce	VERB
njb-93	8	16	strains	strain	NOUN
njb-93	8	17	of	of	ADP
njb-93	8	18	escherichia	escherichia	NOUN
njb-93	8	19	coli	coli	NOUN
njb-93	8	20	and	and	CCONJ
njb-93	8	21	klebsiella	klebsiella	PROPN
njb-93	8	22	spp	spp	PROPN
njb-93	8	23	isolates	isolate	VERB
njb-93	8	24	from	from	ADP
njb-93	8	25	the	the	DET
njb-93	8	26	urine	urine	NOUN
njb-93	8	27	sample	sample	NOUN
njb-93	8	28	of	of	ADP
njb-93	8	29	children	child	NOUN
njb-93	8	30	visiting	visit	VERB
njb-93	8	31	international	international	ADJ
njb-93	8	32	friendship	friendship	NOUN
njb-93	8	33	children	child	NOUN
njb-93	8	34	hospital	hospital	NOUN
njb-93	8	35	.	.	PUNCT
njb-93	9	1	during	during	ADP
njb-93	9	2	the	the	DET
njb-93	9	3	seven	seven	NUM
njb-93	9	4	months	month	NOUN
njb-93	9	5	,	,	PUNCT
njb-93	9	6	between	between	ADP
njb-93	9	7	june	june	PROPN
njb-93	9	8	2016	2016	NUM
njb-93	9	9	to	to	ADP
njb-93	9	10	december	december	PROPN
njb-93	9	11	2016	2016	NUM
njb-93	9	12	,	,	PUNCT
njb-93	9	13	1018	1018	NUM
njb-93	9	14	midstream	midstream	NOUN
njb-93	9	15	urine	urine	NOUN
njb-93	9	16	samples(msu	samples(msu	NOUN
njb-93	9	17	)	)	PUNCT
njb-93	9	18	were	be	AUX
njb-93	9	19	collected	collect	VERB
njb-93	9	20	from	from	ADP
njb-93	9	21	patients	patient	NOUN
njb-93	9	22	suspected	suspect	VERB
njb-93	9	23	of	of	ADP
njb-93	9	24	having	have	VERB
njb-93	9	25	uti	uti	PROPN
njb-93	9	26	.	.	PUNCT
njb-93	10	1	the	the	DET
njb-93	10	2	samples	sample	NOUN
njb-93	10	3	were	be	AUX
njb-93	10	4	investigated	investigate	VERB
njb-93	10	5	by	by	ADP
njb-93	10	6	conventional	conventional	ADJ
njb-93	10	7	semi	semi	ADJ
njb-93	10	8	-	-	ADJ
njb-93	10	9	quantitative	quantitative	ADJ
njb-93	10	10	culture	culture	NOUN
njb-93	10	11	technique	technique	NOUN
njb-93	10	12	and	and	CCONJ
njb-93	10	13	identification	identification	NOUN
njb-93	10	14	of	of	ADP
njb-93	10	15	e.	e.	PROPN
njb-93	10	16	coli	coli	PROPN
njb-93	10	17	and	and	CCONJ
njb-93	10	18	klebsiella	klebsiella	PROPN
njb-93	10	19	spp	spp	PROPN
njb-93	10	20	.	.	PROPN
njb-93	10	21	was	be	AUX
njb-93	10	22	done	do	VERB
njb-93	10	23	by	by	ADP
njb-93	10	24	microscopy	microscopy	NOUN
njb-93	10	25	and	and	CCONJ
njb-93	10	26	biochemical	biochemical	ADJ
njb-93	10	27	test	test	NOUN
njb-93	10	28	.	.	PUNCT
njb-93	11	1	antibiotic	antibiotic	ADJ
njb-93	11	2	susceptibility	susceptibility	NOUN
njb-93	11	3	test	test	NOUN
njb-93	11	4	of	of	ADP
njb-93	11	5	isolates	isolate	NOUN
njb-93	11	6	was	be	AUX
njb-93	11	7	performed	perform	VERB
njb-93	11	8	by	by	ADP
njb-93	11	9	modified	modify	VERB
njb-93	11	10	kirby	kirby	PROPN
njb-93	11	11	bauer	bauer	PROPN
njb-93	11	12	disc	disc	NOUN
njb-93	11	13	diffusion	diffusion	NOUN
njb-93	11	14	test	test	NOUN
njb-93	11	15	.	.	PUNCT
njb-93	12	1	esbl	esbl	PROPN
njb-93	12	2	screening	screening	NOUN
njb-93	12	3	test	test	NOUN
njb-93	12	4	was	be	AUX
njb-93	12	5	done	do	VERB
njb-93	12	6	by	by	ADP
njb-93	12	7	using	use	VERB
njb-93	12	8	3rd	3rd	ADJ
njb-93	12	9	generation	generation	NOUN
njb-93	12	10	cephalosporin	cephalosporin	NOUN
njb-93	12	11	and	and	CCONJ
njb-93	12	12	confirmation	confirmation	NOUN
njb-93	12	13	done	do	VERB
njb-93	12	14	by	by	ADP
njb-93	12	15	combination	combination	NOUN
njb-93	12	16	disc	disc	NOUN
njb-93	12	17	diffusion	diffusion	NOUN
njb-93	12	18	method	method	NOUN
njb-93	12	19	.	.	PUNCT
njb-93	13	1	out	out	ADP
njb-93	13	2	of	of	ADP
njb-93	13	3	total	total	ADJ
njb-93	13	4	1018	1018	NUM
njb-93	13	5	msu	msu	NOUN
njb-93	13	6	samples	sample	NOUN
njb-93	13	7	investigated	investigate	VERB
njb-93	13	8	,	,	PUNCT
njb-93	13	9	200(19.64	200(19.64	NUM
njb-93	13	10	%	%	NOUN
njb-93	13	11	)	)	PUNCT
njb-93	13	12	isolates	isolate	NOUN
njb-93	13	13	of	of	ADP
njb-93	13	14	e.	e.	PROPN
njb-93	13	15	coli	coli	PROPN
njb-93	13	16	and	and	CCONJ
njb-93	13	17	28(2.7	28(2.7	NUM
njb-93	13	18	%	%	NOUN
njb-93	13	19	)	)	PUNCT
njb-93	13	20	isolates	isolate	NOUN
njb-93	13	21	of	of	ADP
njb-93	13	22	klebsiella	klebsiella	PROPN
njb-93	13	23	spp	spp	PROPN
njb-93	13	24	.	.	PUNCT
njb-93	14	1	making	make	VERB
njb-93	14	2	a	a	DET
njb-93	14	3	total	total	NOUN
njb-93	14	4	of	of	ADP
njb-93	14	5	228(22.39	228(22.39	NUM
njb-93	14	6	%	%	NOUN
njb-93	14	7	)	)	PUNCT
njb-93	14	8	were	be	AUX
njb-93	14	9	found	find	VERB
njb-93	14	10	to	to	PART
njb-93	14	11	cause	cause	VERB
njb-93	14	12	significant	significant	ADJ
njb-93	14	13	bacteriuria	bacteriuria	NOUN
njb-93	14	14	.	.	PUNCT
njb-93	15	1	76(33.33	76(33.33	NUM
njb-93	15	2	%	%	NOUN
njb-93	15	3	)	)	PUNCT
njb-93	15	4	isolates	isolate	NOUN
njb-93	15	5	,	,	PUNCT
njb-93	15	6	from	from	ADP
njb-93	15	7	those	those	PRON
njb-93	15	8	causing	cause	VERB
njb-93	15	9	significant	significant	ADJ
njb-93	15	10	bacteriuria	bacteriuria	NOUN
njb-93	15	11	,	,	PUNCT
njb-93	15	12	were	be	AUX
njb-93	15	13	multi	multi	ADJ
njb-93	15	14	-	-	ADJ
njb-93	15	15	drug	drug	ADJ
njb-93	15	16	resistant	resistant	ADJ
njb-93	15	17	organisms	organism	NOUN
njb-93	15	18	.	.	PUNCT
njb-93	16	1	out	out	ADP
njb-93	16	2	of	of	ADP
njb-93	16	3	228	228	NUM
njb-93	16	4	isolates	isolate	NOUN
njb-93	16	5	,	,	PUNCT
njb-93	16	6	54(23.68	54(23.68	NUM
njb-93	16	7	%	%	NOUN
njb-93	16	8	)	)	PUNCT
njb-93	16	9	were	be	AUX
njb-93	16	10	esbl	esbl	NOUN
njb-93	16	11	producers	producer	NOUN
njb-93	16	12	,	,	PUNCT
njb-93	16	13	that	that	PRON
njb-93	16	14	includes	include	VERB
njb-93	16	15	51(25.5	51(25.5	NUM
njb-93	16	16	%	%	NOUN
njb-93	16	17	)	)	PUNCT
njb-93	16	18	escherichia	escherichia	NOUN
njb-93	16	19	coli	coli	NOUN
njb-93	16	20	and	and	CCONJ
njb-93	16	21	3(12.5	3(12.5	NUM
njb-93	16	22	%	%	NOUN
njb-93	16	23	)	)	PUNCT
njb-93	16	24	klebsiella	klebsiella	PROPN
njb-93	16	25	pneumoniae	pneumoniae	NOUN
njb-93	16	26	.	.	PUNCT
njb-93	17	1	esbl	esbl	PROPN
njb-93	17	2	producers	producer	NOUN
njb-93	17	3	were	be	AUX
njb-93	17	4	more	more	ADV
njb-93	17	5	common	common	ADJ
njb-93	17	6	in	in	ADP
njb-93	17	7	in	in	ADP
njb-93	17	8	-	-	PUNCT
njb-93	17	9	patient	patient	ADJ
njb-93	17	10	(	(	PUNCT
njb-93	17	11	36.17	36.17	NUM
njb-93	17	12	%	%	NOUN
njb-93	17	13	)	)	PUNCT
njb-93	17	14	than	than	ADP
njb-93	17	15	out	out	ADV
njb-93	17	16	-	-	PUNCT
njb-93	17	17	patient	patient	ADJ
njb-93	17	18	(	(	PUNCT
njb-93	17	19	20.44	20.44	NUM
njb-93	17	20	%	%	NOUN
njb-93	17	21	)	)	PUNCT
njb-93	17	22	.	.	PUNCT
njb-93	18	1	most	most	ADJ
njb-93	18	2	of	of	ADP
njb-93	18	3	the	the	DET
njb-93	18	4	esbl	esbl	PROPN
njb-93	18	5	producers	producer	NOUN
njb-93	18	6	were	be	AUX
njb-93	18	7	resistance	resistance	NOUN
njb-93	18	8	to	to	ADP
njb-93	18	9	amoxicillin	amoxicillin	PROPN
njb-93	18	10	,	,	PUNCT
njb-93	18	11	followed	follow	VERB
njb-93	18	12	by	by	ADP
njb-93	18	13	cotrimoxazole	cotrimoxazole	PROPN
njb-93	18	14	and	and	CCONJ
njb-93	18	15	ciprofloxacin	ciprofloxacin	VERB
njb-93	18	16	respectively	respectively	ADV
njb-93	18	17	.	.	PUNCT
njb-93	19	1	they	they	PRON
njb-93	19	2	were	be	AUX
njb-93	19	3	highly	highly	ADV
njb-93	19	4	sensitive	sensitive	ADJ
njb-93	19	5	to	to	ADP
njb-93	19	6	imipenem	imipenem	PROPN
njb-93	19	7	,	,	PUNCT
njb-93	19	8	tigecycline	tigecycline	NOUN
njb-93	19	9	,	,	PUNCT
njb-93	19	10	amikacin	amikacin	PROPN
njb-93	19	11	,	,	PUNCT
njb-93	19	12	piperacillin	piperacillin	NOUN
njb-93	19	13	-	-	PUNCT
njb-93	19	14	tazobactam	tazobactam	NOUN
njb-93	19	15	,	,	PUNCT
njb-93	19	16	and	and	CCONJ
njb-93	19	17	nitrofurantoin	nitrofurantoin	NOUN
njb-93	19	18	.	.	PUNCT
njb-93	20	1	high	high	ADJ
njb-93	20	2	prevalence	prevalence	NOUN
njb-93	20	3	of	of	ADP
njb-93	20	4	esbl	esbl	PROPN
njb-93	20	5	producing	produce	VERB
njb-93	20	6	e.	e.	PROPN
njb-93	20	7	coli	coli	PROPN
njb-93	20	8	and	and	CCONJ
njb-93	20	9	klebsiella	klebsiella	PROPN
njb-93	20	10	pneumoniae	pneumoniae	NOUN
njb-93	20	11	was	be	AUX
njb-93	20	12	found	find	VERB
njb-93	20	13	among	among	ADP
njb-93	20	14	children	child	NOUN
njb-93	20	15	.	.	PUNCT
njb-93	21	1	regular	regular	ADJ
njb-93	21	2	and	and	CCONJ
njb-93	21	3	routine	routine	ADJ
njb-93	21	4	monitoring	monitoring	NOUN
njb-93	21	5	of	of	ADP
njb-93	21	6	esbl	esbl	NOUN
njb-93	21	7	producing	produce	VERB
njb-93	21	8	isolates	isolate	NOUN
njb-93	21	9	is	be	AUX
njb-93	21	10	essential	essential	ADJ
njb-93	21	11	.	.	PUNCT
njb-93	22	1	key	key	ADJ
njb-93	22	2	words	word	NOUN
njb-93	22	3	:	:	PUNCT
njb-93	22	4	urinary	urinary	ADJ
njb-93	22	5	tract	tract	NOUN
njb-93	22	6	infection(uti	infection(uti	NOUN
njb-93	22	7	)	)	PUNCT
njb-93	22	8	,	,	PUNCT
njb-93	22	9	extended	extended	ADJ
njb-93	22	10	spectrum	spectrum	NOUN
njb-93	22	11	beta	beta	ADP
njb-93	22	12	lactamase(esbl	lactamase(esbl	NOUN
njb-93	22	13	)	)	PUNCT
njb-93	22	14	,	,	PUNCT
njb-93	22	15	e.	e.	PROPN
njb-93	22	16	coli	coli	PROPN
njb-93	22	17	,	,	PUNCT
njb-93	22	18	klebsiella	klebsiella	PROPN
njb-93	22	19	*	*	PUNCT
njb-93	22	20	corresponding	correspond	VERB
njb-93	22	21	author	author	NOUN
njb-93	22	22	e	e	NOUN
njb-93	22	23	mail	mail	NOUN
njb-93	22	24	:	:	PUNCT
njb-93	22	25	roshani_mh@hotmail.com	roshani_mh@hotmail.com	PROPN
njb-93	22	26	introduction	introduction	PROPN
njb-93	22	27	urinary	urinary	PROPN
njb-93	22	28	tract	tract	NOUN
njb-93	22	29	infection	infection	NOUN
njb-93	22	30	(	(	PUNCT
njb-93	22	31	uti	uti	PROPN
njb-93	22	32	)	)	PUNCT
njb-93	22	33	is	be	AUX
njb-93	22	34	a	a	DET
njb-93	22	35	term	term	NOUN
njb-93	22	36	applied	apply	VERB
njb-93	22	37	to	to	ADP
njb-93	22	38	a	a	DET
njb-93	22	39	variety	variety	NOUN
njb-93	22	40	of	of	ADP
njb-93	22	41	clinical	clinical	ADJ
njb-93	22	42	conditions	condition	NOUN
njb-93	22	43	ranging	range	VERB
njb-93	22	44	in	in	ADP
njb-93	22	45	severity	severity	NOUN
njb-93	22	46	from	from	ADP
njb-93	22	47	asymptomatic	asymptomatic	NOUN
njb-93	22	48	which	which	PRON
njb-93	22	49	is	be	AUX
njb-93	22	50	carrier	carrier	NOUN
njb-93	22	51	status	status	NOUN
njb-93	22	52	in	in	ADP
njb-93	22	53	the	the	DET
njb-93	22	54	urine	urine	NOUN
njb-93	22	55	to	to	ADP
njb-93	22	56	symptomatic	symptomatic	ADJ
njb-93	22	57	acute	acute	ADJ
njb-93	22	58	infection	infection	NOUN
njb-93	22	59	of	of	ADP
njb-93	22	60	the	the	DET
njb-93	22	61	kidney	kidney	NOUN
njb-93	22	62	with	with	ADP
njb-93	22	63	resultant	resultant	NOUN
njb-93	22	64	sepsis	sepsis	NOUN
njb-93	22	65	[	[	X
njb-93	22	66	1	1	NUM
njb-93	22	67	]	]	PUNCT
njb-93	22	68	.	.	PUNCT
njb-93	23	1	the	the	DET
njb-93	23	2	clinical	clinical	ADJ
njb-93	23	3	symptoms	symptom	NOUN
njb-93	23	4	of	of	ADP
njb-93	23	5	uti	uti	PROPN
njb-93	23	6	usually	usually	ADV
njb-93	23	7	include	include	VERB
njb-93	23	8	frequency	frequency	NOUN
njb-93	23	9	,	,	PUNCT
njb-93	23	10	dysuria	dysuria	PROPN
njb-93	23	11	,	,	PUNCT
njb-93	23	12	pyuria	pyuria	PROPN
njb-93	23	13	,	,	PUNCT
njb-93	23	14	suprapubic	suprapubic	ADJ
njb-93	23	15	tenderness	tenderness	NOUN
njb-93	23	16	,	,	PUNCT
njb-93	23	17	back	back	ADJ
njb-93	23	18	pain	pain	NOUN
njb-93	23	19	,	,	PUNCT
njb-93	23	20	fever	fever	NOUN
njb-93	23	21	and	and	CCONJ
njb-93	23	22	urgency	urgency	NOUN
njb-93	23	23	[	[	NOUN
njb-93	23	24	2	2	NUM
njb-93	23	25	]	]	PUNCT
njb-93	23	26	.	.	PUNCT
njb-93	24	1	the	the	DET
njb-93	24	2	most	most	ADV
njb-93	24	3	common	common	ADJ
njb-93	24	4	uropathogenic	uropathogenic	ADJ
njb-93	24	5	gram	gram	NOUN
njb-93	24	6	negative	negative	ADJ
njb-93	24	7	bacteria	bacteria	NOUN
njb-93	24	8	are	be	AUX
njb-93	24	9	escherichia	escherichia	NOUN
njb-93	24	10	coli	coli	NOUN
njb-93	24	11	and	and	CCONJ
njb-93	24	12	klebsiella	klebsiella	PROPN
njb-93	24	13	pneumoniae	pneumoniae	NOUN
njb-93	24	14	[	[	X
njb-93	24	15	3	3	NUM
njb-93	24	16	]	]	X
njb-93	24	17	.	.	PUNCT
njb-93	25	1	extended	extend	VERB
njb-93	25	2	-	-	PUNCT
njb-93	25	3	spectrum	spectrum	NOUN
njb-93	25	4	β	β	NOUN
njb-93	25	5	lactamases	lactamase	NOUN
njb-93	25	6	(	(	PUNCT
njb-93	25	7	esbls	esbls	PROPN
njb-93	25	8	)	)	PUNCT
njb-93	25	9	are	be	AUX
njb-93	25	10	a	a	DET
njb-93	25	11	group	group	NOUN
njb-93	25	12	of	of	ADP
njb-93	25	13	enzymes	enzyme	NOUN
njb-93	25	14	with	with	ADP
njb-93	25	15	the	the	DET
njb-93	25	16	ability	ability	NOUN
njb-93	25	17	to	to	PART
njb-93	25	18	hydrolyze	hydrolyze	VERB
njb-93	25	19	and	and	CCONJ
njb-93	25	20	cause	cause	VERB
njb-93	25	21	resistance	resistance	NOUN
njb-93	25	22	to	to	ADP
njb-93	25	23	the	the	DET
njb-93	25	24	oxyiminocephalosporins	oxyiminocephalosporin	NOUN
njb-93	25	25	(	(	PUNCT
njb-93	25	26	i.e.cefotaxime	i.e.cefotaxime	ADJ
njb-93	25	27	,	,	PUNCT
njb-93	25	28	ceftazidime	ceftazidime	PROPN
njb-93	25	29	,	,	PUNCT
njb-93	25	30	ceftriaxone	ceftriaxone	PROPN
njb-93	25	31	,	,	PUNCT
njb-93	25	32	cefuroxime	cefuroxime	NOUN
njb-93	25	33	and	and	CCONJ
njb-93	25	34	cefepime	cefepime	VERB
njb-93	25	35	)	)	PUNCT
njb-93	25	36	monobactams	monobactam	NOUN
njb-93	25	37	(	(	PUNCT
njb-93	25	38	i.e.	i.e.	X
njb-93	25	39	aztreonam	aztreonam	NOUN
njb-93	25	40	)	)	PUNCT
njb-93	26	1	[	[	X
njb-93	26	2	4	4	NUM
njb-93	26	3	]	]	PUNCT
njb-93	26	4	.	.	PUNCT
njb-93	27	1	beta	beta	NOUN
njb-93	27	2	-	-	PUNCT
njb-93	27	3	lactamases	lactamase	NOUN
njb-93	27	4	are	be	AUX
njb-93	27	5	among	among	ADP
njb-93	27	6	the	the	DET
njb-93	27	7	most	most	ADV
njb-93	27	8	heterogeneous	heterogeneous	ADJ
njb-93	27	9	group	group	NOUN
njb-93	27	10	of	of	ADP
njb-93	27	11	resistance	resistance	NOUN
njb-93	27	12	enzymes	enzyme	NOUN
njb-93	27	13	.	.	PUNCT
njb-93	28	1	despite	despite	SCONJ
njb-93	28	2	a	a	DET
njb-93	28	3	significant	significant	ADJ
njb-93	28	4	amount	amount	NOUN
njb-93	28	5	of	of	ADP
njb-93	28	6	amino	amino	ADJ
njb-93	28	7	acid	acid	NOUN
njb-93	28	8	sequence	sequence	NOUN
njb-93	28	9	variability	variability	NOUN
njb-93	28	10	,	,	PUNCT
njb-93	28	11	betalactamases	betalactamase	NOUN
njb-93	28	12	share	share	VERB
njb-93	28	13	a	a	DET
njb-93	28	14	common	common	ADJ
njb-93	28	15	overall	overall	ADJ
njb-93	28	16	topology	topology	NOUN
njb-93	28	17	[	[	PUNCT
njb-93	28	18	5	5	NUM
njb-93	28	19	]	]	PUNCT
njb-93	28	20	.	.	PUNCT
njb-93	29	1	there	there	PRON
njb-93	29	2	are	be	VERB
njb-93	29	3	several	several	ADJ
njb-93	29	4	esbls	esbls	PROPN
njb-93	29	5	genotypes	genotype	NOUN
njb-93	29	6	.	.	PUNCT
njb-93	30	1	these	these	PRON
njb-93	30	2	are	be	AUX
njb-93	30	3	shv	shv	PROPN
njb-93	30	4	,	,	PUNCT
njb-93	30	5	tem	tem	PROPN
njb-93	30	6	,	,	PUNCT
njb-93	30	7	and	and	CCONJ
njb-93	30	8	ctx	ctx	NOUN
njb-93	30	9	-	-	NOUN
njb-93	30	10	m	m	NOUN
njb-93	30	11	[	[	X
njb-93	30	12	6	6	NUM
njb-93	30	13	]	]	PUNCT
njb-93	30	14	.	.	PUNCT
njb-93	31	1	other	other	ADJ
njb-93	31	2	clinically	clinically	ADV
njb-93	31	3	important	important	ADJ
njb-93	31	4	genotypes	genotype	NOUN
njb-93	31	5	include	include	VERB
njb-93	31	6	oxa	oxa	PROPN
njb-93	31	7	,	,	PUNCT
njb-93	31	8	veb	veb	PROPN
njb-93	31	9	,	,	PUNCT
njb-93	31	10	per	per	ADP
njb-93	31	11	,	,	PUNCT
njb-93	31	12	bes-1	bes-1	PUNCT
njb-93	31	13	,	,	PUNCT
njb-93	31	14	bel-1	bel-1	X
njb-93	31	15	,	,	PUNCT
njb-93	31	16	sfo-1	sfo-1	SYM
njb-93	31	17	,	,	PUNCT
njb-93	31	18	tla	tla	NOUN
njb-93	31	19	,	,	PUNCT
njb-93	31	20	and	and	CCONJ
njb-93	31	21	ibc	ibc	PROPN
njb-93	31	22	[	[	PUNCT
njb-93	31	23	7	7	NUM
njb-93	31	24	]	]	PUNCT
njb-93	31	25	.	.	PUNCT
njb-93	32	1	“	"	PUNCT
njb-93	32	2	classical	classical	ADJ
njb-93	32	3	”	"	PUNCT
njb-93	32	4	esbls	esbls	PROPN
njb-93	32	5	are	be	AUX
njb-93	32	6	derived	derive	VERB
njb-93	32	7	from	from	ADP
njb-93	32	8	tem	tem	PROPN
njb-93	32	9	and	and	CCONJ
njb-93	32	10	shv	shv	PROPN
njb-93	32	11	enzymes	enzyme	NOUN
njb-93	32	12	whereas	whereas	SCONJ
njb-93	32	13	“	"	PUNCT
njb-93	32	14	non	non	ADJ
njb-93	32	15	-	-	ADJ
njb-93	32	16	classical	classical	ADJ
njb-93	32	17	”	"	PUNCT
njb-93	32	18	esbls	esbls	PROPN
njb-93	32	19	are	be	AUX
njb-93	32	20	derived	derive	VERB
njb-93	32	21	from	from	ADP
njb-93	32	22	enzymes	enzyme	NOUN
njb-93	32	23	other	other	ADJ
njb-93	32	24	than	than	ADP
njb-93	32	25	tem	tem	PROPN
njb-93	32	26	or	or	CCONJ
njb-93	32	27	shv	shv	PROPN
njb-93	32	28	.	.	PUNCT
njb-93	33	1	90	90	NUM
njb-93	33	2	%	%	NOUN
njb-93	33	3	of	of	ADP
njb-93	33	4	ampicillin	ampicillin	NOUN
njb-93	33	5	resistance	resistance	NOUN
njb-93	33	6	in	in	ADP
njb-93	33	7	e.	e.	PROPN
njb-93	33	8	coli	coli	PROPN
njb-93	33	9	is	be	AUX
njb-93	33	10	due	due	ADJ
njb-93	33	11	to	to	ADP
njb-93	33	12	the	the	DET
njb-93	33	13	production	production	NOUN
njb-93	33	14	of	of	ADP
njb-93	33	15	tem-1	tem-1	PUNCT
njb-93	33	16	[	[	X
njb-93	33	17	8	8	NUM
njb-93	33	18	]	]	X
njb-93	33	19	.	.	PUNCT
njb-93	34	1	based	base	VERB
njb-93	34	2	on	on	ADP
njb-93	34	3	different	different	ADJ
njb-93	34	4	combinations	combination	NOUN
njb-93	34	5	of	of	ADP
njb-93	34	6	changes	change	NOUN
njb-93	34	7	,	,	PUNCT
njb-93	34	8	currently	currently	ADV
njb-93	34	9	,	,	PUNCT
njb-93	34	10	195	195	NUM
njb-93	34	11	tem	tem	PROPN
njb-93	34	12	-	-	PUNCT
njb-93	34	13	type	type	NOUN
njb-93	34	14	enzymes	enzyme	NOUN
njb-93	34	15	have	have	AUX
njb-93	34	16	been	be	AUX
njb-93	34	17	described	describe	VERB
njb-93	34	18	.	.	PUNCT
njb-93	35	1	tem-2	tem-2	PUNCT
njb-93	35	2	,	,	PUNCT
njb-93	35	3	the	the	DET
njb-93	35	4	first	first	ADJ
njb-93	35	5	variant	variant	NOUN
njb-93	35	6	described	describe	VERB
njb-93	35	7	,	,	PUNCT
njb-93	35	8	differed	differ	VERB
njb-93	35	9	from	from	ADP
njb-93	35	10	tem-1	tem-1	PUNCT
njb-93	35	11	through	through	ADP
njb-93	35	12	the	the	DET
njb-93	35	13	substitution	substitution	NOUN
njb-93	35	14	of	of	ADP
njb-93	35	15	a	a	DET
njb-93	35	16	lysine	lysine	NOUN
njb-93	35	17	for	for	ADP
njb-93	35	18	a	a	DET
njb-93	35	19	glutamine	glutamine	NOUN
njb-93	35	20	at	at	ADP
njb-93	35	21	position	position	NOUN
njb-93	35	22	39	39	NUM
njb-93	35	23	[	[	PUNCT
njb-93	35	24	6	6	NUM
njb-93	35	25	]	]	PUNCT
njb-93	35	26	.	.	PUNCT
njb-93	36	1	a	a	DET
njb-93	36	2	shift	shift	NOUN
njb-93	36	3	in	in	ADP
njb-93	36	4	the	the	DET
njb-93	36	5	distribution	distribution	NOUN
njb-93	36	6	of	of	ADP
njb-93	36	7	different	different	ADJ
njb-93	36	8	esbls	esbls	PROPN
njb-93	36	9	has	have	AUX
njb-93	36	10	recently	recently	ADV
njb-93	36	11	occurred	occur	VERB
njb-93	36	12	in	in	ADP
njb-93	36	13	europe	europe	PROPN
njb-93	36	14	,	,	PUNCT
njb-93	36	15	with	with	ADP
njb-93	36	16	a	a	DET
njb-93	36	17	dramatic	dramatic	ADJ
njb-93	36	18	increase	increase	NOUN
njb-93	36	19	of	of	ADP
njb-93	36	20	ctx	ctx	NOUN
njb-93	36	21	-	-	PUNCT
njb-93	36	22	m	m	NOUN
njb-93	36	23	enzymes	enzyme	NOUN
njb-93	36	24	over	over	ADP
njb-93	36	25	nepal	nepal	ADJ
njb-93	36	26	journal	journal	NOUN
njb-93	36	27	of	of	ADP
njb-93	36	28	biotechnology	biotechnology	NOUN
njb-93	36	29	.	.	PUNCT
njb-93	37	1	d	d	X
njb-93	37	2	e	e	PROPN
njb-93	37	3	c	c	PROPN
njb-93	37	4	.	.	PUNCT
njb-93	38	1	2	2	NUM
njb-93	38	2	0	0	NUM
njb-93	38	3	1	1	NUM
njb-93	38	4	7	7	NUM
njb-93	38	5	vol	vol	NOUN
njb-93	38	6	.	.	PROPN
njb-93	39	1	5	5	NUM
njb-93	39	2	,	,	PUNCT
njb-93	39	3	no	no	NOUN
njb-93	39	4	.	.	NOUN
njb-93	39	5	1	1	NUM
njb-93	39	6	:	:	SYM
njb-93	39	7	32	32	NUM
njb-93	39	8	-	-	SYM
njb-93	39	9	38	38	NUM
njb-93	39	10	rimal	rimal	NOUN
njb-93	39	11	et	et	PROPN
njb-93	39	12	al	al	PROPN
njb-93	39	13	.	.	PUNCT
njb-93	40	1	©	©	PROPN
njb-93	40	2	njb	njb	PROPN
njb-93	40	3	,	,	PUNCT
njb-93	40	4	biotechnology	biotechnology	NOUN
njb-93	40	5	society	society	NOUN
njb-93	40	6	of	of	ADP
njb-93	40	7	nepal	nepal	ADJ
njb-93	40	8	33	33	NUM
njb-93	40	9	nepjol.info/index.php/njb	nepjol.info/index.php/njb	PROPN
njb-93	40	10	tem	tem	PROPN
njb-93	40	11	and	and	CCONJ
njb-93	40	12	shv	shv	PROPN
njb-93	40	13	variants	variant	NOUN
njb-93	40	14	[	[	X
njb-93	40	15	9	9	NUM
njb-93	40	16	]	]	PUNCT
njb-93	40	17	.	.	PUNCT
njb-93	41	1	since	since	SCONJ
njb-93	41	2	2000	2000	NUM
njb-93	41	3	,	,	PUNCT
njb-93	41	4	e.	e.	PROPN
njb-93	41	5	coli	coli	PROPN
njb-93	41	6	producing	produce	VERB
njb-93	41	7	ctx	ctx	NOUN
njb-93	41	8	-	-	PUNCT
njb-93	41	9	m	m	ADJ
njb-93	41	10	β	β	NOUN
njb-93	41	11	-	-	PUNCT
njb-93	41	12	lactamases	lactamase	NOUN
njb-93	41	13	have	have	AUX
njb-93	41	14	emerged	emerge	VERB
njb-93	41	15	worldwide	worldwide	ADV
njb-93	41	16	as	as	ADP
njb-93	41	17	an	an	DET
njb-93	41	18	important	important	ADJ
njb-93	41	19	cause	cause	NOUN
njb-93	41	20	of	of	ADP
njb-93	41	21	communityonset	communityonset	PROPN
njb-93	41	22	urinary	urinary	PROPN
njb-93	41	23	tract	tract	NOUN
njb-93	41	24	infections	infection	NOUN
njb-93	41	25	(	(	PUNCT
njb-93	41	26	utis	utis	PROPN
njb-93	41	27	)	)	PUNCT
njb-93	41	28	and	and	CCONJ
njb-93	41	29	this	this	PRON
njb-93	41	30	has	have	AUX
njb-93	41	31	been	be	AUX
njb-93	41	32	called	call	VERB
njb-93	41	33	the	the	DET
njb-93	41	34	ctx	ctx	NOUN
njb-93	41	35	-	-	PUNCT
njb-93	41	36	m	m	ADJ
njb-93	41	37	pandemic	pandemic	ADJ
njb-93	41	38	[	[	X
njb-93	41	39	10	10	NUM
njb-93	41	40	]	]	PUNCT
njb-93	41	41	.	.	PUNCT
njb-93	42	1	these	these	DET
njb-93	42	2	enzymes	enzyme	NOUN
njb-93	42	3	were	be	AUX
njb-93	42	4	named	name	VERB
njb-93	42	5	for	for	ADP
njb-93	42	6	their	their	PRON
njb-93	42	7	greater	great	ADJ
njb-93	42	8	activity	activity	NOUN
njb-93	42	9	against	against	ADP
njb-93	42	10	cefotaxime	cefotaxime	NOUN
njb-93	42	11	than	than	ADP
njb-93	42	12	other	other	ADJ
njb-93	42	13	oxyimino	oxyimino	ADJ
njb-93	42	14	-	-	PUNCT
njb-93	42	15	betalactam	betalactam	NOUN
njb-93	42	16	substrates	substrate	NOUN
njb-93	42	17	(	(	PUNCT
njb-93	42	18	e.g.	e.g.	ADV
njb-93	42	19	ceftazidime	ceftazidime	PROPN
njb-93	42	20	,	,	PUNCT
njb-93	42	21	ceftriaxone	ceftriaxone	PROPN
njb-93	42	22	,	,	PUNCT
njb-93	42	23	or	or	CCONJ
njb-93	42	24	cefepime	cefepime	VERB
njb-93	42	25	)	)	PUNCT
njb-93	43	1	[	[	X
njb-93	43	2	7	7	NUM
njb-93	43	3	]	]	X
njb-93	43	4	.	.	PUNCT
njb-93	44	1	rather	rather	ADV
njb-93	44	2	than	than	ADP
njb-93	44	3	arising	arise	VERB
njb-93	44	4	from	from	ADP
njb-93	44	5	mutation	mutation	NOUN
njb-93	44	6	,	,	PUNCT
njb-93	44	7	they	they	PRON
njb-93	44	8	represent	represent	VERB
njb-93	44	9	examples	example	NOUN
njb-93	44	10	of	of	ADP
njb-93	44	11	plasmid	plasmid	PROPN
njb-93	44	12	acquisition	acquisition	NOUN
njb-93	44	13	of	of	ADP
njb-93	44	14	beta	beta	NOUN
njb-93	44	15	-	-	PUNCT
njb-93	44	16	lactamase	lactamase	NOUN
njb-93	44	17	genes	gene	NOUN
njb-93	44	18	normally	normally	ADV
njb-93	44	19	found	find	VERB
njb-93	44	20	on	on	ADP
njb-93	44	21	the	the	DET
njb-93	44	22	chromosome	chromosome	NOUN
njb-93	44	23	of	of	ADP
njb-93	44	24	kluyvera	kluyvera	PROPN
njb-93	44	25	species	specie	NOUN
njb-93	44	26	,	,	PUNCT
njb-93	44	27	a	a	DET
njb-93	44	28	group	group	NOUN
njb-93	44	29	of	of	ADP
njb-93	44	30	rarely	rarely	ADV
njb-93	44	31	pathogenic	pathogenic	ADJ
njb-93	44	32	commensal	commensal	NOUN
njb-93	44	33	organisms	organism	NOUN
njb-93	44	34	[	[	X
njb-93	44	35	9	9	NUM
njb-93	44	36	]	]	PUNCT
njb-93	44	37	.	.	PUNCT
njb-93	45	1	in	in	ADP
njb-93	45	2	france	france	PROPN
njb-93	45	3	,	,	PUNCT
njb-93	45	4	a	a	DET
njb-93	45	5	novel	novel	ADJ
njb-93	45	6	derivative	derivative	NOUN
njb-93	45	7	of	of	ADP
njb-93	45	8	oxa-10	oxa-10	PROPN
njb-93	45	9	(	(	PUNCT
njb-93	45	10	numbered	number	VERB
njb-93	45	11	oxa-28	oxa-28	PROPN
njb-93	45	12	)	)	PUNCT
njb-93	45	13	was	be	AUX
njb-93	45	14	found	find	VERB
njb-93	45	15	in	in	ADP
njb-93	45	16	a	a	DET
njb-93	45	17	p.	p.	PROPN
njb-93	45	18	aeruginosa	aeruginosa	PROPN
njb-93	45	19	isolate	isolate	VERB
njb-93	45	20	[	[	SYM
njb-93	45	21	11	11	NUM
njb-93	45	22	]	]	PUNCT
njb-93	45	23	.	.	PUNCT
njb-93	46	1	the	the	DET
njb-93	46	2	rapid	rapid	ADJ
njb-93	46	3	increasing	increase	VERB
njb-93	46	4	rate	rate	NOUN
njb-93	46	5	of	of	ADP
njb-93	46	6	esbl	esbl	PROPN
njb-93	46	7	production	production	NOUN
njb-93	46	8	among	among	ADP
njb-93	46	9	enterobacteriaceae	enterobacteriaceae	PROPN
njb-93	46	10	,	,	PUNCT
njb-93	46	11	mainly	mainly	ADV
njb-93	46	12	e.	e.	PROPN
njb-93	46	13	coli	coli	PROPN
njb-93	46	14	and	and	CCONJ
njb-93	46	15	klebsiella	klebsiella	PROPN
njb-93	46	16	pneumonia	pneumonia	PROPN
njb-93	46	17	,	,	PUNCT
njb-93	46	18	have	have	AUX
njb-93	46	19	created	create	VERB
njb-93	46	20	a	a	DET
njb-93	46	21	serious	serious	ADJ
njb-93	46	22	global	global	ADJ
njb-93	46	23	public	public	ADJ
njb-93	46	24	health	health	NOUN
njb-93	46	25	problem	problem	NOUN
njb-93	46	26	[	[	X
njb-93	46	27	12	12	NUM
njb-93	46	28	]	]	PUNCT
njb-93	46	29	.	.	PUNCT
njb-93	47	1	availability	availability	NOUN
njb-93	47	2	of	of	ADP
njb-93	47	3	limited	limited	ADJ
njb-93	47	4	treatment	treatment	NOUN
njb-93	47	5	options	option	NOUN
njb-93	47	6	for	for	ADP
njb-93	47	7	the	the	DET
njb-93	47	8	infections	infection	NOUN
njb-93	47	9	caused	cause	VERB
njb-93	47	10	esbl	esbl	NOUN
njb-93	47	11	producing	produce	VERB
njb-93	47	12	bacteria	bacteria	NOUN
njb-93	47	13	makes	make	VERB
njb-93	47	14	the	the	DET
njb-93	47	15	treatment	treatment	NOUN
njb-93	47	16	very	very	ADV
njb-93	47	17	difficult	difficult	ADJ
njb-93	47	18	and	and	CCONJ
njb-93	47	19	often	often	ADV
njb-93	47	20	results	result	VERB
njb-93	47	21	into	into	ADP
njb-93	47	22	treatment	treatment	NOUN
njb-93	47	23	failure	failure	NOUN
njb-93	47	24	[	[	PUNCT
njb-93	47	25	13	13	NUM
njb-93	47	26	]	]	PUNCT
njb-93	47	27	.	.	PUNCT
njb-93	48	1	scant	scant	ADJ
njb-93	48	2	number	number	NOUN
njb-93	48	3	of	of	ADP
njb-93	48	4	studies	study	NOUN
njb-93	48	5	had	have	AUX
njb-93	48	6	been	be	AUX
njb-93	48	7	reported	report	VERB
njb-93	48	8	from	from	ADP
njb-93	48	9	nepal	nepal	ADJ
njb-93	48	10	assessing	assess	VERB
njb-93	48	11	the	the	DET
njb-93	48	12	esbl	esbl	PROPN
njb-93	48	13	producers	producer	NOUN
njb-93	48	14	among	among	ADP
njb-93	48	15	e.	e.	PROPN
njb-93	48	16	coli	coli	PROPN
njb-93	48	17	and	and	CCONJ
njb-93	48	18	klebsiella	klebsiella	PROPN
njb-93	48	19	spp	spp	PROPN
njb-93	48	20	in	in	ADP
njb-93	48	21	children	child	NOUN
njb-93	48	22	.	.	PUNCT
njb-93	49	1	hence	hence	ADV
njb-93	49	2	the	the	DET
njb-93	49	3	study	study	NOUN
njb-93	49	4	was	be	AUX
njb-93	49	5	carried	carry	VERB
njb-93	49	6	out	out	ADP
njb-93	49	7	to	to	PART
njb-93	49	8	determine	determine	VERB
njb-93	49	9	the	the	DET
njb-93	49	10	prevalence	prevalence	NOUN
njb-93	49	11	of	of	ADP
njb-93	49	12	esbl	esbl	PROPN
njb-93	49	13	producing	produce	VERB
njb-93	49	14	escherichia	escherichia	NOUN
njb-93	49	15	coli	coli	NOUN
njb-93	49	16	and	and	CCONJ
njb-93	49	17	klebsiella	klebsiella	PROPN
njb-93	49	18	spp	spp	PROPN
njb-93	49	19	isolates	isolate	VERB
njb-93	49	20	from	from	ADP
njb-93	49	21	the	the	DET
njb-93	49	22	urine	urine	NOUN
njb-93	49	23	samples	sample	NOUN
njb-93	49	24	of	of	ADP
njb-93	49	25	children	child	NOUN
njb-93	49	26	.	.	PUNCT
njb-93	50	1	materials	material	NOUN
njb-93	50	2	and	and	CCONJ
njb-93	50	3	methodology	methodology	NOUN
njb-93	50	4	sample	sample	NOUN
njb-93	50	5	collection	collection	NOUN
njb-93	50	6	and	and	CCONJ
njb-93	50	7	identification	identification	NOUN
njb-93	50	8	of	of	ADP
njb-93	50	9	bacteria	bacteria	NOUN
njb-93	50	10	the	the	DET
njb-93	50	11	cross	cross	ADJ
njb-93	50	12	-	-	ADJ
njb-93	50	13	sectional	sectional	ADJ
njb-93	50	14	study	study	NOUN
njb-93	50	15	was	be	AUX
njb-93	50	16	carried	carry	VERB
njb-93	50	17	out	out	ADP
njb-93	50	18	in	in	ADP
njb-93	50	19	pathology	pathology	PROPN
njb-93	50	20	department	department	PROPN
njb-93	50	21	of	of	ADP
njb-93	50	22	international	international	ADJ
njb-93	50	23	friendship	friendship	NOUN
njb-93	50	24	children	child	NOUN
njb-93	50	25	hospital	hospital	NOUN
njb-93	50	26	,	,	PUNCT
njb-93	50	27	maharajgunj	maharajgunj	PROPN
njb-93	50	28	,	,	PUNCT
njb-93	50	29	kathmandu	kathmandu	NOUN
njb-93	50	30	from	from	ADP
njb-93	50	31	june	june	PROPN
njb-93	50	32	2016	2016	NUM
njb-93	50	33	to	to	ADP
njb-93	50	34	december	december	PROPN
njb-93	50	35	2016	2016	NUM
njb-93	50	36	.	.	PUNCT
njb-93	51	1	patients	patient	NOUN
njb-93	51	2	under	under	ADP
njb-93	51	3	the	the	DET
njb-93	51	4	age	age	NOUN
njb-93	51	5	of	of	ADP
njb-93	51	6	13	13	NUM
njb-93	51	7	years	year	NOUN
njb-93	51	8	or	or	CCONJ
njb-93	51	9	their	their	PRON
njb-93	51	10	guardians	guardian	NOUN
njb-93	51	11	visiting	visit	VERB
njb-93	51	12	the	the	DET
njb-93	51	13	pathology	pathology	NOUN
njb-93	51	14	department	department	PROPN
njb-93	51	15	were	be	AUX
njb-93	51	16	directly	directly	ADV
njb-93	51	17	interviewed	interview	VERB
njb-93	51	18	for	for	ADP
njb-93	51	19	his	his	PRON
njb-93	51	20	/	/	SYM
njb-93	51	21	her	her	PRON
njb-93	51	22	clinical	clinical	ADJ
njb-93	51	23	history	history	NOUN
njb-93	51	24	during	during	ADP
njb-93	51	25	the	the	DET
njb-93	51	26	sample	sample	NOUN
njb-93	51	27	collection	collection	NOUN
njb-93	51	28	.	.	PUNCT
njb-93	52	1	during	during	ADP
njb-93	52	2	the	the	DET
njb-93	52	3	study	study	NOUN
njb-93	52	4	period	period	NOUN
njb-93	52	5	,	,	PUNCT
njb-93	52	6	1018	1018	NUM
njb-93	52	7	midstream	midstream	NOUN
njb-93	52	8	urine	urine	NOUN
njb-93	52	9	samples	sample	NOUN
njb-93	52	10	were	be	AUX
njb-93	52	11	collected	collect	VERB
njb-93	52	12	and	and	CCONJ
njb-93	52	13	processed	process	VERB
njb-93	52	14	according	accord	VERB
njb-93	52	15	to	to	ADP
njb-93	52	16	the	the	DET
njb-93	52	17	standard	standard	ADJ
njb-93	52	18	laboratory	laboratory	NOUN
njb-93	52	19	methods	method	NOUN
njb-93	52	20	by	by	ADP
njb-93	52	21	forbes	forbe	NOUN
njb-93	52	22	et	et	PROPN
njb-93	52	23	al	al	PROPN
njb-93	52	24	[	[	PUNCT
njb-93	52	25	14	14	NUM
njb-93	52	26	]	]	PUNCT
njb-93	52	27	.	.	PUNCT
njb-93	53	1	semi	semi	ADJ
njb-93	53	2	-	-	ADJ
njb-93	53	3	quantitative	quantitative	ADJ
njb-93	53	4	culture	culture	NOUN
njb-93	53	5	technique	technique	NOUN
njb-93	53	6	was	be	AUX
njb-93	53	7	used	use	VERB
njb-93	53	8	to	to	PART
njb-93	53	9	detect	detect	VERB
njb-93	53	10	the	the	DET
njb-93	53	11	presence	presence	NOUN
njb-93	53	12	of	of	ADP
njb-93	53	13	significant	significant	ADJ
njb-93	53	14	bacteriuria	bacteriuria	NOUN
njb-93	53	15	.	.	PUNCT
njb-93	54	1	the	the	DET
njb-93	54	2	bacterial	bacterial	ADJ
njb-93	54	3	culture	culture	NOUN
njb-93	54	4	was	be	AUX
njb-93	54	5	done	do	VERB
njb-93	54	6	on	on	ADP
njb-93	54	7	macconkey	macconkey	NOUN
njb-93	54	8	agar	agar	NOUN
njb-93	54	9	(	(	PUNCT
njb-93	54	10	ma	ma	PROPN
njb-93	54	11	)	)	PUNCT
njb-93	54	12	and	and	CCONJ
njb-93	54	13	blood	blood	NOUN
njb-93	54	14	agar	agar	NOUN
njb-93	54	15	(	(	PUNCT
njb-93	54	16	ba	ba	NOUN
njb-93	54	17	)	)	PUNCT
njb-93	54	18	and	and	CCONJ
njb-93	54	19	incubated	incubate	VERB
njb-93	54	20	overnight	overnight	ADV
njb-93	54	21	at	at	ADP
njb-93	54	22	37oc	37oc	NOUN
njb-93	54	23	for	for	ADP
njb-93	54	24	isolation	isolation	NOUN
njb-93	54	25	of	of	ADP
njb-93	54	26	pure	pure	ADJ
njb-93	54	27	culture	culture	NOUN
njb-93	54	28	.	.	PUNCT
njb-93	55	1	diagnosis	diagnosis	NOUN
njb-93	55	2	of	of	ADP
njb-93	55	3	uti	uti	PROPN
njb-93	55	4	was	be	AUX
njb-93	55	5	made	make	VERB
njb-93	55	6	when	when	SCONJ
njb-93	55	7	there	there	PRON
njb-93	55	8	were	be	VERB
njb-93	55	9	colony	colony	NOUN
njb-93	55	10	count	count	NOUN
njb-93	55	11	exceeding	exceed	VERB
njb-93	55	12	105	105	NUM
njb-93	55	13	cfu	cfu	NOUN
njb-93	55	14	/	/	SYM
njb-93	55	15	ml	ml	NOUN
njb-93	55	16	of	of	ADP
njb-93	55	17	urine	urine	NOUN
njb-93	55	18	specimen	speciman	NOUN
njb-93	55	19	.	.	PUNCT
njb-93	56	1	the	the	DET
njb-93	56	2	isolates	isolate	NOUN
njb-93	56	3	were	be	AUX
njb-93	56	4	identified	identify	VERB
njb-93	56	5	based	base	VERB
njb-93	56	6	on	on	ADP
njb-93	56	7	morphology	morphology	NOUN
njb-93	56	8	,	,	PUNCT
njb-93	56	9	gram	gram	PROPN
njb-93	56	10	’s	’s	PART
njb-93	56	11	staining	staining	NOUN
njb-93	56	12	,	,	PUNCT
njb-93	56	13	motility	motility	NOUN
njb-93	56	14	,	,	PUNCT
njb-93	56	15	and	and	CCONJ
njb-93	56	16	standard	standard	ADJ
njb-93	56	17	biochemical	biochemical	ADJ
njb-93	56	18	tests	test	NOUN
njb-93	56	19	as	as	SCONJ
njb-93	56	20	described	describe	VERB
njb-93	56	21	in	in	ADP
njb-93	56	22	forbes	forbes	PROPN
njb-93	56	23	et	et	PROPN
njb-93	56	24	al	al	PROPN
njb-93	57	1	[	[	PUNCT
njb-93	57	2	14	14	NUM
njb-93	57	3	]	]	PUNCT
njb-93	57	4	.	.	PUNCT
njb-93	58	1	modified	modify	VERB
njb-93	58	2	kirby	kirby	PROPN
njb-93	58	3	-	-	PUNCT
njb-93	58	4	bauer	bauer	PROPN
njb-93	58	5	’s	’s	PART
njb-93	58	6	disc	disc	NOUN
njb-93	58	7	diffusion	diffusion	NOUN
njb-93	58	8	method	method	NOUN
njb-93	58	9	was	be	AUX
njb-93	58	10	employed	employ	VERB
njb-93	58	11	for	for	ADP
njb-93	58	12	the	the	DET
njb-93	58	13	antibiotic	antibiotic	ADJ
njb-93	58	14	susceptibility	susceptibility	NOUN
njb-93	58	15	test	test	NOUN
njb-93	58	16	of	of	ADP
njb-93	58	17	potential	potential	ADJ
njb-93	58	18	pathogenic	pathogenic	ADJ
njb-93	58	19	isolates	isolate	NOUN
njb-93	58	20	as	as	ADP
njb-93	58	21	per	per	ADP
njb-93	58	22	standard	standard	ADJ
njb-93	58	23	technique	technique	NOUN
njb-93	58	24	on	on	ADP
njb-93	58	25	muller	muller	PROPN
njb-93	58	26	hilton	hilton	PROPN
njb-93	58	27	agar	agar	PROPN
njb-93	58	28	[	[	PUNCT
njb-93	58	29	15	15	NUM
njb-93	58	30	]	]	PUNCT
njb-93	58	31	.	.	PUNCT
njb-93	59	1	nitrofurantoin(300mcg	nitrofurantoin(300mcg	PROPN
njb-93	59	2	)	)	PUNCT
njb-93	60	1	,	,	PUNCT
njb-93	60	2	amoxicillin	amoxicillin	PROPN
njb-93	60	3	(	(	PUNCT
njb-93	60	4	30mcg	30mcg	NOUN
njb-93	60	5	)	)	PUNCT
njb-93	60	6	,	,	PUNCT
njb-93	60	7	cotrimoxazole	cotrimoxazole	PROPN
njb-93	60	8	(	(	PUNCT
njb-93	60	9	25	25	NUM
njb-93	60	10	mcg	mcg	NOUN
njb-93	60	11	)	)	PUNCT
njb-93	60	12	,	,	PUNCT
njb-93	60	13	ciprofloxacin	ciprofloxacin	NOUN
njb-93	60	14	(	(	PUNCT
njb-93	60	15	5mcg	5mcg	NUM
njb-93	60	16	)	)	PUNCT
njb-93	60	17	,	,	PUNCT
njb-93	60	18	ceftriaxone	ceftriaxone	PROPN
njb-93	60	19	(	(	PUNCT
njb-93	60	20	30	30	NUM
njb-93	60	21	mcg	mcg	NOUN
njb-93	60	22	)	)	PUNCT
njb-93	60	23	,	,	PUNCT
njb-93	60	24	ceftazidime	ceftazidime	NOUN
njb-93	60	25	(	(	PUNCT
njb-93	60	26	30	30	NUM
njb-93	60	27	mcg	mcg	NOUN
njb-93	60	28	)	)	PUNCT
njb-93	60	29	,	,	PUNCT
njb-93	60	30	gentamicin	gentamicin	PROPN
njb-93	60	31	(	(	PUNCT
njb-93	60	32	10	10	NUM
njb-93	60	33	mcg	mcg	NOUN
njb-93	60	34	)	)	PUNCT
njb-93	60	35	,	,	PUNCT
njb-93	60	36	imipenem	imipenem	PROPN
njb-93	60	37	(	(	PUNCT
njb-93	60	38	10	10	NUM
njb-93	60	39	mcg	mcg	NOUN
njb-93	60	40	)	)	PUNCT
njb-93	60	41	and	and	CCONJ
njb-93	60	42	meropenem	meropenem	PROPN
njb-93	60	43	(	(	PUNCT
njb-93	60	44	10	10	NUM
njb-93	60	45	mcg	mcg	NOUN
njb-93	60	46	)	)	PUNCT
njb-93	60	47	were	be	AUX
njb-93	60	48	used	use	VERB
njb-93	60	49	for	for	ADP
njb-93	60	50	antimicrobial	antimicrobial	ADJ
njb-93	60	51	susceptibility	susceptibility	NOUN
njb-93	60	52	testing	testing	NOUN
njb-93	60	53	.	.	PUNCT
njb-93	61	1	screening	screening	NOUN
njb-93	61	2	of	of	ADP
njb-93	61	3	esbl	esbl	VERB
njb-93	61	4	producing	produce	VERB
njb-93	61	5	strains	strain	NOUN
njb-93	61	6	of	of	ADP
njb-93	61	7	e.	e.	PROPN
njb-93	61	8	coli	coli	NOUN
njb-93	61	9	and	and	CCONJ
njb-93	61	10	k.pneumoniae	k.pneumoniae	VERB
njb-93	61	11	the	the	DET
njb-93	61	12	screening	screening	NOUN
njb-93	61	13	test	test	NOUN
njb-93	61	14	for	for	ADP
njb-93	61	15	the	the	DET
njb-93	61	16	production	production	NOUN
njb-93	61	17	of	of	ADP
njb-93	61	18	esbl	esbl	PROPN
njb-93	61	19	was	be	AUX
njb-93	61	20	performed	perform	VERB
njb-93	61	21	using	use	VERB
njb-93	61	22	both	both	DET
njb-93	61	23	ceftazidime	ceftazidime	NOUN
njb-93	61	24	(	(	PUNCT
njb-93	61	25	caz	caz	PROPN
njb-93	61	26	)	)	PUNCT
njb-93	61	27	(	(	PUNCT
njb-93	61	28	30μg	30μg	PROPN
njb-93	61	29	)	)	PUNCT
njb-93	61	30	and	and	CCONJ
njb-93	61	31	ceftriaxone	ceftriaxone	PROPN
njb-93	61	32	(	(	PUNCT
njb-93	61	33	ctr	ctr	PROPN
njb-93	61	34	)	)	PUNCT
njb-93	61	35	(	(	PUNCT
njb-93	61	36	30μg	30μg	NOUN
njb-93	61	37	)	)	PUNCT
njb-93	61	38	disks	disk	NOUN
njb-93	61	39	.	.	PUNCT
njb-93	62	1	if	if	SCONJ
njb-93	62	2	the	the	DET
njb-93	62	3	zone	zone	NOUN
njb-93	62	4	of	of	ADP
njb-93	62	5	inhibition	inhibition	NOUN
njb-93	62	6	was	be	AUX
njb-93	62	7	less	less	ADJ
njb-93	62	8	than	than	ADP
njb-93	62	9	or	or	CCONJ
njb-93	62	10	equal	equal	ADJ
njb-93	62	11	to	to	ADP
njb-93	62	12	22	22	NUM
njb-93	62	13	mm	mm	NOUN
njb-93	62	14	for	for	ADP
njb-93	62	15	caz	caz	PROPN
njb-93	62	16	and/or	and/or	CCONJ
njb-93	62	17	less	less	ADJ
njb-93	62	18	than	than	ADP
njb-93	62	19	or	or	CCONJ
njb-93	62	20	equal	equal	ADJ
njb-93	62	21	to	to	ADP
njb-93	62	22	25	25	NUM
njb-93	62	23	mm	mm	NOUN
njb-93	62	24	for	for	ADP
njb-93	62	25	ctr	ctr	PROPN
njb-93	62	26	,	,	PUNCT
njb-93	62	27	the	the	DET
njb-93	62	28	isolate	isolate	NOUN
njb-93	62	29	was	be	AUX
njb-93	62	30	considered	consider	VERB
njb-93	62	31	a	a	DET
njb-93	62	32	potential	potential	ADJ
njb-93	62	33	esbl	esbl	NOUN
njb-93	62	34	-	-	PUNCT
njb-93	62	35	producer	producer	NOUN
njb-93	62	36	as	as	SCONJ
njb-93	62	37	recommended	recommend	VERB
njb-93	62	38	by	by	ADP
njb-93	62	39	clsi	clsi	NOUN
njb-93	63	1	[	[	X
njb-93	63	2	16	16	NUM
njb-93	63	3	]	]	PUNCT
njb-93	63	4	.	.	PUNCT
njb-93	64	1	phenotypic	phenotypic	ADJ
njb-93	64	2	confirmation	confirmation	NOUN
njb-93	64	3	of	of	ADP
njb-93	64	4	esbl	esbl	PROPN
njb-93	64	5	production	production	NOUN
njb-93	64	6	susceptible	susceptible	ADJ
njb-93	64	7	screened	screen	VERB
njb-93	64	8	esbl	esbl	PROPN
njb-93	64	9	producers	producer	NOUN
njb-93	64	10	were	be	AUX
njb-93	64	11	subjected	subject	VERB
njb-93	64	12	to	to	ADP
njb-93	64	13	combined	combine	VERB
njb-93	64	14	disk	disk	NOUN
njb-93	64	15	test	test	NOUN
njb-93	64	16	as	as	SCONJ
njb-93	64	17	recommended	recommend	VERB
njb-93	64	18	by	by	ADP
njb-93	64	19	the	the	DET
njb-93	64	20	clsi	clsi	NOUN
njb-93	65	1	[	[	X
njb-93	65	2	16	16	NUM
njb-93	65	3	]	]	PUNCT
njb-93	65	4	.	.	PUNCT
njb-93	66	1	combination	combination	NOUN
njb-93	66	2	disk	disk	NOUN
njb-93	66	3	method	method	NOUN
njb-93	66	4	used	use	VERB
njb-93	66	5	for	for	ADP
njb-93	66	6	the	the	DET
njb-93	66	7	confirmation	confirmation	NOUN
njb-93	66	8	of	of	ADP
njb-93	66	9	esbl	esbl	PROPN
njb-93	66	10	-	-	PUNCT
njb-93	66	11	producing	produce	VERB
njb-93	66	12	strains	strain	NOUN
njb-93	66	13	in	in	ADP
njb-93	66	14	which	which	PRON
njb-93	66	15	caz	caz	PROPN
njb-93	66	16	(	(	PUNCT
njb-93	66	17	30μg	30μg	PROPN
njb-93	66	18	)	)	PUNCT
njb-93	66	19	,	,	PUNCT
njb-93	66	20	alone	alone	ADV
njb-93	66	21	and	and	CCONJ
njb-93	66	22	in	in	ADP
njb-93	66	23	combination	combination	NOUN
njb-93	66	24	with	with	ADP
njb-93	66	25	clavulanic	clavulanic	ADJ
njb-93	66	26	acid	acid	NOUN
njb-93	66	27	(	(	PUNCT
njb-93	66	28	ca	can	AUX
njb-93	66	29	)	)	PUNCT
njb-93	66	30	(	(	PUNCT
njb-93	66	31	10μg	10μg	PROPN
njb-93	66	32	)	)	PUNCT
njb-93	66	33	were	be	AUX
njb-93	66	34	used	use	VERB
njb-93	66	35	.	.	PUNCT
njb-93	67	1	after	after	ADP
njb-93	67	2	incubating	incubate	VERB
njb-93	67	3	overnight	overnight	ADV
njb-93	67	4	at	at	ADP
njb-93	67	5	37	37	NUM
njb-93	67	6	°	°	NOUN
njb-93	67	7	c	c	NOUN
njb-93	67	8	,	,	PUNCT
njb-93	67	9	≥	≥	NUM
njb-93	67	10	5	5	NUM
njb-93	67	11	mm	mm	NOUN
njb-93	67	12	increase	increase	NOUN
njb-93	67	13	in	in	ADP
njb-93	67	14	the	the	DET
njb-93	67	15	zone	zone	NOUN
njb-93	67	16	diameter	diameter	NOUN
njb-93	67	17	for	for	ADP
njb-93	67	18	either	either	CCONJ
njb-93	67	19	antimicrobial	antimicrobial	ADJ
njb-93	67	20	agent	agent	NOUN
njb-93	67	21	which	which	PRON
njb-93	67	22	was	be	AUX
njb-93	67	23	tested	test	VERB
njb-93	67	24	in	in	ADP
njb-93	67	25	combination	combination	NOUN
njb-93	67	26	with	with	ADP
njb-93	67	27	clavulanic	clavulanic	ADJ
njb-93	67	28	acid	acid	NOUN
njb-93	67	29	(	(	PUNCT
njb-93	67	30	cac	cac	PROPN
njb-93	67	31	)	)	PUNCT
njb-93	67	32	versus	versus	ADP
njb-93	67	33	its	its	PRON
njb-93	67	34	zone	zone	NOUN
njb-93	67	35	when	when	SCONJ
njb-93	67	36	tested	test	VERB
njb-93	67	37	alone	alone	ADV
njb-93	67	38	,	,	PUNCT
njb-93	67	39	was	be	AUX
njb-93	67	40	interpreted	interpret	VERB
njb-93	67	41	as	as	ADP
njb-93	67	42	positive	positive	ADJ
njb-93	67	43	for	for	ADP
njb-93	67	44	esbl	esbl	PROPN
njb-93	67	45	production	production	NOUN
njb-93	67	46	.	.	PUNCT
njb-93	68	1	results	result	NOUN
njb-93	68	2	table	table	VERB
njb-93	68	3	1	1	NUM
njb-93	68	4	:	:	PUNCT
njb-93	68	5	microbiological	microbiological	ADJ
njb-93	68	6	profile	profile	NOUN
njb-93	68	7	of	of	ADP
njb-93	68	8	bacterial	bacterial	ADJ
njb-93	68	9	isolates	isolate	VERB
njb-93	68	10	s.n	s.n	PROPN
njb-93	68	11	bacterial	bacterial	ADJ
njb-93	68	12	isolates	isolate	NOUN
njb-93	68	13	number	number	NOUN
njb-93	68	14	percent	percent	NOUN
njb-93	68	15	1	1	NUM
njb-93	68	16	escherichia	escherichia	NOUN
njb-93	68	17	coli	coli	NOUN
njb-93	68	18	200	200	NUM
njb-93	68	19	82.30	82.30	NUM
njb-93	68	20	%	%	NOUN
njb-93	68	21	2	2	NUM
njb-93	68	22	klebsiella	klebsiella	X
njb-93	68	23	pneumoniae	pneumoniae	NOUN
njb-93	68	24	24	24	NUM
njb-93	68	25	10	10	NUM
njb-93	68	26	%	%	NOUN
njb-93	68	27	3	3	NUM
njb-93	68	28	klebsiella	klebsiella	PROPN
njb-93	68	29	oxytoca	oxytoca	PROPN
njb-93	68	30	4	4	NUM
njb-93	68	31	1.64	1.64	NUM
njb-93	68	32	%	%	NOUN
njb-93	68	33	4	4	NUM
njb-93	68	34	citrobacter	citrobacter	NOUN
njb-93	68	35	spp	spp	NOUN
njb-93	68	36	3	3	NUM
njb-93	68	37	1.23	1.23	NUM
njb-93	68	38	%	%	NOUN
njb-93	68	39	5	5	NUM
njb-93	68	40	pseudomonas	pseudomona	NOUN
njb-93	68	41	aeruginosa	aeruginosa	PROPN
njb-93	68	42	2	2	NUM
njb-93	68	43	0.82	0.82	NUM
njb-93	68	44	%	%	NOUN
njb-93	68	45	6	6	NUM
njb-93	68	46	acinetobacter	acinetobacter	ADJ
njb-93	68	47	2	2	NUM
njb-93	68	48	0.82	0.82	NUM
njb-93	68	49	%	%	NOUN
njb-93	68	50	7	7	NUM
njb-93	68	51	staphylococcus	staphylococcus	NOUN
njb-93	68	52	aureus	aureus	NOUN
njb-93	68	53	8	8	NUM
njb-93	68	54	3.29	3.29	NUM
njb-93	68	55	%	%	NOUN
njb-93	68	56	total	total	NOUN
njb-93	68	57	243	243	NUM
njb-93	68	58	100	100	NUM
njb-93	68	59	%	%	NOUN
njb-93	68	60	out	out	ADP
njb-93	68	61	of	of	ADP
njb-93	68	62	the	the	DET
njb-93	68	63	total	total	ADJ
njb-93	68	64	1018	1018	NUM
njb-93	68	65	mid	mid	ADJ
njb-93	68	66	-	-	ADJ
njb-93	68	67	stream	stream	ADJ
njb-93	68	68	urine	urine	NOUN
njb-93	68	69	samples	sample	NOUN
njb-93	68	70	,	,	PUNCT
njb-93	68	71	243(23.87	243(23.87	NUM
njb-93	68	72	%	%	NOUN
njb-93	68	73	)	)	PUNCT
njb-93	68	74	samples	sample	NOUN
njb-93	68	75	were	be	AUX
njb-93	68	76	found	find	VERB
njb-93	68	77	to	to	PART
njb-93	68	78	have	have	VERB
njb-93	68	79	a	a	DET
njb-93	68	80	significant	significant	ADJ
njb-93	68	81	growth	growth	NOUN
njb-93	68	82	.	.	PUNCT
njb-93	69	1	out	out	ADP
njb-93	69	2	of	of	ADP
njb-93	69	3	243	243	NUM
njb-93	69	4	culture	culture	NOUN
njb-93	69	5	positive	positive	ADJ
njb-93	69	6	cases	case	NOUN
njb-93	69	7	,	,	PUNCT
njb-93	69	8	escherichia	escherichia	NOUN
njb-93	69	9	coli	coli	NOUN
njb-93	69	10	(	(	PUNCT
njb-93	69	11	200	200	NUM
njb-93	69	12	)	)	PUNCT
njb-93	69	13	(	(	PUNCT
njb-93	69	14	82	82	NUM
njb-93	69	15	%	%	NOUN
njb-93	69	16	)	)	PUNCT
njb-93	69	17	was	be	AUX
njb-93	69	18	found	find	VERB
njb-93	69	19	to	to	PART
njb-93	69	20	be	be	AUX
njb-93	69	21	nepal	nepal	ADJ
njb-93	69	22	journal	journal	NOUN
njb-93	69	23	of	of	ADP
njb-93	69	24	biotechnology	biotechnology	NOUN
njb-93	69	25	.	.	PUNCT
njb-93	70	1	d	d	X
njb-93	70	2	e	e	PROPN
njb-93	70	3	c	c	PROPN
njb-93	70	4	.	.	PUNCT
njb-93	71	1	2	2	NUM
njb-93	71	2	0	0	NUM
njb-93	71	3	1	1	NUM
njb-93	71	4	7	7	NUM
njb-93	71	5	vol	vol	NOUN
njb-93	71	6	.	.	PROPN
njb-93	72	1	5	5	NUM
njb-93	72	2	,	,	PUNCT
njb-93	72	3	no	no	NOUN
njb-93	72	4	.	.	NOUN
njb-93	72	5	1	1	NUM
njb-93	72	6	:	:	SYM
njb-93	72	7	32	32	NUM
njb-93	72	8	-	-	SYM
njb-93	72	9	38	38	NUM
njb-93	72	10	rimal	rimal	NOUN
njb-93	72	11	et	et	PROPN
njb-93	72	12	al	al	PROPN
njb-93	72	13	.	.	PUNCT
njb-93	73	1	©	©	PROPN
njb-93	73	2	njb	njb	PROPN
njb-93	73	3	,	,	PUNCT
njb-93	73	4	biotechnology	biotechnology	NOUN
njb-93	73	5	society	society	NOUN
njb-93	73	6	of	of	ADP
njb-93	73	7	nepal	nepal	ADJ
njb-93	73	8	34	34	NUM
njb-93	73	9	nepjol.info/index.php/njb	nepjol.info/index.php/njb	NOUN
njb-93	73	10	the	the	DET
njb-93	73	11	most	most	ADV
njb-93	73	12	common	common	ADJ
njb-93	73	13	isolates	isolate	NOUN
njb-93	73	14	followed	follow	VERB
njb-93	73	15	by	by	ADP
njb-93	73	16	klebsiella	klebsiella	PROPN
njb-93	73	17	pneumoniae	pneumoniae	PROPN
njb-93	73	18	(	(	PUNCT
njb-93	73	19	24	24	NUM
njb-93	73	20	)	)	PUNCT
njb-93	73	21	(	(	PUNCT
njb-93	73	22	10	10	NUM
njb-93	73	23	%	%	NOUN
njb-93	73	24	)	)	PUNCT
njb-93	73	25	,	,	PUNCT
njb-93	73	26	klebsiella	klebsiella	PROPN
njb-93	73	27	oxytoca	oxytoca	PROPN
njb-93	73	28	(	(	PUNCT
njb-93	73	29	4	4	X
njb-93	73	30	)	)	PUNCT
njb-93	73	31	(	(	PUNCT
njb-93	73	32	1.65	1.65	NUM
njb-93	73	33	%	%	NOUN
njb-93	73	34	)	)	PUNCT
njb-93	73	35	,	,	PUNCT
njb-93	73	36	citrobacter	citrobacter	NOUN
njb-93	73	37	species	specie	NOUN
njb-93	73	38	(	(	PUNCT
njb-93	73	39	3	3	NUM
njb-93	73	40	)	)	PUNCT
njb-93	73	41	(	(	PUNCT
njb-93	73	42	1.15	1.15	NUM
njb-93	73	43	%	%	NOUN
njb-93	73	44	)	)	PUNCT
njb-93	73	45	,	,	PUNCT
njb-93	73	46	pseudomonas	pseudomonas	PROPN
njb-93	73	47	aeruginosa	aeruginosa	PROPN
njb-93	73	48	(	(	PUNCT
njb-93	73	49	2	2	NUM
njb-93	73	50	)	)	PUNCT
njb-93	73	51	(	(	PUNCT
njb-93	73	52	0.85	0.85	NUM
njb-93	73	53	%	%	NOUN
njb-93	73	54	)	)	PUNCT
njb-93	73	55	,	,	PUNCT
njb-93	73	56	acinetobacter	acinetobacter	NOUN
njb-93	73	57	species	specie	NOUN
njb-93	73	58	(	(	PUNCT
njb-93	73	59	2	2	NUM
njb-93	73	60	)	)	PUNCT
njb-93	73	61	(	(	PUNCT
njb-93	73	62	0.85	0.85	NUM
njb-93	73	63	%	%	NOUN
njb-93	73	64	)	)	PUNCT
njb-93	73	65	and	and	CCONJ
njb-93	73	66	the	the	DET
njb-93	73	67	gram	gram	ADJ
njb-93	73	68	positive	positive	ADJ
njb-93	73	69	isolates	isolate	NOUN
njb-93	73	70	,	,	PUNCT
njb-93	73	71	staphylococcus	staphylococcus	NOUN
njb-93	73	72	aureus	aureus	NOUN
njb-93	73	73	(	(	PUNCT
njb-93	73	74	8)	8)	NUM
njb-93	73	75	constitutes	constitute	VERB
njb-93	73	76	(	(	PUNCT
njb-93	73	77	3.30	3.30	NUM
njb-93	73	78	%	%	NOUN
njb-93	73	79	)	)	PUNCT
njb-93	73	80	(	(	PUNCT
njb-93	73	81	table	table	NOUN
njb-93	73	82	1	1	NUM
njb-93	73	83	)	)	PUNCT
njb-93	73	84	.	.	PUNCT
njb-93	74	1	most	most	ADJ
njb-93	74	2	of	of	ADP
njb-93	74	3	the	the	DET
njb-93	74	4	patient	patient	NOUN
njb-93	74	5	were	be	AUX
njb-93	74	6	of	of	ADP
njb-93	74	7	age	age	NOUN
njb-93	74	8	group	group	NOUN
njb-93	74	9	1	1	NUM
njb-93	74	10	-	-	SYM
njb-93	74	11	5	5	NUM
njb-93	74	12	(	(	PUNCT
njb-93	74	13	60.96	60.96	NUM
njb-93	74	14	%	%	NOUN
njb-93	74	15	)	)	PUNCT
njb-93	74	16	followed	follow	VERB
njb-93	74	17	by	by	ADP
njb-93	74	18	age	age	NOUN
njb-93	74	19	<	<	X
njb-93	74	20	1	1	NUM
njb-93	74	21	(	(	PUNCT
njb-93	74	22	18.42	18.42	NUM
njb-93	74	23	%	%	NOUN
njb-93	74	24	)	)	PUNCT
njb-93	74	25	(	(	PUNCT
njb-93	74	26	table	table	NOUN
njb-93	74	27	2	2	NUM
njb-93	74	28	)	)	PUNCT
njb-93	74	29	.	.	PUNCT
njb-93	75	1	table	table	NOUN
njb-93	75	2	2	2	NUM
njb-93	75	3	:	:	PUNCT
njb-93	75	4	demographic	demographic	ADJ
njb-93	75	5	distribution	distribution	NOUN
njb-93	75	6	of	of	ADP
njb-93	75	7	e.	e.	PROPN
njb-93	75	8	coli	coli	PROPN
njb-93	75	9	and	and	CCONJ
njb-93	75	10	klebsiella	klebsiella	PROPN
njb-93	75	11	spp	spp	PROPN
njb-93	75	12	age	age	PROPN
njb-93	75	13	group	group	NOUN
njb-93	75	14	sex	sex	NOUN
njb-93	75	15	of	of	ADP
njb-93	75	16	patient	patient	ADJ
njb-93	75	17	total	total	ADJ
njb-93	75	18	male	male	NOUN
njb-93	75	19	(	(	PUNCT
njb-93	75	20	%	%	INTJ
njb-93	75	21	)	)	PUNCT
njb-93	75	22	female	female	NOUN
njb-93	75	23	(	(	PUNCT
njb-93	75	24	%	%	INTJ
njb-93	75	25	)	)	PUNCT
njb-93	75	26	<	<	X
njb-93	75	27	1	1	NUM
njb-93	75	28	year	year	NOUN
njb-93	75	29	12	12	NUM
njb-93	75	30	(	(	PUNCT
njb-93	75	31	28	28	NUM
njb-93	75	32	%	%	NOUN
njb-93	75	33	)	)	PUNCT
njb-93	75	34	30	30	NUM
njb-93	75	35	(	(	PUNCT
njb-93	75	36	72	72	NUM
njb-93	75	37	%	%	NOUN
njb-93	75	38	)	)	PUNCT
njb-93	75	39	42(18.42	42(18.42	NUM
njb-93	75	40	%	%	NOUN
njb-93	75	41	)	)	PUNCT
njb-93	75	42	1	1	NUM
njb-93	75	43	-	-	SYM
njb-93	75	44	5	5	NUM
njb-93	75	45	49	49	NUM
njb-93	75	46	(	(	PUNCT
njb-93	75	47	35	35	NUM
njb-93	75	48	%	%	NOUN
njb-93	75	49	)	)	PUNCT
njb-93	75	50	90	90	NUM
njb-93	75	51	(	(	PUNCT
njb-93	75	52	65	65	NUM
njb-93	75	53	%	%	NOUN
njb-93	75	54	)	)	PUNCT
njb-93	75	55	139(60.96	139(60.96	NUM
njb-93	75	56	%	%	NOUN
njb-93	75	57	)	)	PUNCT
njb-93	75	58	6	6	NUM
njb-93	75	59	-	-	SYM
njb-93	75	60	10	10	NUM
njb-93	75	61	11	11	NUM
njb-93	75	62	(	(	PUNCT
njb-93	75	63	34.3	34.3	NUM
njb-93	75	64	%	%	NOUN
njb-93	75	65	)	)	PUNCT
njb-93	75	66	21	21	NUM
njb-93	75	67	(	(	PUNCT
njb-93	75	68	65.6	65.6	NUM
njb-93	75	69	%	%	NOUN
njb-93	75	70	)	)	PUNCT
njb-93	75	71	32(14.03	32(14.03	NUM
njb-93	75	72	%	%	NOUN
njb-93	75	73	)	)	PUNCT
njb-93	75	74	11	11	NUM
njb-93	75	75	-	-	SYM
njb-93	75	76	13	13	NUM
njb-93	75	77	3	3	NUM
njb-93	75	78	(	(	PUNCT
njb-93	75	79	20	20	NUM
njb-93	75	80	%	%	NOUN
njb-93	75	81	)	)	PUNCT
njb-93	75	82	12	12	NUM
njb-93	75	83	(	(	PUNCT
njb-93	75	84	80	80	NUM
njb-93	75	85	%	%	NOUN
njb-93	75	86	)	)	PUNCT
njb-93	75	87	15(6.57	15(6.57	NUM
njb-93	75	88	%	%	NOUN
njb-93	75	89	)	)	PUNCT
njb-93	75	90	total	total	NOUN
njb-93	75	91	75	75	NUM
njb-93	75	92	153	153	NUM
njb-93	75	93	228	228	NUM
njb-93	75	94	out	out	ADP
njb-93	75	95	of	of	ADP
njb-93	75	96	200	200	NUM
njb-93	75	97	e.	e.	PROPN
njb-93	75	98	coli	coli	NOUN
njb-93	75	99	isolates	isolate	NOUN
njb-93	75	100	,	,	PUNCT
njb-93	75	101	169(84.5	169(84.5	NUM
njb-93	75	102	%	%	NOUN
njb-93	75	103	)	)	PUNCT
njb-93	75	104	isolates	isolate	NOUN
njb-93	75	105	were	be	AUX
njb-93	75	106	sensitive	sensitive	ADJ
njb-93	75	107	to	to	ADP
njb-93	75	108	nitrofurantoin	nitrofurantoin	NOUN
njb-93	75	109	followed	follow	VERB
njb-93	75	110	by	by	ADP
njb-93	75	111	gentamycin	gentamycin	PROPN
njb-93	75	112	146(73	146(73	NUM
njb-93	75	113	%	%	NOUN
njb-93	75	114	)	)	PUNCT
njb-93	75	115	and	and	CCONJ
njb-93	75	116	cotrimoxazole	cotrimoxazole	PROPN
njb-93	75	117	110(55	110(55	NUM
njb-93	75	118	%	%	NOUN
njb-93	75	119	)	)	PUNCT
njb-93	75	120	.	.	PUNCT
njb-93	76	1	more	more	ADJ
njb-93	76	2	than	than	ADP
njb-93	76	3	30	30	NUM
njb-93	76	4	%	%	NOUN
njb-93	76	5	isolates	isolate	NOUN
njb-93	76	6	were	be	AUX
njb-93	76	7	resistant	resistant	ADJ
njb-93	76	8	to	to	ADP
njb-93	76	9	third	third	ADJ
njb-93	76	10	generation	generation	NOUN
njb-93	76	11	cephalosporins	cephalosporin	NOUN
njb-93	76	12	i.e	i.e	PROPN
njb-93	76	13	ceftriaxone	ceftriaxone	PROPN
njb-93	76	14	and	and	CCONJ
njb-93	76	15	ceftazidime	ceftazidime	PROPN
njb-93	76	16	(	(	PUNCT
njb-93	76	17	table	table	NOUN
njb-93	76	18	3	3	NUM
njb-93	76	19	)	)	PUNCT
njb-93	76	20	.	.	PUNCT
njb-93	77	1	table	table	NOUN
njb-93	77	2	3	3	NUM
njb-93	77	3	:	:	PUNCT
njb-93	77	4	antibiotic	antibiotic	ADJ
njb-93	77	5	susceptibility	susceptibility	NOUN
njb-93	77	6	pattern	pattern	NOUN
njb-93	77	7	of	of	ADP
njb-93	77	8	escherichia	escherichia	NOUN
njb-93	77	9	coli	coli	NOUN
njb-93	77	10	antibiotics	antibiotic	NOUN
njb-93	77	11	susceptibility	susceptibility	NOUN
njb-93	77	12	pattern	pattern	NOUN
njb-93	77	13	(	(	PUNCT
njb-93	77	14	n=200	n=200	PROPN
njb-93	77	15	)	)	PUNCT
njb-93	77	16	sensitive	sensitive	ADJ
njb-93	77	17	(	(	PUNCT
njb-93	77	18	%	%	INTJ
njb-93	77	19	)	)	PUNCT
njb-93	77	20	intermediate	intermediate	ADJ
njb-93	77	21	(	(	PUNCT
njb-93	77	22	%	%	INTJ
njb-93	77	23	)	)	PUNCT
njb-93	77	24	resistance	resistance	NOUN
njb-93	77	25	(	(	PUNCT
njb-93	77	26	%	%	INTJ
njb-93	77	27	)	)	PUNCT
njb-93	77	28	amoxicillin	amoxicillin	PROPN
njb-93	77	29	14	14	NUM
njb-93	77	30	(	(	PUNCT
njb-93	77	31	7	7	NUM
njb-93	77	32	)	)	PUNCT
njb-93	77	33	23	23	NUM
njb-93	77	34	(	(	PUNCT
njb-93	77	35	11.5	11.5	NUM
njb-93	77	36	)	)	PUNCT
njb-93	77	37	163	163	NUM
njb-93	77	38	(	(	PUNCT
njb-93	77	39	81.5	81.5	NUM
njb-93	77	40	)	)	PUNCT
njb-93	77	41	ciprofloxacin	ciprofloxacin	NOUN
njb-93	77	42	91	91	NUM
njb-93	77	43	(	(	PUNCT
njb-93	77	44	45.5	45.5	NUM
njb-93	77	45	)	)	PUNCT
njb-93	77	46	31	31	NUM
njb-93	77	47	(	(	PUNCT
njb-93	77	48	15.5	15.5	NUM
njb-93	77	49	)	)	PUNCT
njb-93	77	50	78	78	NUM
njb-93	77	51	(	(	PUNCT
njb-93	77	52	39	39	NUM
njb-93	77	53	)	)	PUNCT
njb-93	77	54	cotri	cotri	ADJ
njb-93	77	55	-	-	PUNCT
njb-93	77	56	moxazole	moxazole	NOUN
njb-93	77	57	110	110	NUM
njb-93	77	58	(	(	PUNCT
njb-93	77	59	55	55	NUM
njb-93	77	60	)	)	PUNCT
njb-93	77	61	22	22	NUM
njb-93	77	62	(	(	PUNCT
njb-93	77	63	11	11	NUM
njb-93	77	64	)	)	PUNCT
njb-93	77	65	68	68	NUM
njb-93	77	66	(	(	PUNCT
njb-93	77	67	34	34	NUM
njb-93	77	68	)	)	PUNCT
njb-93	77	69	nitrofurantoin	nitrofurantoin	NOUN
njb-93	77	70	169	169	NUM
njb-93	77	71	(	(	PUNCT
njb-93	77	72	84.5	84.5	NUM
njb-93	77	73	)	)	PUNCT
njb-93	77	74	20	20	NUM
njb-93	77	75	(	(	PUNCT
njb-93	77	76	10	10	NUM
njb-93	77	77	)	)	PUNCT
njb-93	77	78	11	11	NUM
njb-93	77	79	(	(	PUNCT
njb-93	77	80	5.5	5.5	NUM
njb-93	77	81	)	)	PUNCT
njb-93	77	82	gentamycin	gentamycin	PROPN
njb-93	77	83	146	146	NUM
njb-93	77	84	(	(	PUNCT
njb-93	77	85	73	73	NUM
njb-93	77	86	)	)	PUNCT
njb-93	77	87	21	21	NUM
njb-93	77	88	(	(	PUNCT
njb-93	77	89	10.5	10.5	NUM
njb-93	77	90	)	)	PUNCT
njb-93	77	91	33	33	NUM
njb-93	77	92	(	(	PUNCT
njb-93	77	93	16.5	16.5	NUM
njb-93	77	94	)	)	PUNCT
njb-93	77	95	ceftriaxone	ceftriaxone	PROPN
njb-93	77	96	108	108	NUM
njb-93	77	97	(	(	PUNCT
njb-93	77	98	54	54	NUM
njb-93	77	99	)	)	PUNCT
njb-93	77	100	30	30	NUM
njb-93	77	101	(	(	PUNCT
njb-93	77	102	15	15	NUM
njb-93	77	103	)	)	PUNCT
njb-93	77	104	62	62	NUM
njb-93	77	105	(	(	PUNCT
njb-93	77	106	31	31	NUM
njb-93	77	107	)	)	PUNCT
njb-93	77	108	ceftazidime	ceftazidime	NOUN
njb-93	77	109	98	98	NUM
njb-93	77	110	(	(	PUNCT
njb-93	77	111	49	49	NUM
njb-93	77	112	)	)	PUNCT
njb-93	77	113	34	34	NUM
njb-93	77	114	(	(	PUNCT
njb-93	77	115	17	17	NUM
njb-93	77	116	)	)	PUNCT
njb-93	77	117	68	68	NUM
njb-93	77	118	(	(	PUNCT
njb-93	77	119	34	34	NUM
njb-93	77	120	)	)	PUNCT
njb-93	77	121	out	out	ADP
njb-93	77	122	of	of	ADP
njb-93	77	123	total	total	ADJ
njb-93	77	124	24k	24k	NOUN
njb-93	77	125	.	.	PUNCT
njb-93	78	1	pneumoniae	pneumoniae	NOUN
njb-93	78	2	isolates	isolate	NOUN
njb-93	78	3	,	,	PUNCT
njb-93	78	4	19(79.2	19(79.2	NUM
njb-93	78	5	%	%	NOUN
njb-93	78	6	)	)	PUNCT
njb-93	78	7	were	be	AUX
njb-93	78	8	sensitive	sensitive	ADJ
njb-93	78	9	towards	towards	ADP
njb-93	78	10	gentamycin	gentamycin	PROPN
njb-93	78	11	,	,	PUNCT
njb-93	78	12	followed	follow	VERB
njb-93	78	13	by	by	ADP
njb-93	78	14	nitrofurantoin	nitrofurantoin	NOUN
njb-93	78	15	17	17	NUM
njb-93	78	16	(	(	PUNCT
njb-93	78	17	71	71	NUM
njb-93	78	18	%	%	NOUN
njb-93	78	19	)	)	PUNCT
njb-93	78	20	,	,	PUNCT
njb-93	78	21	ciprofloxacin	ciprofloxacin	NOUN
njb-93	78	22	16	16	NUM
njb-93	78	23	(	(	PUNCT
njb-93	78	24	67	67	NUM
njb-93	78	25	%	%	NOUN
njb-93	78	26	)	)	PUNCT
njb-93	78	27	and	and	CCONJ
njb-93	78	28	ceftriaxone	ceftriaxone	PROPN
njb-93	78	29	16	16	NUM
njb-93	78	30	(	(	PUNCT
njb-93	78	31	67	67	NUM
njb-93	78	32	%	%	NOUN
njb-93	78	33	)	)	PUNCT
njb-93	78	34	(	(	PUNCT
njb-93	78	35	table	table	NOUN
njb-93	78	36	4	4	NUM
njb-93	78	37	)	)	PUNCT
njb-93	78	38	.	.	PUNCT
njb-93	79	1	table	table	NOUN
njb-93	79	2	4	4	NUM
njb-93	79	3	:	:	PUNCT
njb-93	79	4	antibiotic	antibiotic	ADJ
njb-93	79	5	susceptibility	susceptibility	NOUN
njb-93	79	6	pattern	pattern	NOUN
njb-93	79	7	of	of	ADP
njb-93	79	8	k.	k.	NOUN
njb-93	79	9	pneumoniae	pneumoniae	NOUN
njb-93	79	10	isolates	isolate	NOUN
njb-93	79	11	.	.	PUNCT
njb-93	80	1	antibiotics	antibiotic	NOUN
njb-93	80	2	susceptibility	susceptibility	NOUN
njb-93	80	3	pattern(n=24	pattern(n=24	PROPN
njb-93	80	4	)	)	PUNCT
njb-93	80	5	sensitive	sensitive	ADJ
njb-93	80	6	(	(	PUNCT
njb-93	80	7	%	%	INTJ
njb-93	80	8	)	)	PUNCT
njb-93	80	9	intermediate	intermediate	ADJ
njb-93	80	10	(	(	PUNCT
njb-93	80	11	%	%	INTJ
njb-93	80	12	)	)	PUNCT
njb-93	80	13	resistance	resistance	NOUN
njb-93	80	14	(	(	PUNCT
njb-93	80	15	%	%	INTJ
njb-93	80	16	)	)	PUNCT
njb-93	80	17	amoxicillin	amoxicillin	PROPN
njb-93	80	18	0	0	NUM
njb-93	81	1	(	(	PUNCT
njb-93	81	2	0	0	NUM
njb-93	81	3	)	)	PUNCT
njb-93	81	4	0	0	NUM
njb-93	81	5	(	(	PUNCT
njb-93	81	6	0	0	NUM
njb-93	81	7	)	)	PUNCT
njb-93	81	8	24	24	NUM
njb-93	81	9	(	(	PUNCT
njb-93	81	10	100	100	NUM
njb-93	81	11	)	)	PUNCT
njb-93	81	12	ciprofloxacin	ciprofloxacin	NOUN
njb-93	81	13	16	16	NUM
njb-93	81	14	(	(	PUNCT
njb-93	81	15	67	67	NUM
njb-93	81	16	)	)	PUNCT
njb-93	81	17	4	4	NUM
njb-93	81	18	(	(	PUNCT
njb-93	81	19	17	17	NUM
njb-93	81	20	)	)	PUNCT
njb-93	81	21	4	4	NUM
njb-93	81	22	(	(	PUNCT
njb-93	81	23	17	17	NUM
njb-93	81	24	)	)	PUNCT
njb-93	81	25	cotrimoxazole	cotrimoxazole	PROPN
njb-93	81	26	14	14	NUM
njb-93	81	27	(	(	PUNCT
njb-93	81	28	58	58	NUM
njb-93	81	29	)	)	PUNCT
njb-93	81	30	3	3	NUM
njb-93	81	31	(	(	PUNCT
njb-93	81	32	13	13	NUM
njb-93	81	33	)	)	PUNCT
njb-93	81	34	7	7	NUM
njb-93	81	35	(	(	PUNCT
njb-93	81	36	29	29	NUM
njb-93	81	37	)	)	PUNCT
njb-93	81	38	nitrofurantoin	nitrofurantoin	NOUN
njb-93	81	39	17	17	NUM
njb-93	81	40	(	(	PUNCT
njb-93	81	41	71	71	NUM
njb-93	81	42	)	)	PUNCT
njb-93	81	43	1	1	NUM
njb-93	81	44	(	(	PUNCT
njb-93	81	45	4	4	NUM
njb-93	81	46	)	)	PUNCT
njb-93	81	47	6	6	NUM
njb-93	81	48	(	(	PUNCT
njb-93	81	49	25	25	NUM
njb-93	81	50	)	)	PUNCT
njb-93	81	51	gentamycin	gentamycin	PROPN
njb-93	81	52	19	19	NUM
njb-93	81	53	(	(	PUNCT
njb-93	81	54	79.2	79.2	NUM
njb-93	81	55	)	)	PUNCT
njb-93	81	56	3	3	NUM
njb-93	81	57	(	(	PUNCT
njb-93	81	58	12.5	12.5	NUM
njb-93	81	59	)	)	PUNCT
njb-93	81	60	2	2	NUM
njb-93	81	61	(	(	PUNCT
njb-93	81	62	8.3	8.3	NUM
njb-93	81	63	)	)	PUNCT
njb-93	81	64	ceftriaxone	ceftriaxone	PROPN
njb-93	81	65	16	16	NUM
njb-93	81	66	(	(	PUNCT
njb-93	81	67	67	67	NUM
njb-93	81	68	)	)	PUNCT
njb-93	81	69	2	2	NUM
njb-93	81	70	(	(	PUNCT
njb-93	81	71	8)	8)	NUM
njb-93	81	72	6	6	NUM
njb-93	81	73	(	(	PUNCT
njb-93	81	74	25	25	NUM
njb-93	81	75	)	)	PUNCT
njb-93	81	76	ceftazidime	ceftazidime	NOUN
njb-93	81	77	14	14	NUM
njb-93	81	78	(	(	PUNCT
njb-93	81	79	58	58	NUM
njb-93	81	80	)	)	PUNCT
njb-93	81	81	4	4	NUM
njb-93	81	82	(	(	PUNCT
njb-93	81	83	17	17	NUM
njb-93	81	84	)	)	PUNCT
njb-93	81	85	6	6	NUM
njb-93	81	86	(	(	PUNCT
njb-93	81	87	25	25	NUM
njb-93	81	88	)	)	PUNCT
njb-93	81	89	among	among	ADP
njb-93	81	90	total	total	ADJ
njb-93	81	91	4	4	NUM
njb-93	81	92	k.	k.	NOUN
njb-93	81	93	oxytoca	oxytoca	PROPN
njb-93	81	94	isolates	isolate	NOUN
njb-93	81	95	,	,	PUNCT
njb-93	81	96	all	all	DET
njb-93	81	97	4	4	NUM
njb-93	81	98	were	be	AUX
njb-93	81	99	resistant	resistant	ADJ
njb-93	81	100	to	to	ADP
njb-93	81	101	amoxicillin	amoxicillin	PROPN
njb-93	81	102	,	,	PUNCT
njb-93	81	103	howeversensitive	howeversensitive	ADJ
njb-93	81	104	to	to	ADP
njb-93	81	105	nitrofurantoin	nitrofurantoin	NOUN
njb-93	81	106	.	.	PUNCT
njb-93	81	107	,	,	PUNCT
njb-93	81	108	3	3	NUM
njb-93	81	109	(	(	PUNCT
njb-93	81	110	75	75	NUM
njb-93	81	111	%	%	NOUN
njb-93	81	112	)	)	PUNCT
njb-93	81	113	of	of	ADP
njb-93	81	114	them	they	PRON
njb-93	81	115	were	be	AUX
njb-93	81	116	sensitive	sensitive	ADJ
njb-93	81	117	to	to	ADP
njb-93	81	118	to	to	ADP
njb-93	81	119	cotrimoxazole	cotrimoxazole	PROPN
njb-93	81	120	,	,	PUNCT
njb-93	81	121	followed	follow	VERB
njb-93	81	122	by	by	ADP
njb-93	81	123	ciprofloxacin	ciprofloxacin	NOUN
njb-93	81	124	.	.	PUNCT
njb-93	82	1	68	68	NUM
njb-93	82	2	(	(	PUNCT
njb-93	82	3	34	34	NUM
njb-93	82	4	%	%	NOUN
njb-93	82	5	)	)	PUNCT
njb-93	82	6	of	of	ADP
njb-93	82	7	e.	e.	PROPN
njb-93	82	8	coli	coli	PROPN
njb-93	82	9	isolates	isolate	NOUN
njb-93	82	10	,	,	PUNCT
njb-93	82	11	6(25	6(25	NUM
njb-93	82	12	%	%	NOUN
njb-93	82	13	)	)	PUNCT
njb-93	82	14	of	of	ADP
njb-93	82	15	klebsiella	klebsiella	PROPN
njb-93	82	16	pneumoniae	pneumoniae	PROPN
njb-93	82	17	isolates	isolate	NOUN
njb-93	82	18	and	and	CCONJ
njb-93	82	19	2	2	NUM
njb-93	82	20	(	(	PUNCT
njb-93	82	21	50	50	NUM
njb-93	82	22	%	%	NOUN
njb-93	82	23	)	)	PUNCT
njb-93	82	24	of	of	ADP
njb-93	82	25	klebsiella	klebsiella	PROPN
njb-93	82	26	oxytoca	oxytoca	PROPN
njb-93	82	27	isolates	isolate	NOUN
njb-93	82	28	,	,	PUNCT
njb-93	82	29	making	make	VERB
njb-93	82	30	a	a	DET
njb-93	82	31	total	total	NOUN
njb-93	82	32	of	of	ADP
njb-93	82	33	76(33.33	76(33.33	NUM
njb-93	82	34	%	%	NOUN
njb-93	82	35	)	)	PUNCT
njb-93	82	36	isolates	isolate	NOUN
njb-93	82	37	were	be	AUX
njb-93	82	38	multi	multi	ADJ
njb-93	82	39	-	-	ADJ
njb-93	82	40	drug	drug	ADJ
njb-93	82	41	resistant	resistant	ADJ
njb-93	82	42	(	(	PUNCT
njb-93	82	43	table	table	NOUN
njb-93	82	44	5	5	NUM
njb-93	82	45	)	)	PUNCT
njb-93	82	46	.	.	PUNCT
njb-93	83	1	table	table	NOUN
njb-93	83	2	5	5	NUM
njb-93	83	3	:	:	PUNCT
njb-93	83	4	distribution	distribution	NOUN
njb-93	83	5	of	of	ADP
njb-93	83	6	mdr	mdr	NOUN
njb-93	83	7	isolates	isolate	VERB
njb-93	83	8	bacterial	bacterial	ADJ
njb-93	83	9	isolates	isolate	NOUN
njb-93	83	10	total	total	NOUN
njb-93	83	11	mdr	mdr	NOUN
njb-93	83	12	(	(	PUNCT
njb-93	83	13	%	%	INTJ
njb-93	83	14	)	)	PUNCT
njb-93	83	15	escherichia	escherichia	NOUN
njb-93	83	16	coli	coli	NOUN
njb-93	83	17	200	200	NUM
njb-93	83	18	68	68	NUM
njb-93	83	19	(	(	PUNCT
njb-93	83	20	34	34	NUM
njb-93	83	21	%	%	NOUN
njb-93	83	22	)	)	PUNCT
njb-93	83	23	klebsiella	klebsiella	PROPN
njb-93	83	24	pneumoniae	pneumoniae	NOUN
njb-93	83	25	24	24	NUM
njb-93	83	26	6	6	NUM
njb-93	83	27	(	(	PUNCT
njb-93	83	28	25	25	NUM
njb-93	83	29	%	%	NOUN
njb-93	83	30	)	)	PUNCT
njb-93	83	31	klebsiella	klebsiella	PROPN
njb-93	83	32	oxytoca	oxytoca	PROPN
njb-93	83	33	4	4	NUM
njb-93	83	34	2	2	NUM
njb-93	83	35	(	(	PUNCT
njb-93	83	36	50	50	NUM
njb-93	83	37	%	%	NOUN
njb-93	83	38	)	)	PUNCT
njb-93	83	39	total	total	ADJ
njb-93	83	40	228	228	NUM
njb-93	83	41	76(33.33	76(33.33	NUM
njb-93	83	42	%	%	NOUN
njb-93	83	43	)	)	PUNCT
njb-93	83	44	out	out	ADP
njb-93	83	45	of	of	ADP
njb-93	83	46	228	228	NUM
njb-93	83	47	isolates	isolate	NOUN
njb-93	83	48	,	,	PUNCT
njb-93	83	49	61	61	NUM
njb-93	83	50	isolates	isolate	NOUN
njb-93	83	51	gave	give	VERB
njb-93	83	52	esbl	esbl	PROPN
njb-93	83	53	screening	screen	VERB
njb-93	83	54	test	test	NOUN
njb-93	83	55	positive	positive	ADJ
njb-93	83	56	.	.	PUNCT
njb-93	84	1	51	51	NUM
njb-93	84	2	isolates	isolate	NOUN
njb-93	84	3	of	of	ADP
njb-93	84	4	e.	e.	PROPN
njb-93	84	5	coli	coli	PROPN
njb-93	84	6	and	and	CCONJ
njb-93	84	7	3	3	NUM
njb-93	84	8	isolates	isolate	NOUN
njb-93	84	9	of	of	ADP
njb-93	84	10	klebsiella	klebsiella	PROPN
njb-93	84	11	pneumoniae	pneumoniae	NOUN
njb-93	84	12	making	make	VERB
njb-93	84	13	a	a	DET
njb-93	84	14	total	total	NOUN
njb-93	84	15	of	of	ADP
njb-93	84	16	54(23.68	54(23.68	NUM
njb-93	84	17	%	%	NOUN
njb-93	84	18	)	)	PUNCT
njb-93	84	19	were	be	AUX
njb-93	84	20	confirmed	confirm	VERB
njb-93	84	21	as	as	ADP
njb-93	84	22	esbl	esbl	NOUN
njb-93	84	23	producers	producer	NOUN
njb-93	84	24	.	.	PUNCT
njb-93	85	1	none	none	NOUN
njb-93	85	2	of	of	ADP
njb-93	85	3	k.	k.	PROPN
njb-93	85	4	oxytoca	oxytoca	PROPN
njb-93	85	5	was	be	AUX
njb-93	85	6	esbl	esbl	PROPN
njb-93	85	7	producer	producer	NOUN
njb-93	85	8	(	(	PUNCT
njb-93	85	9	table	table	NOUN
njb-93	85	10	6	6	NUM
njb-93	85	11	)	)	PUNCT
njb-93	85	12	.	.	PUNCT
njb-93	86	1	table	table	NOUN
njb-93	86	2	6	6	NUM
njb-93	86	3	:	:	PUNCT
njb-93	86	4	detection	detection	NOUN
njb-93	86	5	of	of	ADP
njb-93	86	6	esbl	esbl	NOUN
njb-93	86	7	by	by	ADP
njb-93	86	8	combination	combination	NOUN
njb-93	86	9	disk	disk	NOUN
njb-93	86	10	method	method	NOUN
njb-93	86	11	.	.	PUNCT
njb-93	87	1	organism	organism	NOUN
njb-93	87	2	significant	significant	ADJ
njb-93	87	3	growth	growth	NOUN
njb-93	87	4	screening	screen	VERB
njb-93	87	5	test	test	NOUN
njb-93	87	6	positive	positive	ADJ
njb-93	87	7	confirmatory	confirmatory	ADJ
njb-93	87	8	test(combination	test(combination	NOUN
njb-93	87	9	disk	disk	NOUN
njb-93	87	10	method	method	NOUN
njb-93	87	11	)	)	PUNCT
njb-93	87	12	increase	increase	NOUN
njb-93	87	13	in	in	ADP
njb-93	87	14	diameter	diameter	NOUN
njb-93	87	15	≥5	≥5	NUM
njb-93	87	16	mm	mm	NOUN
njb-93	87	17	escherichia	escherichia	NOUN
njb-93	87	18	coli	coli	NOUN
njb-93	87	19	200	200	NUM
njb-93	87	20	57	57	NUM
njb-93	87	21	51(25.5	51(25.5	NUM
njb-93	87	22	%	%	NOUN
njb-93	87	23	)	)	PUNCT
njb-93	87	24	klebsiella	klebsiella	PROPN
njb-93	87	25	pneumonia	pneumonia	PROPN
njb-93	87	26	24	24	NUM
njb-93	87	27	4	4	NUM
njb-93	87	28	3(12.5	3(12.5	NUM
njb-93	87	29	%	%	NOUN
njb-93	87	30	)	)	PUNCT
njb-93	87	31	klebsiella	klebsiella	PROPN
njb-93	87	32	oxytoca	oxytoca	PROPN
njb-93	87	33	4	4	NUM
njb-93	87	34	total	total	NOUN
njb-93	87	35	228	228	NUM
njb-93	87	36	61	61	NUM
njb-93	87	37	54(23.68	54(23.68	NUM
njb-93	87	38	%	%	NOUN
njb-93	87	39	)	)	PUNCT
njb-93	87	40	out	out	ADP
njb-93	87	41	of	of	ADP
njb-93	87	42	75	75	NUM
njb-93	87	43	isolates	isolate	NOUN
njb-93	87	44	from	from	ADP
njb-93	87	45	male	male	NOUN
njb-93	87	46	,	,	PUNCT
njb-93	87	47	12(16	12(16	NUM
njb-93	87	48	%	%	NOUN
njb-93	87	49	)	)	PUNCT
njb-93	87	50	were	be	AUX
njb-93	87	51	esbl	esbl	NOUN
njb-93	87	52	producer	producer	NOUN
njb-93	87	53	and	and	CCONJ
njb-93	87	54	out	out	ADP
njb-93	87	55	of	of	ADP
njb-93	87	56	153	153	NUM
njb-93	87	57	isolates	isolate	NOUN
njb-93	87	58	from	from	ADP
njb-93	87	59	female	female	ADJ
njb-93	87	60	42(27.54	42(27.54	NUM
njb-93	87	61	%	%	NOUN
njb-93	87	62	)	)	PUNCT
njb-93	87	63	were	be	AUX
njb-93	87	64	esbl	esbl	NOUN
njb-93	87	65	producer	producer	NOUN
njb-93	87	66	.	.	PUNCT
njb-93	88	1	more	more	ADJ
njb-93	88	2	female	female	ADJ
njb-93	88	3	was	be	AUX
njb-93	88	4	infected	infect	VERB
njb-93	88	5	as	as	ADP
njb-93	88	6	compared	compare	VERB
njb-93	88	7	to	to	ADP
njb-93	88	8	male	male	NOUN
njb-93	88	9	,	,	PUNCT
njb-93	88	10	also	also	ADV
njb-93	88	11	chi	chi	ADJ
njb-93	88	12	-	-	PUNCT
njb-93	88	13	square	square	ADJ
njb-93	88	14	test	test	NOUN
njb-93	88	15	suggests	suggest	VERB
njb-93	88	16	a	a	DET
njb-93	88	17	significant	significant	ADJ
njb-93	88	18	association	association	NOUN
njb-93	88	19	in	in	ADP
njb-93	88	20	between	between	ADP
njb-93	88	21	sex	sex	NOUN
njb-93	88	22	of	of	ADP
njb-93	88	23	a	a	DET
njb-93	88	24	patient	patient	NOUN
njb-93	88	25	and	and	CCONJ
njb-93	88	26	esbl	esbl	PROPN
njb-93	89	1	producers(p	producers(p	PROPN
njb-93	89	2	-	-	PUNCT
njb-93	89	3	value<0.05	value<0.05	PROPN
njb-93	89	4	)	)	PUNCT
njb-93	89	5	(	(	PUNCT
njb-93	89	6	table	table	NOUN
njb-93	89	7	7	7	NUM
njb-93	89	8	)	)	PUNCT
njb-93	89	9	.	.	PUNCT
njb-93	90	1	table	table	NOUN
njb-93	90	2	7	7	NUM
njb-93	90	3	:	:	PUNCT
njb-93	90	4	gender	gender	NOUN
njb-93	90	5	wise	wise	ADJ
njb-93	90	6	distribution	distribution	NOUN
njb-93	90	7	of	of	ADP
njb-93	90	8	esbl	esbl	NOUN
njb-93	90	9	producing	produce	VERB
njb-93	90	10	isolates	isolate	NOUN
njb-93	90	11	.	.	PUNCT
njb-93	91	1	sex	sex	NOUN
njb-93	91	2	esbl	esbl	PROPN
njb-93	91	3	producer	producer	NOUN
njb-93	91	4	esbl	esbl	NOUN
njb-93	91	5	nonproducer	nonproducer	NOUN
njb-93	91	6	total	total	ADJ
njb-93	91	7	p	p	NOUN
njb-93	91	8	-	-	PUNCT
njb-93	91	9	value	value	NOUN
njb-93	91	10	male	male	ADJ
njb-93	91	11	12(16	12(16	NUM
njb-93	91	12	%	%	NOUN
njb-93	91	13	)	)	PUNCT
njb-93	91	14	63(84	63(84	NUM
njb-93	91	15	%	%	NOUN
njb-93	91	16	)	)	PUNCT
njb-93	91	17	75	75	NUM
njb-93	91	18	<	<	X
njb-93	91	19	0.05	0.05	NUM
njb-93	91	20	female	female	ADJ
njb-93	91	21	42(27.45	42(27.45	NUM
njb-93	91	22	%	%	NOUN
njb-93	91	23	)	)	PUNCT
njb-93	92	1	111(72.54	111(72.54	NUM
njb-93	92	2	%	%	NOUN
njb-93	92	3	)	)	PUNCT
njb-93	92	4	153	153	NUM
njb-93	92	5	total	total	ADJ
njb-93	92	6	54(23.68	54(23.68	NUM
njb-93	92	7	%	%	NOUN
njb-93	92	8	)	)	PUNCT
njb-93	92	9	174(76.31	174(76.31	NUM
njb-93	92	10	%	%	NOUN
njb-93	92	11	)	)	PUNCT
njb-93	92	12	228	228	NUM
njb-93	93	1	among	among	ADP
njb-93	93	2	culture	culture	NOUN
njb-93	93	3	positive	positive	ADJ
njb-93	93	4	cases	case	NOUN
njb-93	93	5	,	,	PUNCT
njb-93	93	6	47	47	NUM
njb-93	93	7	were	be	AUX
njb-93	93	8	from	from	ADP
njb-93	93	9	inpatient	inpatient	NOUN
njb-93	93	10	and	and	CCONJ
njb-93	93	11	remaining	remain	VERB
njb-93	93	12	181	181	NUM
njb-93	93	13	were	be	AUX
njb-93	93	14	from	from	ADP
njb-93	93	15	out	out	ADJ
njb-93	93	16	-	-	PUNCT
njb-93	93	17	patient	patient	NOUN
njb-93	93	18	.	.	PUNCT
njb-93	94	1	among	among	ADP
njb-93	94	2	47	47	NUM
njb-93	94	3	in	in	ADP
njb-93	94	4	-	-	PUNCT
njb-93	94	5	patient	patient	NOUN
njb-93	94	6	,	,	PUNCT
njb-93	94	7	17(36.17	17(36.17	NUM
njb-93	94	8	%	%	NOUN
njb-93	94	9	)	)	PUNCT
njb-93	94	10	was	be	AUX
njb-93	94	11	found	find	VERB
njb-93	94	12	to	to	PART
njb-93	94	13	be	be	AUX
njb-93	94	14	esbl	esbl	NOUN
njb-93	94	15	positives	positive	NOUN
njb-93	94	16	.	.	PUNCT
njb-93	95	1	similarly	similarly	ADV
njb-93	95	2	,	,	PUNCT
njb-93	95	3	among	among	ADP
njb-93	95	4	181	181	NUM
njb-93	95	5	out	out	NOUN
njb-93	95	6	-	-	PUNCT
njb-93	95	7	patient	patient	NOUN
njb-93	95	8	,	,	PUNCT
njb-93	95	9	37(20.44	37(20.44	NUM
njb-93	95	10	%	%	NOUN
njb-93	95	11	)	)	PUNCT
njb-93	95	12	was	be	AUX
njb-93	95	13	found	find	VERB
njb-93	95	14	to	to	PART
njb-93	95	15	be	be	AUX
njb-93	95	16	esbl	esbl	NOUN
njb-93	95	17	positives	positive	NOUN
njb-93	95	18	(	(	PUNCT
njb-93	95	19	table	table	NOUN
njb-93	95	20	8)	8)	NUM
njb-93	95	21	.	.	PUNCT
njb-93	96	1	all	all	DET
njb-93	96	2	51	51	NUM
njb-93	96	3	esbl	esbl	X
njb-93	96	4	producing	produce	VERB
njb-93	96	5	isolates	isolate	NOUN
njb-93	96	6	of	of	ADP
njb-93	96	7	e.	e.	PROPN
njb-93	96	8	coli	coli	PROPN
njb-93	96	9	were	be	AUX
njb-93	96	10	sensitive	sensitive	ADJ
njb-93	96	11	to	to	ADP
njb-93	96	12	imipenem	imipenem	PROPN
njb-93	96	13	,	,	PUNCT
njb-93	96	14	piperacillin	piperacillin	PROPN
njb-93	96	15	-	-	PUNCT
njb-93	96	16	tazobactam	tazobactam	NOUN
njb-93	96	17	,	,	PUNCT
njb-93	96	18	tigecycline	tigecycline	NOUN
njb-93	96	19	and	and	CCONJ
njb-93	96	20	amikacin	amikacin	PROPN
njb-93	96	21	.	.	PUNCT
njb-93	97	1	94.2%and	94.2%and	NUM
njb-93	97	2	92.2	92.2	NUM
njb-93	97	3	%	%	NOUN
njb-93	97	4	of	of	ADP
njb-93	97	5	e.	e.	PROPN
njb-93	97	6	coli	coli	PROPN
njb-93	97	7	were	be	AUX
njb-93	97	8	resistant	resistant	ADJ
njb-93	97	9	to	to	ADP
njb-93	97	10	ceftriaxone	ceftriaxone	PROPN
njb-93	97	11	and	and	CCONJ
njb-93	97	12	ceftazidime	ceftazidime	PROPN
njb-93	97	13	,	,	PUNCT
njb-93	97	14	respectively	respectively	ADV
njb-93	97	15	.	.	PUNCT
njb-93	98	1	nepal	nepal	ADJ
njb-93	98	2	journal	journal	PROPN
njb-93	98	3	of	of	ADP
njb-93	98	4	biotechnology	biotechnology	NOUN
njb-93	98	5	.	.	PUNCT
njb-93	99	1	d	d	X
njb-93	99	2	e	e	PROPN
njb-93	99	3	c	c	PROPN
njb-93	99	4	.	.	PUNCT
njb-93	100	1	2	2	NUM
njb-93	100	2	0	0	NUM
njb-93	100	3	1	1	NUM
njb-93	100	4	7	7	NUM
njb-93	100	5	vol	vol	NOUN
njb-93	100	6	.	.	PROPN
njb-93	101	1	5	5	NUM
njb-93	101	2	,	,	PUNCT
njb-93	101	3	no	no	NOUN
njb-93	101	4	.	.	NOUN
njb-93	101	5	1	1	NUM
njb-93	101	6	:	:	SYM
njb-93	101	7	32	32	NUM
njb-93	101	8	-	-	SYM
njb-93	101	9	38	38	NUM
njb-93	101	10	rimal	rimal	NOUN
njb-93	101	11	et	et	PROPN
njb-93	101	12	al	al	PROPN
njb-93	101	13	.	.	PUNCT
njb-93	102	1	©	©	PROPN
njb-93	102	2	njb	njb	PROPN
njb-93	102	3	,	,	PUNCT
njb-93	102	4	biotechnology	biotechnology	NOUN
njb-93	102	5	society	society	NOUN
njb-93	102	6	of	of	ADP
njb-93	102	7	nepal	nepal	ADJ
njb-93	102	8	35	35	NUM
njb-93	102	9	nepjol.info/index.php/njb	nepjol.info/index.php/njb	ADJ
njb-93	102	10	furthermore	furthermore	ADV
njb-93	102	11	,	,	PUNCT
njb-93	102	12	88.2	88.2	NUM
njb-93	102	13	%	%	NOUN
njb-93	102	14	and	and	CCONJ
njb-93	102	15	31.4	31.4	NUM
njb-93	102	16	%	%	NOUN
njb-93	102	17	of	of	ADP
njb-93	102	18	e.	e.	PROPN
njb-93	102	19	coli	coli	PROPN
njb-93	102	20	were	be	AUX
njb-93	102	21	resistant	resistant	ADJ
njb-93	102	22	to	to	PART
njb-93	102	23	cefepime	cefepime	VERB
njb-93	102	24	and	and	CCONJ
njb-93	102	25	meropenem	meropenem	PROPN
njb-93	102	26	,	,	PUNCT
njb-93	102	27	respectively	respectively	ADV
njb-93	102	28	(	(	PUNCT
njb-93	102	29	table	table	NOUN
njb-93	102	30	9	9	NUM
njb-93	102	31	)	)	PUNCT
njb-93	102	32	.	.	PUNCT
njb-93	103	1	all	all	PRON
njb-93	103	2	of	of	ADP
njb-93	103	3	the	the	DET
njb-93	103	4	3	3	NUM
njb-93	103	5	esbl	esbl	X
njb-93	103	6	producing	produce	VERB
njb-93	103	7	k.	k.	NOUN
njb-93	103	8	pneumoniae	pneumoniae	NOUN
njb-93	103	9	isolates	isolate	NOUN
njb-93	103	10	were	be	AUX
njb-93	103	11	sensitive	sensitive	ADJ
njb-93	103	12	to	to	ADP
njb-93	103	13	imipenem	imipenem	PROPN
njb-93	103	14	,	,	PUNCT
njb-93	103	15	meropenem	meropenem	PROPN
njb-93	103	16	,	,	PUNCT
njb-93	103	17	piperacillin	piperacillin	PROPN
njb-93	103	18	-	-	PUNCT
njb-93	103	19	tazobactam	tazobactam	NOUN
njb-93	103	20	,	,	PUNCT
njb-93	103	21	tigecycline	tigecycline	NOUN
njb-93	103	22	,	,	PUNCT
njb-93	103	23	and	and	CCONJ
njb-93	103	24	amikacin	amikacin	PROPN
njb-93	103	25	.	.	PUNCT
njb-93	104	1	all	all	PRON
njb-93	104	2	of	of	ADP
njb-93	104	3	the	the	DET
njb-93	104	4	isolates	isolate	NOUN
njb-93	104	5	were	be	AUX
njb-93	104	6	resistant	resistant	ADJ
njb-93	104	7	to	to	PART
njb-93	104	8	cefepime	cefepime	VERB
njb-93	104	9	and	and	CCONJ
njb-93	104	10	amoxicillin	amoxicillin	PROPN
njb-93	104	11	.	.	PUNCT
njb-93	105	1	table	table	NOUN
njb-93	105	2	9	9	NUM
njb-93	105	3	:	:	PUNCT
njb-93	105	4	antibioitic	antibioitic	ADJ
njb-93	105	5	susceptibility	susceptibility	NOUN
njb-93	105	6	pattern	pattern	NOUN
njb-93	105	7	of	of	ADP
njb-93	105	8	esbl	esbl	NOUN
njb-93	105	9	producing	produce	VERB
njb-93	105	10	strain	strain	NOUN
njb-93	105	11	of	of	ADP
njb-93	105	12	e.	e.	PROPN
njb-93	105	13	coli	coli	PROPN
njb-93	105	14	antibiotics	antibiotics	PROPN
njb-93	105	15	e.	e.	PROPN
njb-93	105	16	coli	coli	PROPN
njb-93	105	17	(	(	PUNCT
njb-93	105	18	n=51	n=51	PROPN
njb-93	105	19	)	)	PUNCT
njb-93	105	20	sensitive	sensitive	ADJ
njb-93	105	21	sensitive	sensitive	ADJ
njb-93	105	22	%	%	NOUN
njb-93	105	23	resistance	resistance	NOUN
njb-93	105	24	resistance	resistance	NOUN
njb-93	105	25	%	%	NOUN
njb-93	105	26	amoxicillin	amoxicillin	PROPN
njb-93	105	27	51	51	NUM
njb-93	105	28	100	100	NUM
njb-93	105	29	ciprofloxacin	ciprofloxacin	NOUN
njb-93	105	30	13	13	NUM
njb-93	105	31	25.5	25.5	NUM
njb-93	105	32	38	38	NUM
njb-93	105	33	74.5	74.5	NUM
njb-93	105	34	cotrimoxazole	cotrimoxazole	PROPN
njb-93	105	35	13	13	NUM
njb-93	105	36	25.5	25.5	NUM
njb-93	105	37	38	38	NUM
njb-93	105	38	74.5	74.5	NUM
njb-93	105	39	nitrofurantoin	nitrofurantoin	NOUN
njb-93	105	40	48	48	NUM
njb-93	105	41	94.1	94.1	NUM
njb-93	105	42	3	3	NUM
njb-93	105	43	5.9	5.9	NUM
njb-93	105	44	gentamicin	gentamicin	NOUN
njb-93	105	45	32	32	NUM
njb-93	105	46	66.7	66.7	NUM
njb-93	105	47	19	19	NUM
njb-93	105	48	37.3	37.3	NUM
njb-93	105	49	ceftriaxone	ceftriaxone	NOUN
njb-93	105	50	3	3	NUM
njb-93	105	51	5.9	5.9	NUM
njb-93	105	52	48	48	NUM
njb-93	105	53	94.1	94.1	NUM
njb-93	105	54	ceftazidime	ceftazidime	NOUN
njb-93	105	55	4	4	NUM
njb-93	105	56	7.8	7.8	NUM
njb-93	105	57	47	47	NUM
njb-93	105	58	92.2	92.2	NUM
njb-93	105	59	imipenem	imipenem	PROPN
njb-93	105	60	51	51	NUM
njb-93	105	61	100	100	NUM
njb-93	105	62	0	0	NUM
njb-93	105	63	0	0	NUM
njb-93	105	64	meropenem	meropenem	NOUN
njb-93	105	65	35	35	NUM
njb-93	105	66	68.6	68.6	NUM
njb-93	105	67	16	16	NUM
njb-93	105	68	31.4	31.4	NUM
njb-93	105	69	cefepime	cefepime	ADV
njb-93	105	70	6	6	NUM
njb-93	105	71	11.8	11.8	NUM
njb-93	105	72	45	45	NUM
njb-93	105	73	88.2	88.2	NUM
njb-93	105	74	piperacillin	piperacillin	NOUN
njb-93	105	75	51	51	NUM
njb-93	105	76	100	100	NUM
njb-93	105	77	tigecycline	tigecycline	NOUN
njb-93	105	78	51	51	NUM
njb-93	105	79	100	100	NUM
njb-93	105	80	amikacin	amikacin	PROPN
njb-93	105	81	51	51	NUM
njb-93	105	82	100	100	NUM
njb-93	105	83	discussion	discussion	NOUN
njb-93	105	84	out	out	ADP
njb-93	105	85	of	of	ADP
njb-93	105	86	1018	1018	NUM
njb-93	105	87	mid	mid	ADJ
njb-93	105	88	-	-	ADJ
njb-93	105	89	stream	stream	ADJ
njb-93	105	90	urine	urine	NOUN
njb-93	105	91	sample	sample	NOUN
njb-93	105	92	,	,	PUNCT
njb-93	105	93	243	243	NUM
njb-93	105	94	(	(	PUNCT
njb-93	105	95	23.87	23.87	NUM
njb-93	105	96	%	%	NOUN
njb-93	105	97	)	)	PUNCT
njb-93	105	98	showed	show	VERB
njb-93	105	99	significant	significant	ADJ
njb-93	105	100	growth	growth	NOUN
njb-93	105	101	.	.	PUNCT
njb-93	106	1	similar	similar	ADJ
njb-93	106	2	result	result	NOUN
njb-93	106	3	was	be	AUX
njb-93	106	4	obtained	obtain	VERB
njb-93	106	5	by	by	ADP
njb-93	106	6	bhandari	bhandari	PROPN
njb-93	106	7	(	(	PUNCT
njb-93	106	8	2013	2013	NUM
njb-93	106	9	)	)	PUNCT
njb-93	106	10	where	where	SCONJ
njb-93	106	11	growth	growth	NOUN
njb-93	106	12	positivity	positivity	NOUN
njb-93	106	13	was	be	AUX
njb-93	106	14	found	find	VERB
njb-93	106	15	to	to	PART
njb-93	106	16	be	be	AUX
njb-93	106	17	23.36	23.36	NUM
njb-93	106	18	%	%	NOUN
njb-93	106	19	[	[	PUNCT
njb-93	106	20	17	17	NUM
njb-93	106	21	]	]	PUNCT
njb-93	106	22	.	.	PUNCT
njb-93	107	1	similarly	similarly	ADV
njb-93	107	2	,	,	PUNCT
njb-93	107	3	the	the	DET
njb-93	107	4	study	study	NOUN
njb-93	107	5	carried	carry	VERB
njb-93	107	6	out	out	ADP
njb-93	107	7	in	in	ADP
njb-93	107	8	india	india	PROPN
njb-93	107	9	by	by	ADP
njb-93	107	10	niranjan	niranjan	PROPN
njb-93	107	11	et	et	PROPN
njb-93	107	12	al	al	PROPN
njb-93	107	13	(	(	PUNCT
njb-93	107	14	2014	2014	NUM
njb-93	107	15	)	)	PUNCT
njb-93	107	16	yielded	yield	VERB
njb-93	107	17	18.5	18.5	NUM
njb-93	107	18	%	%	NOUN
njb-93	107	19	significant	significant	ADJ
njb-93	107	20	growth	growth	NOUN
njb-93	107	21	[	[	PUNCT
njb-93	107	22	18	18	NUM
njb-93	107	23	]	]	PUNCT
njb-93	107	24	.	.	PUNCT
njb-93	108	1	however	however	ADV
njb-93	108	2	,	,	PUNCT
njb-93	108	3	our	our	PRON
njb-93	108	4	result	result	NOUN
njb-93	108	5	is	be	AUX
njb-93	108	6	low	low	ADJ
njb-93	108	7	as	as	SCONJ
njb-93	108	8	compared	compare	VERB
njb-93	108	9	to	to	ADP
njb-93	108	10	that	that	PRON
njb-93	108	11	reported	report	VERB
njb-93	108	12	from	from	ADP
njb-93	108	13	south	south	PROPN
njb-93	108	14	africa	africa	PROPN
njb-93	108	15	(	(	PUNCT
njb-93	108	16	51	51	NUM
njb-93	108	17	%	%	NOUN
njb-93	108	18	)	)	PUNCT
njb-93	108	19	by	by	ADP
njb-93	108	20	habte	habte	PROPN
njb-93	108	21	et	et	X
njb-93	108	22	al	al	PROPN
njb-93	108	23	(	(	PUNCT
njb-93	108	24	2009	2009	NUM
njb-93	108	25	)	)	PUNCT
njb-93	109	1	[	[	PUNCT
njb-93	109	2	19	19	NUM
njb-93	109	3	]	]	PUNCT
njb-93	109	4	.	.	PUNCT
njb-93	110	1	a	a	DET
njb-93	110	2	study	study	NOUN
njb-93	110	3	conducted	conduct	VERB
njb-93	110	4	in	in	ADP
njb-93	110	5	nepal	nepal	ADJ
njb-93	110	6	by	by	ADP
njb-93	110	7	bhatta	bhatta	PROPN
njb-93	110	8	et	et	X
njb-93	110	9	al	al	PROPN
njb-93	110	10	(	(	PUNCT
njb-93	110	11	2013	2013	NUM
njb-93	110	12	)	)	PUNCT
njb-93	110	13	,	,	PUNCT
njb-93	110	14	demonstrated	demonstrate	VERB
njb-93	110	15	similar	similar	ADJ
njb-93	110	16	result	result	NOUN
njb-93	110	17	with	with	ADP
njb-93	110	18	27.3	27.3	NUM
njb-93	110	19	%	%	NOUN
njb-93	110	20	significant	significant	ADJ
njb-93	110	21	growth	growth	NOUN
njb-93	110	22	[	[	PUNCT
njb-93	110	23	20	20	NUM
njb-93	110	24	]	]	PUNCT
njb-93	110	25	.	.	PUNCT
njb-93	111	1	the	the	DET
njb-93	111	2	rate	rate	NOUN
njb-93	111	3	of	of	ADP
njb-93	111	4	infection	infection	NOUN
njb-93	111	5	found	find	VERB
njb-93	111	6	in	in	ADP
njb-93	111	7	female	female	ADJ
njb-93	111	8	patients	patient	NOUN
njb-93	111	9	was	be	AUX
njb-93	111	10	163/684	163/684	PROPN
njb-93	111	11	(	(	PUNCT
njb-93	111	12	23.83	23.83	NUM
njb-93	111	13	%	%	NOUN
njb-93	111	14	)	)	PUNCT
njb-93	111	15	and	and	CCONJ
njb-93	111	16	in	in	ADP
njb-93	111	17	male	male	NOUN
njb-93	111	18	,	,	PUNCT
njb-93	111	19	the	the	DET
njb-93	111	20	rate	rate	NOUN
njb-93	111	21	of	of	ADP
njb-93	111	22	infections	infection	NOUN
njb-93	111	23	was	be	AUX
njb-93	111	24	found	find	VERB
njb-93	111	25	to	to	PART
njb-93	111	26	be	be	AUX
njb-93	111	27	80/354	80/354	NUM
njb-93	111	28	(	(	PUNCT
njb-93	111	29	22.59	22.59	NUM
njb-93	111	30	%	%	NOUN
njb-93	111	31	)	)	PUNCT
njb-93	111	32	.	.	PUNCT
njb-93	112	1	there	there	PRON
njb-93	112	2	was	be	VERB
njb-93	112	3	n’t	not	PART
njb-93	112	4	any	any	DET
njb-93	112	5	huge	huge	ADJ
njb-93	112	6	difference	difference	NOUN
njb-93	112	7	between	between	ADP
njb-93	112	8	rate	rate	NOUN
njb-93	112	9	of	of	ADP
njb-93	112	10	infection	infection	NOUN
njb-93	112	11	in	in	ADP
njb-93	112	12	male	male	ADJ
njb-93	112	13	and	and	CCONJ
njb-93	112	14	female	female	ADJ
njb-93	112	15	children	child	NOUN
njb-93	112	16	patient	patient	NOUN
njb-93	112	17	.	.	PUNCT
njb-93	113	1	this	this	DET
njb-93	113	2	result	result	NOUN
njb-93	113	3	is	be	AUX
njb-93	113	4	in	in	ADP
njb-93	113	5	contrast	contrast	NOUN
njb-93	113	6	to	to	ADP
njb-93	113	7	the	the	DET
njb-93	113	8	earlier	early	ADJ
njb-93	113	9	studies	study	NOUN
njb-93	113	10	by	by	ADP
njb-93	113	11	thakur	thakur	PROPN
njb-93	113	12	et	et	X
njb-93	113	13	al	al	PROPN
njb-93	113	14	(	(	PUNCT
njb-93	113	15	2013	2013	NUM
njb-93	113	16	)	)	PUNCT
njb-93	113	17	where	where	SCONJ
njb-93	113	18	56.64	56.64	NUM
njb-93	113	19	%	%	NOUN
njb-93	113	20	female	female	NOUN
njb-93	113	21	and	and	CCONJ
njb-93	113	22	43.36	43.36	NUM
njb-93	113	23	%	%	NOUN
njb-93	113	24	male	male	ADJ
njb-93	113	25	patient	patient	NOUN
njb-93	113	26	were	be	AUX
njb-93	113	27	infected	infect	VERB
njb-93	113	28	[	[	PUNCT
njb-93	113	29	21	21	NUM
njb-93	113	30	]	]	PUNCT
njb-93	113	31	.	.	PUNCT
njb-93	114	1	the	the	DET
njb-93	114	2	growth	growth	NOUN
njb-93	114	3	positivity	positivity	NOUN
njb-93	114	4	with	with	ADP
njb-93	114	5	33.5	33.5	NUM
njb-93	114	6	%	%	NOUN
njb-93	114	7	among	among	ADP
njb-93	114	8	female	female	ADJ
njb-93	114	9	patients	patient	NOUN
njb-93	114	10	and	and	CCONJ
njb-93	114	11	23.7	23.7	NUM
njb-93	114	12	%	%	NOUN
njb-93	114	13	in	in	ADP
njb-93	114	14	male	male	ADJ
njb-93	114	15	patients	patient	NOUN
njb-93	114	16	was	be	AUX
njb-93	114	17	observed	observe	VERB
njb-93	114	18	in	in	ADP
njb-93	114	19	a	a	DET
njb-93	114	20	similar	similar	ADJ
njb-93	114	21	study	study	NOUN
njb-93	114	22	by	by	ADP
njb-93	114	23	baral	baral	ADJ
njb-93	114	24	et	et	PROPN
njb-93	114	25	al	al	PROPN
njb-93	114	26	(	(	PUNCT
njb-93	114	27	2012)[22	2012)[22	NUM
njb-93	114	28	]	]	X
njb-93	114	29	.	.	PUNCT
njb-93	115	1	the	the	DET
njb-93	115	2	predominant	predominant	PROPN
njb-93	115	3	isolate	isolate	VERB
njb-93	115	4	was	be	AUX
njb-93	115	5	e.	e.	PROPN
njb-93	115	6	coli	coli	PROPN
njb-93	115	7	(	(	PUNCT
njb-93	115	8	82.30	82.30	NUM
njb-93	115	9	%	%	NOUN
njb-93	115	10	)	)	PUNCT
njb-93	115	11	followed	follow	VERB
njb-93	115	12	by	by	ADP
njb-93	115	13	klebsiella	klebsiella	PROPN
njb-93	115	14	species	species	PROPN
njb-93	115	15	(	(	PUNCT
njb-93	115	16	11.53	11.53	NUM
njb-93	115	17	%	%	NOUN
njb-93	115	18	)	)	PUNCT
njb-93	115	19	and	and	CCONJ
njb-93	115	20	staphylococcus	staphylococcus	NOUN
njb-93	115	21	aureus	aureus	PROPN
njb-93	115	22	(	(	PUNCT
njb-93	115	23	3.29	3.29	NUM
njb-93	115	24	%	%	NOUN
njb-93	115	25	)	)	PUNCT
njb-93	115	26	.	.	PUNCT
njb-93	116	1	e.	e.	PROPN
njb-93	116	2	coli	coli	PROPN
njb-93	116	3	is	be	AUX
njb-93	116	4	a	a	DET
njb-93	116	5	predominant	predominant	NOUN
njb-93	116	6	isolate	isolate	NOUN
njb-93	116	7	,	,	PUNCT
njb-93	116	8	because	because	SCONJ
njb-93	116	9	e.	e.	PROPN
njb-93	116	10	coli	coli	PROPN
njb-93	116	11	can	can	AUX
njb-93	116	12	bind	bind	VERB
njb-93	116	13	to	to	ADP
njb-93	116	14	the	the	DET
njb-93	116	15	glycol	glycol	ADJ
njb-93	116	16	-	-	PUNCT
njb-93	116	17	conjugate	conjugate	NOUN
njb-93	116	18	receptor	receptor	NOUN
njb-93	116	19	of	of	ADP
njb-93	116	20	the	the	DET
njb-93	116	21	uroepithelial	uroepithelial	ADJ
njb-93	116	22	cells	cell	NOUN
njb-93	116	23	of	of	ADP
njb-93	116	24	human	human	ADJ
njb-93	116	25	urinary	urinary	ADJ
njb-93	116	26	tract	tract	NOUN
njb-93	116	27	so	so	SCONJ
njb-93	116	28	it	it	PRON
njb-93	116	29	can	can	AUX
njb-93	116	30	initiate	initiate	VERB
njb-93	116	31	infection	infection	NOUN
njb-93	116	32	itself	itself	PRON
njb-93	116	33	.	.	PUNCT
njb-93	117	1	e.	e.	PROPN
njb-93	117	2	coli	coli	PROPN
njb-93	117	3	is	be	AUX
njb-93	117	4	isolated	isolate	VERB
njb-93	117	5	in	in	ADP
njb-93	117	6	90	90	NUM
njb-93	117	7	%	%	NOUN
njb-93	117	8	of	of	ADP
njb-93	117	9	infection	infection	NOUN
njb-93	117	10	and	and	CCONJ
njb-93	117	11	strains	strain	NOUN
njb-93	117	12	are	be	AUX
njb-93	117	13	characterized	characterize	VERB
njb-93	117	14	by	by	ADP
njb-93	117	15	presence	presence	NOUN
njb-93	117	16	of	of	ADP
njb-93	117	17	unique	unique	ADJ
njb-93	117	18	virulence	virulence	NOUN
njb-93	117	19	determinant	determinant	VERB
njb-93	117	20	the	the	DET
njb-93	117	21	pilus	pilus	NOUN
njb-93	117	22	(	(	PUNCT
njb-93	117	23	gal	gal	ADJ
njb-93	117	24	-	-	ADJ
njb-93	117	25	gal	gal	ADJ
njb-93	117	26	)	)	PUNCT
njb-93	117	27	receptor	receptor	NOUN
njb-93	117	28	[	[	X
njb-93	117	29	23	23	NUM
njb-93	117	30	]	]	PUNCT
njb-93	117	31	.	.	PUNCT
njb-93	118	1	similar	similar	ADJ
njb-93	118	2	result	result	NOUN
njb-93	118	3	was	be	AUX
njb-93	118	4	obtained	obtain	VERB
njb-93	118	5	by	by	ADP
njb-93	118	6	other	other	ADJ
njb-93	118	7	studies	study	NOUN
njb-93	118	8	[	[	PUNCT
njb-93	118	9	24	24	NUM
njb-93	118	10	,	,	PUNCT
njb-93	118	11	25	25	NUM
njb-93	118	12	]	]	PUNCT
njb-93	118	13	.	.	PUNCT
njb-93	119	1	e.	e.	PROPN
njb-93	119	2	coli	coli	PROPN
njb-93	119	3	was	be	AUX
njb-93	119	4	found	find	VERB
njb-93	119	5	to	to	PART
njb-93	119	6	be	be	AUX
njb-93	119	7	resistant	resistant	ADJ
njb-93	119	8	towards	towards	ADP
njb-93	119	9	amoxicillin	amoxicillin	PROPN
njb-93	119	10	(	(	PUNCT
njb-93	119	11	81.5	81.5	NUM
njb-93	119	12	%	%	NOUN
njb-93	119	13	)	)	PUNCT
njb-93	119	14	,	,	PUNCT
njb-93	119	15	co	co	NOUN
njb-93	119	16	-	-	NOUN
njb-93	119	17	trimoxazole	trimoxazole	ADJ
njb-93	119	18	(	(	PUNCT
njb-93	119	19	35	35	NUM
njb-93	119	20	%	%	NOUN
njb-93	119	21	)	)	PUNCT
njb-93	119	22	,	,	PUNCT
njb-93	119	23	and	and	CCONJ
njb-93	119	24	ciprofloxacin	ciprofloxacin	NOUN
njb-93	119	25	(	(	PUNCT
njb-93	119	26	38	38	NUM
njb-93	119	27	%	%	NOUN
njb-93	119	28	)	)	PUNCT
njb-93	119	29	.	.	PUNCT
njb-93	120	1	in	in	ADP
njb-93	120	2	our	our	PRON
njb-93	120	3	study	study	NOUN
njb-93	120	4	,	,	PUNCT
njb-93	120	5	25	25	NUM
njb-93	120	6	%	%	NOUN
njb-93	120	7	of	of	ADP
njb-93	120	8	k.	k.	NOUN
njb-93	120	9	pneumoniae	pneumoniae	NOUN
njb-93	120	10	were	be	AUX
njb-93	120	11	resistant	resistant	ADJ
njb-93	120	12	to	to	ADP
njb-93	120	13	both	both	CCONJ
njb-93	120	14	ceftriaxone	ceftriaxone	NOUN
njb-93	120	15	and	and	CCONJ
njb-93	120	16	ceftazidime	ceftazidime	PROPN
njb-93	120	17	.	.	PUNCT
njb-93	121	1	other	other	ADJ
njb-93	121	2	studies	study	NOUN
njb-93	121	3	from	from	ADP
njb-93	121	4	nepal	nepal	ADJ
njb-93	121	5	reported	report	VERB
njb-93	121	6	that	that	SCONJ
njb-93	121	7	the	the	DET
njb-93	121	8	resistance	resistance	NOUN
njb-93	121	9	rates	rate	NOUN
njb-93	121	10	of	of	ADP
njb-93	121	11	k.	k.	NOUN
njb-93	121	12	pneumoniae	pneumoniae	NOUN
njb-93	121	13	to	to	PART
njb-93	121	14	thirdgeneration	thirdgeneration	NOUN
njb-93	121	15	cephalosporin	cephalosporin	PROPN
njb-93	121	16	were	be	AUX
njb-93	121	17	between	between	ADP
njb-93	121	18	20	20	NUM
njb-93	121	19	%	%	NOUN
njb-93	121	20	to	to	PART
njb-93	121	21	75	75	NUM
njb-93	121	22	%	%	NOUN
njb-93	121	23	[	[	PUNCT
njb-93	121	24	26,27	26,27	NUM
njb-93	121	25	]	]	PUNCT
njb-93	121	26	.	.	PUNCT
njb-93	122	1	likewise	likewise	ADV
njb-93	122	2	,	,	PUNCT
njb-93	122	3	25	25	NUM
njb-93	122	4	%	%	NOUN
njb-93	122	5	and	and	CCONJ
njb-93	122	6	8.3	8.3	NUM
njb-93	122	7	%	%	NOUN
njb-93	122	8	of	of	ADP
njb-93	122	9	k.	k.	NOUN
njb-93	122	10	pneumoniae	pneumoniae	NOUN
njb-93	122	11	were	be	AUX
njb-93	122	12	found	find	VERB
njb-93	122	13	resistant	resistant	ADJ
njb-93	122	14	to	to	ADP
njb-93	122	15	nitrofurantoin	nitrofurantoin	NOUN
njb-93	122	16	and	and	CCONJ
njb-93	122	17	gentamicin	gentamicin	PROPN
njb-93	122	18	,	,	PUNCT
njb-93	122	19	respectively	respectively	ADV
njb-93	122	20	.	.	PUNCT
njb-93	123	1	all	all	DET
njb-93	123	2	k.	k.	NOUN
njb-93	123	3	pneumoniae	pneumoniae	NOUN
njb-93	123	4	strains	strain	NOUN
njb-93	123	5	were	be	AUX
njb-93	123	6	resistant	resistant	ADJ
njb-93	123	7	(	(	PUNCT
njb-93	123	8	100	100	NUM
njb-93	123	9	%	%	NOUN
njb-93	123	10	)	)	PUNCT
njb-93	123	11	to	to	ADP
njb-93	123	12	amoxicillin	amoxicillin	PROPN
njb-93	123	13	,	,	PUNCT
njb-93	123	14	while	while	SCONJ
njb-93	123	15	resistance	resistance	NOUN
njb-93	123	16	rate	rate	NOUN
njb-93	123	17	for	for	ADP
njb-93	123	18	e.	e.	PROPN
njb-93	123	19	coli	coli	PROPN
njb-93	123	20	was	be	AUX
njb-93	123	21	81.5	81.5	NUM
njb-93	123	22	%	%	NOUN
njb-93	123	23	.	.	PUNCT
njb-93	124	1	similar	similar	ADJ
njb-93	124	2	result	result	NOUN
njb-93	124	3	was	be	AUX
njb-93	124	4	observed	observe	VERB
njb-93	124	5	in	in	ADP
njb-93	124	6	a	a	DET
njb-93	124	7	study	study	NOUN
njb-93	124	8	carried	carry	VERB
njb-93	124	9	out	out	ADP
njb-93	124	10	at	at	ADP
njb-93	124	11	madagascar	madagascar	NOUN
njb-93	124	12	,	,	PUNCT
njb-93	124	13	where	where	SCONJ
njb-93	124	14	80	80	NUM
njb-93	124	15	%	%	NOUN
njb-93	124	16	of	of	ADP
njb-93	124	17	the	the	DET
njb-93	124	18	e.	e.	PROPN
njb-93	124	19	coli	coli	PROPN
njb-93	124	20	isolates	isolate	NOUN
njb-93	124	21	were	be	AUX
njb-93	124	22	resistant	resistant	ADJ
njb-93	124	23	to	to	ADP
njb-93	124	24	amoxicillin	amoxicillin	PROPN
njb-93	124	25	[	[	PUNCT
njb-93	124	26	28	28	NUM
njb-93	124	27	]	]	PUNCT
njb-93	124	28	.	.	PUNCT
njb-93	125	1	in	in	ADP
njb-93	125	2	our	our	PRON
njb-93	125	3	study	study	NOUN
njb-93	125	4	,	,	PUNCT
njb-93	125	5	e.	e.	PROPN
njb-93	125	6	coli	coli	PROPN
njb-93	125	7	showed	show	VERB
njb-93	125	8	a	a	DET
njb-93	125	9	high	high	ADJ
njb-93	125	10	resistance	resistance	NOUN
njb-93	125	11	rate	rate	NOUN
njb-93	125	12	68	68	NUM
njb-93	125	13	%	%	NOUN
njb-93	125	14	to	to	PART
njb-93	125	15	co	co	NOUN
njb-93	125	16	-	-	NOUN
njb-93	125	17	trimoxazole	trimoxazole	ADJ
njb-93	125	18	whereas	whereas	SCONJ
njb-93	125	19	the	the	DET
njb-93	125	20	k.	k.	NOUN
njb-93	125	21	pneumoniae	pneumoniae	NOUN
njb-93	125	22	showed	show	VERB
njb-93	125	23	resistance	resistance	NOUN
njb-93	125	24	rate	rate	NOUN
njb-93	125	25	30	30	NUM
njb-93	125	26	%	%	NOUN
njb-93	125	27	to	to	PART
njb-93	125	28	co	co	NOUN
njb-93	125	29	-	-	NOUN
njb-93	125	30	trimoxazole	trimoxazole	ADJ
njb-93	125	31	.	.	PUNCT
njb-93	126	1	a	a	DET
njb-93	126	2	comparable	comparable	ADJ
njb-93	126	3	resistance	resistance	NOUN
njb-93	126	4	rate	rate	NOUN
njb-93	126	5	of	of	ADP
njb-93	126	6	80	80	NUM
njb-93	126	7	%	%	NOUN
njb-93	126	8	and	and	CCONJ
njb-93	126	9	45	45	NUM
njb-93	126	10	%	%	NOUN
njb-93	126	11	to	to	ADP
njb-93	126	12	cotrimoxazole	cotrimoxazole	PROPN
njb-93	126	13	was	be	AUX
njb-93	126	14	shown	show	VERB
njb-93	126	15	among	among	ADP
njb-93	126	16	esbl	esbl	PROPN
njb-93	126	17	producing	produce	VERB
njb-93	126	18	e.	e.	PROPN
njb-93	126	19	coli	coli	PROPN
njb-93	126	20	and	and	CCONJ
njb-93	126	21	k.	k.	NOUN
njb-93	126	22	pneumoniae	pneumoniae	NOUN
njb-93	126	23	isolates	isolate	VERB
njb-93	126	24	in	in	ADP
njb-93	126	25	a	a	DET
njb-93	126	26	study	study	NOUN
njb-93	126	27	conducted	conduct	VERB
njb-93	126	28	in	in	ADP
njb-93	126	29	iran	iran	PROPN
njb-93	127	1	[	[	PUNCT
njb-93	127	2	29	29	NUM
njb-93	127	3	]	]	PUNCT
njb-93	127	4	.	.	PUNCT
njb-93	128	1	bazzaz	bazzaz	PROPN
njb-93	128	2	et	et	PROPN
njb-93	128	3	al	al	PROPN
njb-93	128	4	(	(	PUNCT
njb-93	128	5	2009	2009	NUM
njb-93	128	6	)	)	PUNCT
njb-93	128	7	reported	report	VERB
njb-93	128	8	esbl	esbl	NOUN
njb-93	128	9	-	-	PUNCT
njb-93	128	10	producing	produce	VERB
njb-93	128	11	isolates	isolate	NOUN
njb-93	128	12	of	of	ADP
njb-93	128	13	k.	k.	NOUN
njb-93	128	14	pneumoniae	pneumoniae	NOUN
njb-93	128	15	and	and	CCONJ
njb-93	128	16	e.	e.	PROPN
njb-93	128	17	coli	coli	NOUN
njb-93	128	18	as	as	ADP
njb-93	128	19	59.2	59.2	NUM
njb-93	128	20	%	%	NOUN
njb-93	128	21	[	[	PUNCT
njb-93	128	22	30	30	NUM
njb-93	128	23	]	]	PUNCT
njb-93	128	24	.	.	PUNCT
njb-93	129	1	in	in	ADP
njb-93	129	2	this	this	DET
njb-93	129	3	study	study	NOUN
njb-93	129	4	,	,	PUNCT
njb-93	129	5	17	17	NUM
njb-93	129	6	%	%	NOUN
njb-93	129	7	isolates	isolate	NOUN
njb-93	129	8	of	of	ADP
njb-93	129	9	k.	k.	NOUN
njb-93	129	10	pneumoniae	pneumoniae	NOUN
njb-93	129	11	were	be	AUX
njb-93	129	12	resistant	resistant	ADJ
njb-93	129	13	to	to	PART
njb-93	129	14	ciprofloxacin	ciprofloxacin	VERB
njb-93	129	15	.	.	PUNCT
njb-93	130	1	resistant	resistant	ADJ
njb-93	130	2	to	to	ADP
njb-93	130	3	fluoroquinolones	fluoroquinolones	PROPN
njb-93	130	4	is	be	AUX
njb-93	130	5	due	due	ADJ
njb-93	130	6	to	to	ADP
njb-93	130	7	the	the	DET
njb-93	130	8	result	result	NOUN
njb-93	130	9	of	of	ADP
njb-93	130	10	alterations	alteration	NOUN
njb-93	130	11	in	in	ADP
njb-93	130	12	target	target	NOUN
njb-93	130	13	enzyme	enzyme	NOUN
njb-93	130	14	(	(	PUNCT
njb-93	130	15	dna	dna	PROPN
njb-93	130	16	gyrase	gyrase	NOUN
njb-93	130	17	and	and	CCONJ
njb-93	130	18	topoisomerase	topoisomerase	PROPN
njb-93	130	19	iv	iv	PROPN
njb-93	130	20	)	)	PUNCT
njb-93	130	21	and	and	CCONJ
njb-93	130	22	because	because	SCONJ
njb-93	130	23	of	of	ADP
njb-93	130	24	change	change	NOUN
njb-93	130	25	in	in	ADP
njb-93	130	26	drug	drug	NOUN
njb-93	130	27	entry	entry	NOUN
njb-93	130	28	and	and	CCONJ
njb-93	130	29	efflux	efflux	NOUN
njb-93	130	30	[	[	PUNCT
njb-93	130	31	31	31	NUM
njb-93	130	32	]	]	PUNCT
njb-93	130	33	.	.	PUNCT
njb-93	131	1	klebsiella	klebsiella	PROPN
njb-93	131	2	pneumoniae	pneumoniae	PROPN
njb-93	131	3	sensitivity	sensitivity	NOUN
njb-93	131	4	towards	towards	ADP
njb-93	131	5	gentamicin	gentamicin	PROPN
njb-93	131	6	was	be	AUX
njb-93	131	7	found	find	VERB
njb-93	131	8	in	in	ADP
njb-93	131	9	79.2	79.2	NUM
njb-93	131	10	%	%	NOUN
njb-93	131	11	which	which	PRON
njb-93	131	12	was	be	AUX
njb-93	131	13	significantly	significantly	ADV
njb-93	131	14	higher	high	ADJ
njb-93	131	15	than	than	SCONJ
njb-93	131	16	that	that	PRON
njb-93	131	17	was	be	AUX
njb-93	131	18	reported	report	VERB
njb-93	131	19	in	in	ADP
njb-93	131	20	karanchi	karanchi	PROPN
njb-93	131	21	,	,	PUNCT
njb-93	131	22	pakistan	pakistan	PROPN
njb-93	131	23	where	where	SCONJ
njb-93	131	24	a	a	DET
njb-93	131	25	resistance	resistance	NOUN
njb-93	131	26	rate	rate	NOUN
njb-93	131	27	for	for	ADP
njb-93	131	28	gentamicin	gentamicin	NOUN
njb-93	131	29	was	be	AUX
njb-93	131	30	46.7	46.7	NUM
njb-93	131	31	%	%	NOUN
njb-93	131	32	[	[	PUNCT
njb-93	131	33	32	32	NUM
njb-93	131	34	]	]	PUNCT
njb-93	131	35	.	.	PUNCT
njb-93	132	1	however	however	ADV
njb-93	132	2	,	,	PUNCT
njb-93	132	3	the	the	DET
njb-93	132	4	rate	rate	NOUN
njb-93	132	5	was	be	AUX
njb-93	132	6	only	only	ADV
njb-93	132	7	slightly	slightly	ADV
njb-93	132	8	higher	high	ADJ
njb-93	132	9	than	than	ADP
njb-93	132	10	to	to	ADP
njb-93	132	11	the	the	DET
njb-93	132	12	findings	finding	NOUN
njb-93	132	13	from	from	ADP
njb-93	132	14	previous	previous	ADJ
njb-93	132	15	study	study	NOUN
njb-93	132	16	done	do	VERB
njb-93	132	17	in	in	ADP
njb-93	132	18	nepal	nepal	NOUN
njb-93	132	19	where	where	SCONJ
njb-93	132	20	the	the	DET
njb-93	132	21	sensitivity	sensitivity	NOUN
njb-93	132	22	was	be	AUX
njb-93	132	23	72.9	72.9	NUM
njb-93	132	24	%	%	NOUN
njb-93	132	25	[	[	PUNCT
njb-93	132	26	22	22	NUM
njb-93	132	27	]	]	PUNCT
njb-93	132	28	.	.	PUNCT
njb-93	133	1	these	these	DET
njb-93	133	2	significant	significant	ADJ
njb-93	133	3	variations	variation	NOUN
njb-93	133	4	may	may	AUX
njb-93	133	5	be	be	AUX
njb-93	133	6	attributed	attribute	VERB
njb-93	133	7	to	to	ADP
njb-93	133	8	selective	selective	ADJ
njb-93	133	9	pressures	pressure	NOUN
njb-93	133	10	table	table	NOUN
njb-93	133	11	8	8	NUM
njb-93	133	12	:	:	PUNCT
njb-93	133	13	department	department	NOUN
njb-93	133	14	wise	wise	ADJ
njb-93	133	15	distribution	distribution	NOUN
njb-93	133	16	of	of	ADP
njb-93	133	17	esbl	esbl	PROPN
njb-93	133	18	producers	producer	NOUN
njb-93	133	19	.	.	PUNCT
njb-93	134	1	in	in	ADP
njb-93	134	2	-	-	PUNCT
njb-93	134	3	patients	patient	NOUN
njb-93	134	4	out	out	ADJ
njb-93	134	5	-	-	PUNCT
njb-93	134	6	patients	patient	NOUN
njb-93	134	7	total	total	ADJ
njb-93	134	8	p	p	NOUN
njb-93	134	9	-	-	PUNCT
njb-93	134	10	value	value	NOUN
njb-93	134	11	esbl	esbl	NOUN
njb-93	134	12	producer	producer	NOUN
njb-93	134	13	17(36.17	17(36.17	NUM
njb-93	134	14	%	%	NOUN
njb-93	134	15	)	)	PUNCT
njb-93	134	16	37(20.44	37(20.44	NUM
njb-93	134	17	%	%	NOUN
njb-93	134	18	)	)	PUNCT
njb-93	134	19	54	54	NUM
njb-93	134	20	<	<	SYM
njb-93	134	21	0.05	0.05	NUM
njb-93	134	22	esbl	esbl	NOUN
njb-93	134	23	nonproducer	nonproducer	NOUN
njb-93	134	24	30(63.82	30(63.82	NUM
njb-93	134	25	%	%	NOUN
njb-93	134	26	)	)	PUNCT
njb-93	134	27	144(79.55	144(79.55	NUM
njb-93	134	28	%	%	NOUN
njb-93	134	29	)	)	PUNCT
njb-93	134	30	174	174	NUM
njb-93	134	31	total	total	VERB
njb-93	134	32	47	47	NUM
njb-93	134	33	181	181	NUM
njb-93	134	34	228	228	NUM
njb-93	134	35	nepal	nepal	ADJ
njb-93	134	36	journal	journal	NOUN
njb-93	134	37	of	of	ADP
njb-93	134	38	biotechnology	biotechnology	NOUN
njb-93	134	39	.	.	PUNCT
njb-93	135	1	d	d	X
njb-93	135	2	e	e	PROPN
njb-93	135	3	c	c	PROPN
njb-93	135	4	.	.	PUNCT
njb-93	136	1	2	2	NUM
njb-93	136	2	0	0	NUM
njb-93	136	3	1	1	NUM
njb-93	136	4	7	7	NUM
njb-93	136	5	vol	vol	NOUN
njb-93	136	6	.	.	PROPN
njb-93	137	1	5	5	NUM
njb-93	137	2	,	,	PUNCT
njb-93	137	3	no	no	NOUN
njb-93	137	4	.	.	NOUN
njb-93	137	5	1	1	NUM
njb-93	137	6	:	:	SYM
njb-93	137	7	32	32	NUM
njb-93	137	8	-	-	SYM
njb-93	137	9	38	38	NUM
njb-93	137	10	rimal	rimal	NOUN
njb-93	137	11	et	et	PROPN
njb-93	137	12	al	al	PROPN
njb-93	137	13	.	.	PUNCT
njb-93	138	1	©	©	PROPN
njb-93	138	2	njb	njb	PROPN
njb-93	138	3	,	,	PUNCT
njb-93	138	4	biotechnology	biotechnology	NOUN
njb-93	138	5	society	society	NOUN
njb-93	138	6	of	of	ADP
njb-93	138	7	nepal	nepal	ADJ
njb-93	138	8	36	36	NUM
njb-93	138	9	nepjol.info/index.php/njb	nepjol.info/index.php/njb	NOUN
njb-93	138	10	by	by	ADP
njb-93	138	11	drugs	drug	NOUN
njb-93	138	12	in	in	ADP
njb-93	138	13	different	different	ADJ
njb-93	138	14	regions	region	NOUN
njb-93	138	15	.	.	PUNCT
njb-93	139	1	resistance	resistance	NOUN
njb-93	139	2	of	of	ADP
njb-93	139	3	aminoglycosides	aminoglycoside	NOUN
njb-93	139	4	is	be	AUX
njb-93	139	5	done	do	VERB
njb-93	139	6	by	by	ADP
njb-93	139	7	the	the	DET
njb-93	139	8	enzymes	enzyme	NOUN
njb-93	139	9	that	that	PRON
njb-93	139	10	cause	cause	VERB
njb-93	139	11	modification	modification	NOUN
njb-93	139	12	of	of	ADP
njb-93	139	13	drug	drug	NOUN
njb-93	139	14	by	by	ADP
njb-93	139	15	phosphorylation	phosphorylation	NOUN
njb-93	139	16	,	,	PUNCT
njb-93	139	17	acetylation	acetylation	NOUN
njb-93	139	18	or	or	CCONJ
njb-93	139	19	adenylation	adenylation	NOUN
njb-93	139	20	and	and	CCONJ
njb-93	139	21	less	less	ADV
njb-93	139	22	or	or	CCONJ
njb-93	139	23	more	more	ADJ
njb-93	139	24	by	by	ADP
njb-93	139	25	other	other	ADJ
njb-93	139	26	methods	method	NOUN
njb-93	139	27	[	[	X
njb-93	139	28	33	33	NUM
njb-93	139	29	]	]	PUNCT
njb-93	139	30	.	.	PUNCT
njb-93	140	1	in	in	ADP
njb-93	140	2	our	our	PRON
njb-93	140	3	study	study	NOUN
njb-93	140	4	,	,	PUNCT
njb-93	140	5	31.4	31.4	NUM
njb-93	140	6	%	%	NOUN
njb-93	140	7	of	of	ADP
njb-93	140	8	esbl	esbl	PROPN
njb-93	140	9	positive	positive	PROPN
njb-93	140	10	e.	e.	PROPN
njb-93	140	11	coli	coli	PROPN
njb-93	140	12	was	be	AUX
njb-93	140	13	resistant	resistant	ADJ
njb-93	140	14	to	to	ADP
njb-93	140	15	meropenem	meropenem	PROPN
njb-93	140	16	,	,	PUNCT
njb-93	140	17	whereas	whereas	SCONJ
njb-93	140	18	all	all	DET
njb-93	140	19	isolates	isolate	NOUN
njb-93	140	20	were	be	AUX
njb-93	140	21	sensitive	sensitive	ADJ
njb-93	140	22	to	to	ADP
njb-93	140	23	imipenem	imipenem	PROPN
njb-93	140	24	which	which	PRON
njb-93	140	25	is	be	AUX
njb-93	140	26	similar	similar	ADJ
njb-93	140	27	to	to	ADP
njb-93	140	28	the	the	DET
njb-93	140	29	study	study	NOUN
njb-93	140	30	done	do	VERB
njb-93	140	31	in	in	ADP
njb-93	140	32	peshawar	peshawar	NOUN
njb-93	140	33	,	,	PUNCT
njb-93	140	34	pakistan	pakistan	PROPN
njb-93	141	1	[	[	X
njb-93	141	2	34	34	NUM
njb-93	141	3	]	]	PUNCT
njb-93	141	4	.	.	PUNCT
njb-93	142	1	the	the	DET
njb-93	142	2	emergence	emergence	NOUN
njb-93	142	3	of	of	ADP
njb-93	142	4	carbapenem	carbapenem	PROPN
njb-93	142	5	resistance	resistance	NOUN
njb-93	142	6	in	in	ADP
njb-93	142	7	k.	k.	NOUN
njb-93	142	8	pneumoniae	pneumoniae	NOUN
njb-93	142	9	is	be	AUX
njb-93	142	10	typically	typically	ADV
njb-93	142	11	attributed	attribute	VERB
njb-93	142	12	to	to	ADP
njb-93	142	13	the	the	DET
njb-93	142	14	production	production	NOUN
njb-93	142	15	of	of	ADP
njb-93	142	16	klebsiella	klebsiella	PROPN
njb-93	142	17	pneumoniae	pneumoniae	PROPN
njb-93	142	18	carbapenemase	carbapenemase	PROPN
njb-93	142	19	(	(	PUNCT
njb-93	142	20	kpc	kpc	NOUN
njb-93	142	21	)	)	PUNCT
njb-93	142	22	[	[	X
njb-93	142	23	35	35	NUM
njb-93	142	24	]	]	PUNCT
njb-93	142	25	.	.	PUNCT
njb-93	143	1	we	we	PRON
njb-93	143	2	found	find	VERB
njb-93	143	3	the	the	DET
njb-93	143	4	76	76	NUM
njb-93	143	5	(	(	PUNCT
njb-93	143	6	33.33	33.33	NUM
njb-93	143	7	%	%	NOUN
njb-93	143	8	)	)	PUNCT
njb-93	143	9	isolates	isolate	NOUN
njb-93	143	10	of	of	ADP
njb-93	143	11	e.	e.	PROPN
njb-93	143	12	coli	coli	PROPN
njb-93	143	13	and	and	CCONJ
njb-93	143	14	klebsiella	klebsiella	PROPN
njb-93	143	15	spp	spp	PROPN
njb-93	143	16	were	be	AUX
njb-93	143	17	multidrug	multidrug	NOUN
njb-93	143	18	resistant	resistant	ADJ
njb-93	143	19	.	.	PUNCT
njb-93	144	1	similar	similar	ADJ
njb-93	144	2	findings	finding	NOUN
njb-93	144	3	were	be	AUX
njb-93	144	4	observed	observe	VERB
njb-93	144	5	in	in	ADP
njb-93	144	6	the	the	DET
njb-93	144	7	study	study	NOUN
njb-93	144	8	done	do	VERB
njb-93	144	9	by	by	ADP
njb-93	144	10	tuladhar	tuladhar	PROPN
njb-93	144	11	et	et	PROPN
njb-93	144	12	al	al	PROPN
njb-93	144	13	(	(	PUNCT
njb-93	144	14	2003	2003	NUM
njb-93	144	15	)	)	PUNCT
njb-93	144	16	,	,	PUNCT
njb-93	144	17	in	in	ADP
njb-93	144	18	a	a	DET
njb-93	144	19	hospital	hospital	NOUN
njb-93	144	20	in	in	ADP
njb-93	144	21	kathmandu	kathmandu	NOUN
njb-93	144	22	,	,	PUNCT
njb-93	144	23	where	where	SCONJ
njb-93	144	24	35.21	35.21	NUM
njb-93	144	25	%	%	NOUN
njb-93	144	26	of	of	ADP
njb-93	144	27	bacterial	bacterial	ADJ
njb-93	144	28	strain	strain	NOUN
njb-93	144	29	were	be	AUX
njb-93	144	30	mdr	mdr	PROPN
njb-93	144	31	[	[	PUNCT
njb-93	144	32	36	36	NUM
njb-93	144	33	]	]	PUNCT
njb-93	144	34	.	.	PUNCT
njb-93	145	1	but	but	CCONJ
njb-93	145	2	the	the	DET
njb-93	145	3	result	result	NOUN
njb-93	145	4	was	be	AUX
njb-93	145	5	in	in	ADP
njb-93	145	6	contrast	contrast	NOUN
njb-93	145	7	to	to	ADP
njb-93	145	8	the	the	DET
njb-93	145	9	study	study	NOUN
njb-93	145	10	by	by	ADP
njb-93	145	11	upadhaya	upadhaya	PROPN
njb-93	145	12	et	et	PROPN
njb-93	145	13	al	al	PROPN
njb-93	145	14	(	(	PUNCT
njb-93	145	15	2013	2013	NUM
njb-93	145	16	)	)	PUNCT
njb-93	145	17	where	where	SCONJ
njb-93	145	18	48	48	NUM
njb-93	145	19	%	%	NOUN
njb-93	145	20	were	be	AUX
njb-93	145	21	mdr	mdr	PROPN
njb-93	145	22	[	[	PUNCT
njb-93	145	23	37	37	NUM
njb-93	145	24	]	]	PUNCT
njb-93	145	25	.	.	PUNCT
njb-93	146	1	the	the	DET
njb-93	146	2	prevalence	prevalence	NOUN
njb-93	146	3	of	of	ADP
njb-93	146	4	mdr	mdr	PROPN
njb-93	146	5	varied	vary	VERB
njb-93	146	6	among	among	ADP
njb-93	146	7	different	different	ADJ
njb-93	146	8	studies	study	NOUN
njb-93	146	9	and	and	CCONJ
njb-93	146	10	outcome	outcome	NOUN
njb-93	146	11	of	of	ADP
njb-93	146	12	the	the	DET
njb-93	146	13	prevalence	prevalence	NOUN
njb-93	146	14	may	may	AUX
njb-93	146	15	depend	depend	VERB
njb-93	146	16	on	on	ADP
njb-93	146	17	various	various	ADJ
njb-93	146	18	factors	factor	NOUN
njb-93	146	19	such	such	ADJ
njb-93	146	20	as	as	ADP
njb-93	146	21	mdr	mdr	PROPN
njb-93	146	22	criterion	criterion	NOUN
njb-93	146	23	,	,	PUNCT
njb-93	146	24	how	how	SCONJ
njb-93	146	25	the	the	DET
njb-93	146	26	antibiotics	antibiotic	NOUN
njb-93	146	27	are	be	AUX
njb-93	146	28	used	use	VERB
njb-93	146	29	,	,	PUNCT
njb-93	146	30	and	and	CCONJ
njb-93	146	31	organism	organism	NOUN
njb-93	146	32	encoding	encode	VERB
njb-93	146	33	multiple	multiple	ADJ
njb-93	146	34	resistance	resistance	NOUN
njb-93	146	35	gene	gene	NOUN
njb-93	146	36	which	which	PRON
njb-93	146	37	is	be	AUX
njb-93	146	38	becoming	become	VERB
njb-93	146	39	more	more	ADV
njb-93	146	40	prevalent	prevalent	ADJ
njb-93	146	41	.	.	PUNCT
njb-93	147	1	out	out	ADP
njb-93	147	2	of	of	ADP
njb-93	147	3	228	228	NUM
njb-93	147	4	isolates	isolate	NOUN
njb-93	147	5	,	,	PUNCT
njb-93	147	6	54	54	NUM
njb-93	147	7	(	(	PUNCT
njb-93	147	8	23.68	23.68	NUM
njb-93	147	9	%	%	NOUN
njb-93	147	10	)	)	PUNCT
njb-93	147	11	were	be	AUX
njb-93	147	12	esbl	esbl	NOUN
njb-93	147	13	producer	producer	NOUN
njb-93	147	14	.	.	PUNCT
njb-93	148	1	our	our	PRON
njb-93	148	2	finding	finding	NOUN
njb-93	148	3	was	be	AUX
njb-93	148	4	lower	low	ADJ
njb-93	148	5	in	in	ADP
njb-93	148	6	comparison	comparison	NOUN
njb-93	148	7	to	to	ADP
njb-93	148	8	the	the	DET
njb-93	148	9	study	study	NOUN
njb-93	148	10	conducted	conduct	VERB
njb-93	148	11	by	by	ADP
njb-93	148	12	dahal	dahal	PROPN
njb-93	148	13	et	et	X
njb-93	148	14	al	al	PROPN
njb-93	148	15	(	(	PUNCT
njb-93	148	16	2016	2016	NUM
njb-93	148	17	)	)	PUNCT
njb-93	148	18	,	,	PUNCT
njb-93	148	19	in	in	ADP
njb-93	148	20	a	a	DET
njb-93	148	21	community	community	NOUN
njb-93	148	22	hospital	hospital	NOUN
njb-93	148	23	of	of	ADP
njb-93	148	24	kathmandu	kathmandu	NOUN
njb-93	148	25	that	that	PRON
njb-93	148	26	reported	report	VERB
njb-93	148	27	47.75	47.75	NUM
njb-93	148	28	%	%	NOUN
njb-93	148	29	as	as	ADP
njb-93	148	30	esbl	esbl	NOUN
njb-93	148	31	producer	producer	NOUN
njb-93	149	1	[	[	X
njb-93	149	2	25	25	NUM
njb-93	149	3	]	]	PUNCT
njb-93	149	4	.	.	PUNCT
njb-93	150	1	a	a	DET
njb-93	150	2	study	study	NOUN
njb-93	150	3	done	do	VERB
njb-93	150	4	in	in	ADP
njb-93	150	5	india	india	PROPN
njb-93	150	6	reported	report	VERB
njb-93	150	7	nearly	nearly	ADV
njb-93	150	8	40	40	NUM
njb-93	150	9	%	%	NOUN
njb-93	150	10	of	of	ADP
njb-93	150	11	urinary	urinary	ADJ
njb-93	150	12	isolates	isolate	NOUN
njb-93	150	13	of	of	ADP
njb-93	150	14	e.	e.	PROPN
njb-93	150	15	coli	coli	PROPN
njb-93	150	16	and	and	CCONJ
njb-93	150	17	k.	k.	NOUN
njb-93	150	18	pneumoniae	pneumoniae	NOUN
njb-93	150	19	were	be	AUX
njb-93	150	20	esbl	esbl	VERB
njb-93	150	21	positive	positive	ADJ
njb-93	151	1	[	[	X
njb-93	151	2	38	38	NUM
njb-93	151	3	]	]	PUNCT
njb-93	151	4	.	.	PUNCT
njb-93	152	1	our	our	PRON
njb-93	152	2	result	result	NOUN
njb-93	152	3	was	be	AUX
njb-93	152	4	similar	similar	ADJ
njb-93	152	5	to	to	ADP
njb-93	152	6	the	the	DET
njb-93	152	7	study	study	NOUN
njb-93	152	8	done	do	VERB
njb-93	152	9	by	by	ADP
njb-93	152	10	poudyal	poudyal	NOUN
njb-93	152	11	(	(	PUNCT
njb-93	152	12	2010	2010	NUM
njb-93	152	13	)	)	PUNCT
njb-93	152	14	where	where	SCONJ
njb-93	152	15	25.7	25.7	NUM
njb-93	152	16	%	%	NOUN
njb-93	152	17	esbl	esbl	NOUN
njb-93	152	18	producer	producer	NOUN
njb-93	152	19	were	be	AUX
njb-93	152	20	isolated	isolate	VERB
njb-93	152	21	from	from	ADP
njb-93	152	22	urine	urine	NOUN
njb-93	152	23	sample	sample	NOUN
njb-93	152	24	[	[	X
njb-93	152	25	39	39	NUM
njb-93	152	26	]	]	PUNCT
njb-93	152	27	.	.	PUNCT
njb-93	153	1	however	however	ADV
njb-93	153	2	,	,	PUNCT
njb-93	153	3	our	our	PRON
njb-93	153	4	result	result	NOUN
njb-93	153	5	showed	show	VERB
njb-93	153	6	higher	high	ADJ
njb-93	153	7	prevalence	prevalence	NOUN
njb-93	153	8	as	as	ADP
njb-93	153	9	compared	compare	VERB
njb-93	153	10	to	to	ADP
njb-93	153	11	the	the	DET
njb-93	153	12	study	study	NOUN
njb-93	153	13	by	by	ADP
njb-93	153	14	logan	logan	PROPN
njb-93	153	15	et	et	X
njb-93	153	16	al	al	PROPN
njb-93	153	17	(	(	PUNCT
njb-93	153	18	2014	2014	NUM
njb-93	153	19	)	)	PUNCT
njb-93	153	20	in	in	ADP
njb-93	153	21	the	the	DET
njb-93	153	22	united	united	PROPN
njb-93	153	23	states	states	PROPN
njb-93	153	24	with	with	ADP
njb-93	153	25	esbls	esbls	PROPN
njb-93	153	26	representing	represent	VERB
njb-93	153	27	only	only	ADV
njb-93	153	28	0.28	0.28	NUM
njb-93	153	29	%	%	NOUN
njb-93	153	30	of	of	ADP
njb-93	153	31	all	all	DET
njb-93	153	32	e.	e.	PROPN
njb-93	153	33	coli	coli	NOUN
njb-93	153	34	,	,	PUNCT
njb-93	153	35	k.	k.	NOUN
njb-93	153	36	pneumoniae	pneumoniae	NOUN
njb-93	153	37	,	,	PUNCT
njb-93	153	38	and	and	CCONJ
njb-93	153	39	p.	p.	NOUN
njb-93	153	40	mirabilis	mirabili	NOUN
njb-93	153	41	in	in	ADP
njb-93	153	42	children	child	NOUN
njb-93	153	43	from	from	ADP
njb-93	153	44	1999	1999	NUM
njb-93	153	45	to	to	ADP
njb-93	153	46	2001	2001	NUM
njb-93	153	47	and	and	CCONJ
njb-93	153	48	later	later	ADV
njb-93	153	49	increasing	increase	VERB
njb-93	153	50	to	to	ADP
njb-93	153	51	0.92	0.92	NUM
njb-93	153	52	%	%	NOUN
njb-93	153	53	of	of	ADP
njb-93	153	54	all	all	DET
njb-93	153	55	isolates	isolate	NOUN
njb-93	153	56	in	in	ADP
njb-93	153	57	2010–2011	2010–2011	NUM
njb-93	153	58	[	[	PUNCT
njb-93	153	59	40	40	NUM
njb-93	153	60	]	]	PUNCT
njb-93	153	61	.	.	PUNCT
njb-93	154	1	the	the	DET
njb-93	154	2	occurrence	occurrence	NOUN
njb-93	154	3	of	of	ADP
njb-93	154	4	esbls	esbls	PROPN
njb-93	154	5	among	among	ADP
njb-93	154	6	clinical	clinical	ADJ
njb-93	154	7	isolates	isolate	NOUN
njb-93	154	8	varies	vary	VERB
njb-93	154	9	greatly	greatly	ADV
njb-93	154	10	from	from	ADP
njb-93	154	11	country	country	NOUN
njb-93	154	12	to	to	ADP
njb-93	154	13	country	country	NOUN
njb-93	154	14	,	,	PUNCT
njb-93	154	15	among	among	ADP
njb-93	154	16	the	the	DET
njb-93	154	17	hospitals	hospital	NOUN
njb-93	154	18	,	,	PUNCT
njb-93	154	19	within	within	ADP
njb-93	154	20	the	the	DET
njb-93	154	21	country	country	NOUN
njb-93	154	22	.	.	PUNCT
njb-93	155	1	in	in	ADP
njb-93	155	2	our	our	PRON
njb-93	155	3	study	study	NOUN
njb-93	155	4	,	,	PUNCT
njb-93	155	5	25.5	25.5	NUM
njb-93	155	6	%	%	NOUN
njb-93	155	7	of	of	ADP
njb-93	155	8	e.	e.	PROPN
njb-93	155	9	coli	coli	PROPN
njb-93	155	10	isolates	isolate	NOUN
njb-93	155	11	and	and	CCONJ
njb-93	155	12	12.5	12.5	NUM
njb-93	155	13	%	%	NOUN
njb-93	155	14	of	of	ADP
njb-93	155	15	klebsiella	klebsiella	PROPN
njb-93	155	16	pneumoniae	pneumoniae	PROPN
njb-93	155	17	isolates	isolate	NOUN
njb-93	155	18	were	be	AUX
njb-93	155	19	esbl	esbl	NOUN
njb-93	155	20	producer	producer	NOUN
njb-93	155	21	.	.	PUNCT
njb-93	156	1	these	these	DET
njb-93	156	2	findings	finding	NOUN
njb-93	156	3	were	be	AUX
njb-93	156	4	comparable	comparable	ADJ
njb-93	156	5	to	to	ADP
njb-93	156	6	the	the	DET
njb-93	156	7	study	study	NOUN
njb-93	156	8	done	do	VERB
njb-93	156	9	by	by	ADP
njb-93	156	10	chander	chander	NOUN
njb-93	156	11	and	and	CCONJ
njb-93	156	12	shrestha	shrestha	X
njb-93	156	13	(	(	PUNCT
njb-93	156	14	2013	2013	NUM
njb-93	156	15	)	)	PUNCT
njb-93	156	16	in	in	ADP
njb-93	156	17	nepal	nepal	ADJ
njb-93	156	18	tertiary	tertiary	ADJ
njb-93	156	19	hospital	hospital	NOUN
njb-93	156	20	in	in	ADP
njb-93	156	21	which	which	PRON
njb-93	156	22	13.51	13.51	NUM
njb-93	156	23	%	%	NOUN
njb-93	156	24	of	of	ADP
njb-93	156	25	e.	e.	PROPN
njb-93	156	26	coli	coli	PROPN
njb-93	156	27	and	and	CCONJ
njb-93	156	28	16.55	16.55	NUM
njb-93	156	29	%	%	NOUN
njb-93	156	30	of	of	ADP
njb-93	156	31	klebsiella	klebsiella	PROPN
njb-93	156	32	pneumoniae	pneumoniae	NOUN
njb-93	156	33	were	be	AUX
njb-93	156	34	esbl	esbl	NOUN
njb-93	156	35	producers	producer	NOUN
njb-93	157	1	[	[	X
njb-93	157	2	41	41	NUM
njb-93	157	3	]	]	PUNCT
njb-93	157	4	.	.	PUNCT
njb-93	158	1	esbl	esbl	PROPN
njb-93	158	2	occurrence	occurrence	NOUN
njb-93	158	3	among	among	ADP
njb-93	158	4	e.	e.	PROPN
njb-93	158	5	coli	coli	PROPN
njb-93	158	6	and	and	CCONJ
njb-93	158	7	klebsiella	klebsiella	PROPN
njb-93	158	8	is	be	AUX
njb-93	158	9	of	of	ADP
njb-93	158	10	great	great	ADJ
njb-93	158	11	concern	concern	NOUN
njb-93	158	12	since	since	SCONJ
njb-93	158	13	infections	infection	NOUN
njb-93	158	14	caused	cause	VERB
njb-93	158	15	by	by	ADP
njb-93	158	16	these	these	DET
njb-93	158	17	bacteria	bacteria	NOUN
njb-93	158	18	are	be	AUX
njb-93	158	19	very	very	ADV
njb-93	158	20	common	common	ADJ
njb-93	158	21	and	and	CCONJ
njb-93	158	22	resistance	resistance	NOUN
njb-93	158	23	of	of	ADP
njb-93	158	24	the	the	DET
njb-93	158	25	organism	organism	NOUN
njb-93	158	26	may	may	AUX
njb-93	158	27	be	be	AUX
njb-93	158	28	due	due	ADJ
njb-93	158	29	to	to	ADP
njb-93	158	30	the	the	DET
njb-93	158	31	presence	presence	NOUN
njb-93	158	32	of	of	ADP
njb-93	158	33	capsule	capsule	NOUN
njb-93	158	34	that	that	PRON
njb-93	158	35	gives	give	VERB
njb-93	158	36	some	some	DET
njb-93	158	37	level	level	NOUN
njb-93	158	38	of	of	ADP
njb-93	158	39	protection	protection	NOUN
njb-93	158	40	to	to	ADP
njb-93	158	41	the	the	DET
njb-93	158	42	cells	cell	NOUN
njb-93	158	43	,	,	PUNCT
njb-93	158	44	presence	presence	NOUN
njb-93	158	45	of	of	ADP
njb-93	158	46	multidrug	multidrug	NOUN
njb-93	158	47	resistance	resistance	NOUN
njb-93	158	48	efflux	efflux	NOUN
njb-93	158	49	pump	pump	NOUN
njb-93	158	50	,	,	PUNCT
njb-93	158	51	they	they	PRON
njb-93	158	52	also	also	ADV
njb-93	158	53	spread	spread	VERB
njb-93	158	54	easily	easily	ADV
njb-93	158	55	,	,	PUNCT
njb-93	158	56	are	be	AUX
njb-93	158	57	pathogenic	pathogenic	ADJ
njb-93	158	58	and	and	CCONJ
njb-93	158	59	efficient	efficient	ADJ
njb-93	158	60	at	at	ADP
njb-93	158	61	acquiring	acquire	VERB
njb-93	158	62	and	and	CCONJ
njb-93	158	63	disseminating	disseminate	VERB
njb-93	158	64	resistance	resistance	NOUN
njb-93	158	65	plasmid	plasmid	NOUN
njb-93	159	1	[	[	PUNCT
njb-93	159	2	42	42	NUM
njb-93	159	3	]	]	PUNCT
njb-93	159	4	.	.	PUNCT
njb-93	160	1	more	more	ADJ
njb-93	160	2	female	female	ADJ
njb-93	160	3	(	(	PUNCT
njb-93	160	4	27.45	27.45	NUM
njb-93	160	5	%	%	NOUN
njb-93	160	6	)	)	PUNCT
njb-93	160	7	were	be	AUX
njb-93	160	8	infected	infect	VERB
njb-93	160	9	as	as	ADP
njb-93	160	10	compared	compare	VERB
njb-93	160	11	to	to	ADP
njb-93	160	12	male	male	NOUN
njb-93	160	13	(	(	PUNCT
njb-93	160	14	16	16	NUM
njb-93	160	15	%	%	NOUN
njb-93	160	16	)	)	PUNCT
njb-93	160	17	.	.	PUNCT
njb-93	161	1	similar	similar	ADJ
njb-93	161	2	result	result	NOUN
njb-93	161	3	was	be	AUX
njb-93	161	4	obtained	obtain	VERB
njb-93	161	5	by	by	ADP
njb-93	161	6	bhandari	bhandari	PROPN
njb-93	161	7	(	(	PUNCT
njb-93	161	8	2013	2013	NUM
njb-93	161	9	)	)	PUNCT
njb-93	162	1	[	[	PUNCT
njb-93	162	2	17	17	NUM
njb-93	162	3	]	]	PUNCT
njb-93	162	4	.	.	PUNCT
njb-93	163	1	though	though	SCONJ
njb-93	163	2	some	some	PRON
njb-93	163	3	of	of	ADP
njb-93	163	4	our	our	PRON
njb-93	163	5	results	result	NOUN
njb-93	163	6	were	be	AUX
njb-93	163	7	very	very	ADV
njb-93	163	8	much	much	ADJ
njb-93	163	9	contrast	contrast	NOUN
njb-93	163	10	with	with	ADP
njb-93	163	11	other	other	ADJ
njb-93	163	12	studies	study	NOUN
njb-93	163	13	,	,	PUNCT
njb-93	163	14	the	the	DET
njb-93	163	15	prevalence	prevalence	NOUN
njb-93	163	16	rate	rate	NOUN
njb-93	163	17	of	of	ADP
njb-93	163	18	esbl	esbl	NOUN
njb-93	163	19	producing	produce	VERB
njb-93	163	20	isolates	isolate	NOUN
njb-93	163	21	in	in	ADP
njb-93	163	22	our	our	PRON
njb-93	163	23	study	study	NOUN
njb-93	163	24	was	be	AUX
njb-93	163	25	considered	consider	VERB
njb-93	163	26	significant	significant	ADJ
njb-93	163	27	and	and	CCONJ
njb-93	163	28	high	high	ADJ
njb-93	163	29	.	.	PUNCT
njb-93	164	1	the	the	DET
njb-93	164	2	higher	high	ADJ
njb-93	164	3	number	number	NOUN
njb-93	164	4	of	of	ADP
njb-93	164	5	esbl	esbl	PROPN
njb-93	164	6	producers	producer	NOUN
njb-93	164	7	might	might	AUX
njb-93	164	8	be	be	AUX
njb-93	164	9	due	due	ADJ
njb-93	164	10	to	to	ADP
njb-93	164	11	more	more	ADJ
njb-93	164	12	reliance	reliance	NOUN
njb-93	164	13	on	on	ADP
njb-93	164	14	third	third	ADJ
njb-93	164	15	generation	generation	NOUN
njb-93	164	16	cephalosporins	cephalosporin	NOUN
njb-93	164	17	to	to	PART
njb-93	164	18	treat	treat	VERB
njb-93	164	19	gram	gram	ADJ
njb-93	164	20	negative	negative	ADJ
njb-93	164	21	infections	infection	NOUN
njb-93	164	22	and	and	CCONJ
njb-93	164	23	unscrupulous	unscrupulous	ADJ
njb-93	164	24	hospital	hospital	NOUN
njb-93	164	25	antibiotic	antibiotic	ADJ
njb-93	164	26	policy	policy	NOUN
njb-93	164	27	.	.	PUNCT
njb-93	165	1	moreover	moreover	ADV
njb-93	165	2	,	,	PUNCT
njb-93	165	3	high	high	ADJ
njb-93	165	4	prevalence	prevalence	NOUN
njb-93	165	5	of	of	ADP
njb-93	165	6	esbl	esbl	NOUN
njb-93	165	7	isolates	isolate	NOUN
njb-93	165	8	among	among	ADP
njb-93	165	9	children	child	NOUN
njb-93	165	10	might	might	AUX
njb-93	165	11	be	be	AUX
njb-93	165	12	due	due	ADJ
njb-93	165	13	to	to	ADP
njb-93	165	14	immaturity	immaturity	NOUN
njb-93	165	15	of	of	ADP
njb-93	165	16	the	the	DET
njb-93	165	17	immune	immune	ADJ
njb-93	165	18	system	system	NOUN
njb-93	165	19	in	in	ADP
njb-93	165	20	these	these	DET
njb-93	165	21	infection	infection	NOUN
njb-93	165	22	in	in	ADP
njb-93	165	23	these	these	DET
njb-93	165	24	age	age	NOUN
njb-93	165	25	group	group	NOUN
njb-93	165	26	.	.	PUNCT
njb-93	166	1	further	further	ADJ
njb-93	166	2	studies	study	NOUN
njb-93	166	3	are	be	AUX
njb-93	166	4	required	require	VERB
njb-93	166	5	to	to	PART
njb-93	166	6	know	know	VERB
njb-93	166	7	the	the	DET
njb-93	166	8	current	current	ADJ
njb-93	166	9	burden	burden	NOUN
njb-93	166	10	in	in	ADP
njb-93	166	11	these	these	DET
njb-93	166	12	population	population	NOUN
njb-93	166	13	.	.	PUNCT
njb-93	167	1	conclusion	conclusion	NOUN
njb-93	167	2	high	high	ADJ
njb-93	167	3	prevalence	prevalence	NOUN
njb-93	167	4	of	of	ADP
njb-93	167	5	esbl	esbl	PROPN
njb-93	167	6	producing	produce	VERB
njb-93	167	7	e.	e.	PROPN
njb-93	167	8	coli	coli	NOUN
njb-93	167	9	and	and	CCONJ
njb-93	167	10	k.	k.	NOUN
njb-93	167	11	pneumoniae	pneumoniae	NOUN
njb-93	167	12	was	be	AUX
njb-93	167	13	observed	observe	VERB
njb-93	167	14	in	in	ADP
njb-93	167	15	our	our	PRON
njb-93	167	16	study	study	NOUN
njb-93	167	17	.	.	PUNCT
njb-93	168	1	e.	e.	PROPN
njb-93	168	2	coli	coli	PROPN
njb-93	168	3	is	be	AUX
njb-93	168	4	predominant	predominant	ADJ
njb-93	168	5	esbl	esbl	PROPN
njb-93	168	6	producers	producer	NOUN
njb-93	168	7	than	than	ADP
njb-93	168	8	k.	k.	NOUN
njb-93	168	9	pneumoniae	pneumoniae	NOUN
njb-93	168	10	.	.	PUNCT
njb-93	169	1	children	child	NOUN
njb-93	169	2	under	under	ADP
njb-93	169	3	age	age	NOUN
njb-93	169	4	five	five	NUM
njb-93	169	5	were	be	AUX
njb-93	169	6	found	find	VERB
njb-93	169	7	to	to	PART
njb-93	169	8	be	be	AUX
njb-93	169	9	highly	highly	ADV
njb-93	169	10	infected	infect	VERB
njb-93	169	11	with	with	ADP
njb-93	169	12	urinary	urinary	ADJ
njb-93	169	13	tract	tract	NOUN
njb-93	169	14	infection	infection	NOUN
njb-93	169	15	.	.	PUNCT
njb-93	170	1	escherichia	escherichia	PROPN
njb-93	170	2	coli	coli	PROPN
njb-93	170	3	and	and	CCONJ
njb-93	170	4	klebsiella	klebsiella	PROPN
njb-93	170	5	spp	spp	PROPN
njb-93	170	6	are	be	AUX
njb-93	170	7	emerging	emerge	VERB
njb-93	170	8	highly	highly	ADV
njb-93	170	9	as	as	ADP
njb-93	170	10	a	a	DET
njb-93	170	11	multi	multi	ADJ
njb-93	170	12	-	-	ADJ
njb-93	170	13	drug	drug	ADJ
njb-93	170	14	resistant	resistant	ADJ
njb-93	170	15	.	.	PUNCT
njb-93	171	1	imipenem	imipenem	PROPN
njb-93	171	2	,	,	PUNCT
njb-93	171	3	tigecycline	tigecycline	NOUN
njb-93	171	4	,	,	PUNCT
njb-93	171	5	amikacin	amikacin	PROPN
njb-93	171	6	,	,	PUNCT
njb-93	171	7	piperacillin	piperacillin	PROPN
njb-93	171	8	-	-	PUNCT
njb-93	171	9	tazobactam	tazobactam	NOUN
njb-93	171	10	were	be	AUX
njb-93	171	11	found	find	VERB
njb-93	171	12	to	to	PART
njb-93	171	13	be	be	AUX
njb-93	171	14	the	the	DET
njb-93	171	15	most	most	ADV
njb-93	171	16	effective	effective	ADJ
njb-93	171	17	drug	drug	NOUN
njb-93	171	18	against	against	ADP
njb-93	171	19	the	the	DET
njb-93	171	20	esbl	esbl	NOUN
njb-93	171	21	producing	produce	VERB
njb-93	171	22	isolates	isolate	NOUN
njb-93	171	23	.	.	PUNCT
njb-93	172	1	nitrofurantoin	nitrofurantoin	NOUN
njb-93	172	2	and	and	CCONJ
njb-93	172	3	gentamycin	gentamycin	PROPN
njb-93	172	4	can	can	AUX
njb-93	172	5	be	be	AUX
njb-93	172	6	used	use	VERB
njb-93	172	7	as	as	ADP
njb-93	172	8	a	a	DET
njb-93	172	9	drug	drug	NOUN
njb-93	172	10	of	of	ADP
njb-93	172	11	choice	choice	NOUN
njb-93	172	12	against	against	ADP
njb-93	172	13	non	non	ADJ
njb-93	172	14	-	-	ADJ
njb-93	172	15	esbl	esbl	ADJ
njb-93	172	16	producing	produce	VERB
njb-93	172	17	isolates	isolate	NOUN
njb-93	172	18	.	.	PUNCT
njb-93	173	1	declaration	declaration	NOUN
njb-93	173	2	ethics	ethic	NOUN
njb-93	173	3	approval	approval	NOUN
njb-93	173	4	and	and	CCONJ
njb-93	173	5	consent	consent	NOUN
njb-93	173	6	to	to	PART
njb-93	173	7	participate	participate	VERB
njb-93	173	8	ethical	ethical	ADJ
njb-93	173	9	approval	approval	NOUN
njb-93	173	10	was	be	AUX
njb-93	173	11	taken	take	VERB
njb-93	173	12	from	from	ADP
njb-93	173	13	the	the	DET
njb-93	173	14	ethical	ethical	ADJ
njb-93	173	15	review	review	PROPN
njb-93	173	16	committee	committee	NOUN
njb-93	173	17	of	of	ADP
njb-93	173	18	international	international	ADJ
njb-93	173	19	friendship	friendship	NOUN
njb-93	173	20	children	child	NOUN
njb-93	173	21	’s	’s	PART
njb-93	173	22	hospital	hospital	NOUN
njb-93	173	23	and	and	CCONJ
njb-93	173	24	tri	tri	ADJ
njb-93	173	25	-	-	ADJ
njb-93	173	26	chandra	chandra	ADJ
njb-93	173	27	multiple	multiple	ADJ
njb-93	173	28	campus	campus	NOUN
njb-93	173	29	.	.	PUNCT
njb-93	174	1	informed	informed	ADJ
njb-93	174	2	consent	consent	NOUN
njb-93	174	3	form	form	NOUN
njb-93	174	4	was	be	AUX
njb-93	174	5	obtained	obtain	VERB
njb-93	174	6	from	from	ADP
njb-93	174	7	parents	parent	NOUN
njb-93	174	8	of	of	ADP
njb-93	174	9	the	the	DET
njb-93	174	10	participants	participant	NOUN
njb-93	174	11	before	before	ADP
njb-93	174	12	their	their	PRON
njb-93	174	13	participation	participation	NOUN
njb-93	174	14	.	.	PUNCT
njb-93	175	1	competing	compete	VERB
njb-93	175	2	interests	interest	NOUN
njb-93	175	3	we	we	PRON
njb-93	175	4	have	have	AUX
njb-93	175	5	read	read	VERB
njb-93	175	6	nepal	nepal	ADJ
njb-93	175	7	journal	journal	NOUN
njb-93	175	8	of	of	ADP
njb-93	175	9	biotechnology	biotechnology	NOUN
njb-93	175	10	policy	policy	NOUN
njb-93	175	11	on	on	ADP
njb-93	175	12	declaration	declaration	NOUN
njb-93	175	13	of	of	ADP
njb-93	175	14	competing	compete	VERB
njb-93	175	15	interest	interest	NOUN
njb-93	175	16	and	and	CCONJ
njb-93	175	17	declare	declare	VERB
njb-93	175	18	that	that	SCONJ
njb-93	175	19	we	we	PRON
njb-93	175	20	have	have	VERB
njb-93	175	21	no	no	DET
njb-93	175	22	competing	compete	VERB
njb-93	175	23	interests	interest	NOUN
njb-93	175	24	.	.	PUNCT
njb-93	176	1	nepal	nepal	ADJ
njb-93	176	2	journal	journal	PROPN
njb-93	176	3	of	of	ADP
njb-93	176	4	biotechnology	biotechnology	NOUN
njb-93	176	5	.	.	PUNCT
njb-93	177	1	d	d	X
njb-93	177	2	e	e	PROPN
njb-93	177	3	c	c	PROPN
njb-93	177	4	.	.	PUNCT
njb-93	178	1	2	2	NUM
njb-93	178	2	0	0	NUM
njb-93	178	3	1	1	NUM
njb-93	178	4	7	7	NUM
njb-93	178	5	vol	vol	NOUN
njb-93	178	6	.	.	PROPN
njb-93	179	1	5	5	NUM
njb-93	179	2	,	,	PUNCT
njb-93	179	3	no	no	NOUN
njb-93	179	4	.	.	NOUN
njb-93	179	5	1	1	NUM
njb-93	179	6	:	:	SYM
njb-93	179	7	32	32	NUM
njb-93	179	8	-	-	SYM
njb-93	179	9	38	38	NUM
njb-93	179	10	rimal	rimal	NOUN
njb-93	179	11	et	et	PROPN
njb-93	179	12	al	al	PROPN
njb-93	179	13	.	.	PUNCT
njb-93	180	1	©	©	PROPN
njb-93	180	2	njb	njb	PROPN
njb-93	180	3	,	,	PUNCT
njb-93	180	4	biotechnology	biotechnology	NOUN
njb-93	180	5	society	society	NOUN
njb-93	180	6	of	of	ADP
njb-93	180	7	nepal	nepal	ADJ
njb-93	180	8	37	37	NUM
njb-93	180	9	nepjol.info/index.php/njb	nepjol.info/index.php/njb	ADJ
njb-93	180	10	authors	author	NOUN
njb-93	180	11	’	'	PUNCT
njb-93	180	12	contribution	contribution	NOUN
njb-93	180	13	mr	mr	PROPN
njb-93	180	14	.	.	PROPN
njb-93	180	15	ujjwal	ujjwal	PROPN
njb-93	180	16	rimal	rimal	PROPN
njb-93	180	17	,	,	PUNCT
njb-93	180	18	mrs	mrs	PROPN
njb-93	180	19	.	.	PROPN
njb-93	180	20	roshani	roshani	PROPN
njb-93	180	21	maharjan	maharjan	PROPN
njb-93	180	22	,	,	PUNCT
njb-93	180	23	and	and	CCONJ
njb-93	180	24	dr	dr	PROPN
njb-93	180	25	.	.	PROPN
njb-93	180	26	shovana	shovana	PROPN
njb-93	180	27	thapa	thapa	VERB
njb-93	180	28	jointly	jointly	ADV
njb-93	180	29	performed	perform	VERB
njb-93	180	30	the	the	DET
njb-93	180	31	study	study	NOUN
njb-93	180	32	.	.	PUNCT
njb-93	181	1	acknowledgement	acknowledgement	VERB
njb-93	181	2	the	the	DET
njb-93	181	3	authors	author	NOUN
njb-93	181	4	would	would	AUX
njb-93	181	5	like	like	VERB
njb-93	181	6	to	to	PART
njb-93	181	7	convey	convey	VERB
njb-93	181	8	special	special	ADJ
njb-93	181	9	thanks	thank	NOUN
njb-93	181	10	to	to	ADP
njb-93	181	11	staffs	staff	NOUN
njb-93	181	12	of	of	ADP
njb-93	181	13	international	international	ADJ
njb-93	181	14	friendship	friendship	NOUN
njb-93	181	15	children	child	NOUN
njb-93	181	16	hospital	hospital	NOUN
njb-93	181	17	,	,	PUNCT
njb-93	181	18	participant	participant	ADJ
njb-93	181	19	children	child	NOUN
njb-93	181	20	,	,	PUNCT
njb-93	181	21	their	their	PRON
njb-93	181	22	parents	parent	NOUN
njb-93	181	23	and	and	CCONJ
njb-93	181	24	to	to	ADP
njb-93	181	25	all	all	DET
njb-93	181	26	the	the	DET
njb-93	181	27	people	people	NOUN
njb-93	181	28	who	who	PRON
njb-93	181	29	directly	directly	ADV
njb-93	181	30	or	or	CCONJ
njb-93	181	31	indirectly	indirectly	ADV
njb-93	181	32	helped	help	VERB
njb-93	181	33	us	we	PRON
njb-93	181	34	in	in	ADP
njb-93	181	35	completing	complete	VERB
njb-93	181	36	this	this	DET
njb-93	181	37	work	work	NOUN
njb-93	181	38	.	.	PUNCT
njb-93	182	1	references	reference	NOUN
njb-93	182	2	1	1	NUM
njb-93	182	3	.	.	PUNCT
njb-93	182	4	tanagho	tanagho	VERB
njb-93	182	5	ea	ea	PROPN
njb-93	182	6	,	,	PUNCT
njb-93	182	7	mcaninch	mcaninch	PROPN
njb-93	182	8	jw	jw	PROPN
njb-93	182	9	:	:	PUNCT
njb-93	182	10	smith	smith	PROPN
njb-93	182	11	's	's	PART
njb-93	182	12	general	general	ADJ
njb-93	182	13	urology	urology	NOUN
njb-93	182	14	:	:	PUNCT
njb-93	182	15	bacterial	bacterial	ADJ
njb-93	182	16	infections	infection	NOUN
njb-93	182	17	of	of	ADP
njb-93	182	18	the	the	DET
njb-93	182	19	genitourinary	genitourinary	ADJ
njb-93	182	20	tract	tract	NOUN
njb-93	182	21	.	.	PUNCT
njb-93	183	1	united	united	PROPN
njb-93	183	2	states	states	PROPN
njb-93	183	3	of	of	ADP
njb-93	183	4	america	america	PROPN
njb-93	183	5	:	:	PUNCT
njb-93	183	6	mcgraw	mcgraw	NOUN
njb-93	183	7	-	-	PUNCT
njb-93	183	8	hill	hill	PROPN
njb-93	183	9	companies	companies	PROPN
njb-93	183	10	inc	inc	PROPN
njb-93	183	11	,	,	PUNCT
njb-93	183	12	2004	2004	NUM
njb-93	183	13	,	,	PUNCT
njb-93	183	14	203	203	NUM
njb-93	183	15	-	-	SYM
njb-93	183	16	227	227	NUM
njb-93	183	17	.	.	PUNCT
njb-93	184	1	2	2	NUM
njb-93	184	2	.	.	X
njb-93	184	3	gupta	gupta	PROPN
njb-93	184	4	k	k	PROPN
njb-93	184	5	,	,	PUNCT
njb-93	184	6	hooton	hooton	PROPN
njb-93	184	7	tm	tm	PROPN
njb-93	184	8	,	,	PUNCT
njb-93	184	9	naber	naber	PROPN
njb-93	184	10	kg	kg	NOUN
njb-93	184	11	:	:	PUNCT
njb-93	184	12	international	international	ADJ
njb-93	184	13	clinical	clinical	ADJ
njb-93	184	14	practice	practice	NOUN
njb-93	184	15	guidelines	guideline	NOUN
njb-93	184	16	for	for	ADP
njb-93	184	17	the	the	DET
njb-93	184	18	treatment	treatment	NOUN
njb-93	184	19	of	of	ADP
njb-93	184	20	acute	acute	ADJ
njb-93	184	21	uncomplicated	uncomplicated	ADJ
njb-93	184	22	cystitis	cystitis	NOUN
njb-93	184	23	and	and	CCONJ
njb-93	184	24	pyelonephritis	pyelonephritis	NOUN
njb-93	184	25	in	in	ADP
njb-93	184	26	women	woman	NOUN
njb-93	184	27	:	:	PUNCT
njb-93	184	28	a	a	DET
njb-93	184	29	2010	2010	NUM
njb-93	184	30	update	update	NOUN
njb-93	184	31	by	by	ADP
njb-93	184	32	the	the	DET
njb-93	184	33	infectious	infectious	ADJ
njb-93	184	34	diseases	disease	NOUN
njb-93	184	35	society	society	NOUN
njb-93	184	36	of	of	ADP
njb-93	184	37	america	america	PROPN
njb-93	184	38	and	and	CCONJ
njb-93	184	39	the	the	DET
njb-93	184	40	european	european	PROPN
njb-93	184	41	society	society	PROPN
njb-93	184	42	for	for	ADP
njb-93	184	43	microbiology	microbiology	NOUN
njb-93	184	44	and	and	CCONJ
njb-93	184	45	infectious	infectious	ADJ
njb-93	184	46	diseases	disease	NOUN
njb-93	184	47	.	.	PUNCT
njb-93	185	1	clin	clin	PROPN
njb-93	185	2	infect	infect	PROPN
njb-93	185	3	dis	dis	PROPN
njb-93	185	4	.	.	PROPN
njb-93	185	5	2011	2011	NUM
njb-93	185	6	52:103	52:103	NUM
njb-93	185	7	-	-	SYM
njb-93	185	8	120	120	NUM
njb-93	185	9	3	3	NUM
njb-93	185	10	.	.	PUNCT
njb-93	185	11	behzadi	behzadi	PROPN
njb-93	185	12	p	p	PROPN
njb-93	185	13	,	,	PUNCT
njb-93	185	14	behzadi	behzadi	PROPN
njb-93	185	15	e	e	PROPN
njb-93	185	16	,	,	PUNCT
njb-93	185	17	yazdanbod	yazdanbod	PROPN
njb-93	185	18	h	h	PROPN
njb-93	185	19	,	,	PUNCT
njb-93	185	20	aghapour	aghapour	PROPN
njb-93	185	21	r	r	NOUN
njb-93	185	22	,	,	PUNCT
njb-93	185	23	akbari	akbari	PROPN
njb-93	185	24	cheshmeh	cheshmeh	PROPN
njb-93	185	25	m	m	PROPN
njb-93	185	26	,	,	PUNCT
njb-93	185	27	salehian	salehian	PROPN
njb-93	185	28	omran	omran	PROPN
njb-93	185	29	d	d	PROPN
njb-93	185	30	:	:	PUNCT
njb-93	185	31	a	a	DET
njb-93	185	32	survey	survey	NOUN
njb-93	185	33	on	on	ADP
njb-93	185	34	urinary	urinary	ADJ
njb-93	185	35	tract	tract	NOUN
njb-93	185	36	infections	infection	NOUN
njb-93	185	37	associated	associate	VERB
njb-93	185	38	with	with	ADP
njb-93	185	39	the	the	DET
njb-93	185	40	three	three	NUM
njb-93	185	41	most	most	ADV
njb-93	185	42	common	common	ADJ
njb-93	185	43	uropathogenic	uropathogenic	ADJ
njb-93	185	44	bacteria	bacteria	NOUN
njb-93	185	45	.	.	PUNCT
njb-93	186	1	maedica	maedica	PROPN
njb-93	186	2	(	(	PUNCT
njb-93	186	3	buchar	buchar	PROPN
njb-93	186	4	)	)	PUNCT
njb-93	186	5	.	.	PUNCT
njb-93	187	1	2010	2010	NUM
njb-93	187	2	5(2):111–115	5(2):111–115	NUM
njb-93	187	3	.	.	PUNCT
njb-93	188	1	4	4	X
njb-93	188	2	.	.	PROPN
njb-93	188	3	peiran	peiran	PROPN
njb-93	188	4	g	g	PROPN
njb-93	188	5	,	,	PUNCT
njb-93	188	6	pitout	pitout	PROPN
njb-93	188	7	jd	jd	PROPN
njb-93	188	8	:	:	PUNCT
njb-93	188	9	molecular	molecular	ADJ
njb-93	188	10	epidemiology	epidemiology	NOUN
njb-93	188	11	of	of	ADP
njb-93	188	12	escherichia	escherichia	NOUN
njb-93	188	13	coli	coli	NOUN
njb-93	188	14	producing	produce	VERB
njb-93	188	15	ctx	ctx	NOUN
njb-93	188	16	-	-	NOUN
njb-93	188	17	m	m	NOUN
njb-93	188	18	β	β	NOUN
njb-93	188	19	lactamases	lactamase	NOUN
njb-93	188	20	:	:	PUNCT
njb-93	188	21	worldwide	worldwide	ADJ
njb-93	188	22	emergence	emergence	NOUN
njb-93	188	23	of	of	ADP
njb-93	188	24	clone	clone	NOUN
njb-93	188	25	st131	st131	PROPN
njb-93	188	26	025	025	NOUN
njb-93	188	27	:	:	PUNCT
njb-93	188	28	h4	h4	PROPN
njb-93	188	29	.	.	PROPN
njb-93	188	30	international	international	PROPN
njb-93	188	31	j	j	PROPN
njb-93	188	32	antimicrobial	antimicrobial	ADJ
njb-93	188	33	agents	agent	NOUN
njb-93	188	34	.	.	PUNCT
njb-93	189	1	2010	2010	NUM
njb-93	189	2	35	35	NUM
njb-93	189	3	:	:	PUNCT
njb-93	189	4	316321	316321	NUM
njb-93	189	5	.	.	PUNCT
njb-93	190	1	5	5	X
njb-93	190	2	.	.	X
njb-93	190	3	perez	perez	PROPN
njb-93	190	4	f	f	PROPN
njb-93	190	5	,	,	PUNCT
njb-93	190	6	endimiani	endimiani	PROPN
njb-93	190	7	a	a	PRON
njb-93	190	8	,	,	PUNCT
njb-93	190	9	hujer	hujer	ADJ
njb-93	190	10	km	km	PROPN
njb-93	190	11	,	,	PUNCT
njb-93	190	12	bonomo	bonomo	PROPN
njb-93	190	13	ra	ra	PROPN
njb-93	190	14	:	:	PUNCT
njb-93	190	15	the	the	DET
njb-93	190	16	continuing	continue	VERB
njb-93	190	17	challenges	challenge	NOUN
njb-93	190	18	of	of	ADP
njb-93	190	19	esbls	esbls	PROPN
njb-93	190	20	.	.	PUNCT
njb-93	191	1	current	current	ADJ
njb-93	191	2	opinion	opinion	NOUN
njb-93	191	3	in	in	ADP
njb-93	191	4	pharmacology	pharmacology	PROPN
njb-93	191	5	.	.	PUNCT
njb-93	192	1	curr	curr	PROPN
njb-93	192	2	opin	opin	PROPN
njb-93	192	3	pharmacol	pharmacol	PROPN
njb-93	192	4	.	.	PROPN
njb-93	192	5	2007	2007	NUM
njb-93	192	6	7(5):459	7(5):459	NUM
njb-93	192	7	-	-	SYM
njb-93	192	8	469	469	NUM
njb-93	192	9	.	.	NUM
njb-93	193	1	6	6	NUM
njb-93	193	2	.	.	X
njb-93	193	3	rupp	rupp	PROPN
njb-93	193	4	me	i	PRON
njb-93	193	5	and	and	CCONJ
njb-93	193	6	paul	paul	PROPN
njb-93	193	7	d	d	PROPN
njb-93	193	8	:	:	PUNCT
njb-93	193	9	extended	extended	ADJ
njb-93	193	10	spectrum	spectrum	NOUN
njb-93	193	11	βlactamase	βlactamase	NOUN
njb-93	193	12	(	(	PUNCT
njb-93	193	13	esbl	esbl	PROPN
njb-93	193	14	)	)	PUNCT
njb-93	193	15	producing	produce	VERB
njb-93	193	16	enterobacteriaceae	enterobacteriaceae	PROPN
njb-93	193	17	.	.	PUNCT
njb-93	194	1	drugs	drug	NOUN
njb-93	194	2	.	.	PUNCT
njb-93	195	1	2003	2003	NUM
njb-93	195	2	63(4):353	63(4):353	PROPN
njb-93	195	3	-	-	PUNCT
njb-93	195	4	356	356	NUM
njb-93	195	5	.	.	NUM
njb-93	195	6	7	7	NUM
njb-93	195	7	.	.	PUNCT
njb-93	196	1	pitout	pitout	PROPN
njb-93	196	2	jd	jd	PROPN
njb-93	196	3	and	and	CCONJ
njb-93	196	4	laupland	laupland	PROPN
njb-93	196	5	kb	kb	PROPN
njb-93	196	6	:	:	PUNCT
njb-93	196	7	extended	extend	VERB
njb-93	196	8	-	-	PUNCT
njb-93	196	9	spectrum	spectrum	NOUN
njb-93	196	10	beta	beta	NOUN
njb-93	196	11	-	-	PUNCT
njb-93	196	12	lactamase	lactamase	NOUN
njb-93	196	13	producing	produce	VERB
njb-93	196	14	enterobacteriaceae	enterobacteriaceae	PROPN
njb-93	196	15	:	:	PUNCT
njb-93	196	16	an	an	DET
njb-93	196	17	emerging	emerge	VERB
njb-93	196	18	public	public	ADJ
njb-93	196	19	-	-	PUNCT
njb-93	196	20	health	health	NOUN
njb-93	196	21	concern	concern	NOUN
njb-93	196	22	.	.	PUNCT
njb-93	197	1	the	the	DET
njb-93	197	2	lancet	lancet	PROPN
njb-93	197	3	infectious	infectious	ADJ
njb-93	197	4	diseases	disease	NOUN
njb-93	197	5	.	.	PUNCT
njb-93	198	1	2008	2008	NUM
njb-93	198	2	8	8	NUM
njb-93	198	3	:	:	PUNCT
njb-93	198	4	159	159	NUM
njb-93	198	5	-	-	SYM
njb-93	198	6	166	166	NUM
njb-93	198	7	.	.	NUM
njb-93	198	8	8	8	NUM
njb-93	198	9	.	.	PUNCT
njb-93	199	1	sohei	sohei	PROPN
njb-93	199	2	h	h	PROPN
njb-93	199	3	,	,	PUNCT
njb-93	199	4	yoshikazu	yoshikazu	PROPN
njb-93	199	5	i	i	PROPN
njb-93	199	6	,	,	PUNCT
njb-93	199	7	keizo	keizo	PROPN
njb-93	199	8	y	y	PROPN
njb-93	199	9	:	:	PUNCT
njb-93	199	10	extended	extend	VERB
njb-93	199	11	-	-	PUNCT
njb-93	199	12	spectrum	spectrum	NOUN
njb-93	199	13	β	β	PROPN
njb-93	199	14	-	-	PUNCT
njb-93	199	15	lactamases	lactamase	NOUN
njb-93	199	16	:	:	PUNCT
njb-93	199	17	implications	implication	NOUN
njb-93	199	18	for	for	ADP
njb-93	199	19	the	the	DET
njb-93	199	20	clinical	clinical	ADJ
njb-93	199	21	laboratory	laboratory	NOUN
njb-93	199	22	and	and	CCONJ
njb-93	199	23	therapy	therapy	NOUN
njb-93	199	24	.	.	PUNCT
njb-93	200	1	korean	korean	PROPN
njb-93	200	2	j	j	PROPN
njb-93	200	3	laboratory	laboratory	PROPN
njb-93	200	4	medicine	medicine	NOUN
njb-93	200	5	.	.	PUNCT
njb-93	201	1	2008	2008	NUM
njb-93	201	2	28:401	28:401	NUM
njb-93	201	3	-	-	SYM
njb-93	201	4	41	41	NUM
njb-93	201	5	.	.	SYM
njb-93	201	6	9	9	NUM
njb-93	201	7	.	.	PUNCT
njb-93	201	8	coque	coque	PROPN
njb-93	201	9	tm	tm	PROPN
njb-93	201	10	,	,	PUNCT
njb-93	201	11	baquero	baquero	PROPN
njb-93	201	12	f	f	PROPN
njb-93	201	13	,	,	PUNCT
njb-93	201	14	cantón	cantón	PROPN
njb-93	201	15	r	r	NOUN
njb-93	201	16	:	:	PUNCT
njb-93	201	17	increasing	increase	VERB
njb-93	201	18	prevalence	prevalence	NOUN
njb-93	201	19	of	of	ADP
njb-93	201	20	esbl	esbl	PROPN
njb-93	201	21	-	-	PUNCT
njb-93	201	22	producing	produce	VERB
njb-93	201	23	enterobacteriaceae	enterobacteriaceae	PROPN
njb-93	201	24	in	in	ADP
njb-93	201	25	europe	europe	PROPN
njb-93	201	26	.	.	PUNCT
njb-93	202	1	euro	euro	PROPN
njb-93	202	2	surveillance	surveillance	PROPN
njb-93	202	3	.	.	PUNCT
njb-93	203	1	2008	2008	NUM
njb-93	203	2	13	13	NUM
njb-93	203	3	,	,	PUNCT
njb-93	203	4	1–11	1–11	PROPN
njb-93	203	5	10	10	NUM
njb-93	203	6	.	.	PUNCT
njb-93	204	1	gutkind	gutkind	PROPN
njb-93	204	2	g	g	PROPN
njb-93	204	3	,	,	PUNCT
njb-93	204	4	radice	radice	PROPN
njb-93	204	5	m	m	PROPN
njb-93	204	6	,	,	PUNCT
njb-93	204	7	gonzalez	gonzalez	PROPN
njb-93	204	8	c	c	PROPN
njb-93	204	9	,	,	PUNCT
njb-93	204	10	power	power	PROPN
njb-93	204	11	p	p	PROPN
njb-93	204	12	,	,	PUNCT
njb-93	204	13	vidal	vidal	PROPN
njb-93	204	14	m	m	PROPN
njb-93	204	15	:	:	PUNCT
njb-93	204	16	third	third	ADJ
njb-93	204	17	generation	generation	NOUN
njb-93	204	18	cephalosporin	cephalosporin	NOUN
njb-93	204	19	resistance	resistance	NOUN
njb-93	204	20	in	in	ADP
njb-93	204	21	shigella	shigella	PROPN
njb-93	204	22	sonnei	sonnei	PROPN
njb-93	204	23	,	,	PUNCT
njb-93	204	24	argentina	argentina	PROPN
njb-93	204	25	.	.	PUNCT
njb-93	205	1	emerging	emerge	VERB
njb-93	205	2	infectious	infectious	ADJ
njb-93	205	3	diseases	disease	NOUN
njb-93	205	4	.	.	PUNCT
njb-93	206	1	2001	2001	NUM
njb-93	206	2	7(3):442	7(3):442	NUM
njb-93	206	3	.	.	PUNCT
njb-93	207	1	11	11	NUM
njb-93	207	2	.	.	PUNCT
njb-93	208	1	poirel	poirel	PROPN
njb-93	208	2	l	l	PROPN
njb-93	208	3	,	,	PUNCT
njb-93	208	4	naas	naas	PROPN
njb-93	208	5	t	t	PROPN
njb-93	208	6	,	,	PUNCT
njb-93	208	7	thomas	thomas	PROPN
njb-93	208	8	le	le	PROPN
njb-93	208	9	,	,	PUNCT
njb-93	208	10	karim	karim	PROPN
njb-93	208	11	a	a	PROPN
njb-93	208	12	,	,	PUNCT
njb-93	208	13	bingen	bingen	PROPN
njb-93	208	14	e	e	PROPN
njb-93	208	15	,	,	PUNCT
njb-93	208	16	nordmann	nordmann	PROPN
njb-93	208	17	p	p	PROPN
njb-93	208	18	:	:	PUNCT
njb-93	208	19	ctx	ctx	VERB
njb-93	208	20	-	-	PUNCT
njb-93	208	21	m	m	ADJ
njb-93	208	22	-	-	ADJ
njb-93	208	23	type	type	NOUN
njb-93	208	24	extended	extend	VERB
njb-93	208	25	-	-	PUNCT
njb-93	208	26	spectrum	spectrum	NOUN
njb-93	208	27	beta	beta	NOUN
njb-93	208	28	-	-	PUNCT
njb-93	208	29	lactamase	lactamase	NOUN
njb-93	208	30	that	that	PRON
njb-93	208	31	hydrolyzes	hydrolyze	VERB
njb-93	208	32	ceftazidime	ceftazidime	NOUN
njb-93	208	33	through	through	ADP
njb-93	208	34	a	a	DET
njb-93	208	35	single	single	ADJ
njb-93	208	36	amino	amino	NOUN
njb-93	208	37	acid	acid	NOUN
njb-93	208	38	substitution	substitution	NOUN
njb-93	208	39	in	in	ADP
njb-93	208	40	the	the	DET
njb-93	208	41	omega	omega	NOUN
njb-93	208	42	loop	loop	NOUN
njb-93	208	43	.	.	PUNCT
njb-93	209	1	antimicrob	antimicrob	PROPN
njb-93	209	2	.	.	PUNCT
njb-93	210	1	agents	agents	PROPN
njb-93	210	2	chemother	chemother	PROPN
njb-93	210	3	.	.	PUNCT
njb-93	211	1	2001	2001	NUM
njb-93	211	2	45:3355	45:3355	NUM
njb-93	211	3	-	-	SYM
njb-93	211	4	3361	3361	NUM
njb-93	211	5	.	.	PUNCT
njb-93	212	1	12	12	NUM
njb-93	212	2	.	.	PUNCT
njb-93	212	3	bora	bora	VERB
njb-93	212	4	a	a	PRON
njb-93	212	5	,	,	PUNCT
njb-93	212	6	sanjana	sanjana	PROPN
njb-93	212	7	r	r	PROPN
njb-93	212	8	,	,	PUNCT
njb-93	212	9	jha	jha	PROPN
njb-93	212	10	bk	bk	PROPN
njb-93	212	11	,	,	PUNCT
njb-93	212	12	mahaseth	mahaseth	PROPN
njb-93	212	13	sn	sn	PROPN
njb-93	212	14	,	,	PUNCT
njb-93	212	15	pokharel	pokharel	PROPN
njb-93	212	16	k	k	PROPN
njb-93	212	17	:	:	PUNCT
njb-93	212	18	incidence	incidence	NOUN
njb-93	212	19	of	of	ADP
njb-93	212	20	metallo	metallo	ADJ
njb-93	212	21	-	-	PUNCT
njb-93	212	22	beta	beta	NOUN
njb-93	212	23	-	-	PUNCT
njb-93	212	24	lactamase	lactamase	NOUN
njb-93	212	25	producing	produce	VERB
njb-93	212	26	clinical	clinical	ADJ
njb-93	212	27	isolates	isolate	NOUN
njb-93	212	28	of	of	ADP
njb-93	212	29	escherichia	escherichia	NOUN
njb-93	212	30	coli	coli	NOUN
njb-93	212	31	and	and	CCONJ
njb-93	212	32	klebsiella	klebsiella	PROPN
njb-93	212	33	pneumoniae	pneumoniae	NOUN
njb-93	212	34	in	in	ADP
njb-93	212	35	central	central	ADJ
njb-93	212	36	nepal	nepal	NOUN
njb-93	212	37	.	.	PUNCT
njb-93	213	1	bmc	bmc	PROPN
njb-93	213	2	res	res	PROPN
njb-93	213	3	notes	note	NOUN
njb-93	213	4	.	.	PUNCT
njb-93	214	1	2014	2014	NUM
njb-93	214	2	7:557	7:557	NUM
njb-93	214	3	.	.	PROPN
njb-93	214	4	13	13	NUM
njb-93	214	5	.	.	PUNCT
njb-93	215	1	mishra	mishra	PROPN
njb-93	215	2	sk	sk	PROPN
njb-93	215	3	,	,	PUNCT
njb-93	215	4	acharya	acharya	PROPN
njb-93	215	5	j	j	PROPN
njb-93	215	6	,	,	PUNCT
njb-93	215	7	kattel	kattel	PROPN
njb-93	215	8	h	h	PROPN
njb-93	215	9	,	,	PUNCT
njb-93	215	10	pokhrel	pokhrel	PROPN
njb-93	215	11	bm	bm	PROPN
njb-93	215	12	,	,	PUNCT
njb-93	215	13	rijal	rijal	ADJ
njb-93	215	14	bp	bp	PROPN
njb-93	215	15	:	:	PUNCT
njb-93	215	16	extended	extend	VERB
njb-93	215	17	-	-	PUNCT
njb-93	215	18	spectrum	spectrum	NOUN
njb-93	215	19	beta	beta	NOUN
njb-93	215	20	-	-	PUNCT
njb-93	215	21	lactamase	lactamase	NOUN
njb-93	215	22	and	and	CCONJ
njb-93	215	23	metallo	metallo	ADJ
njb-93	215	24	-	-	PUNCT
njb-93	215	25	beta	beta	NOUN
njb-93	215	26	-	-	PUNCT
njb-93	215	27	lactamase	lactamase	NOUN
njb-93	215	28	-	-	PUNCT
njb-93	215	29	producing	produce	VERB
njb-93	215	30	bacterial	bacterial	ADJ
njb-93	215	31	strains	strain	NOUN
njb-93	215	32	among	among	ADP
njb-93	215	33	the	the	DET
njb-93	215	34	patients	patient	NOUN
njb-93	215	35	attending	attend	VERB
njb-93	215	36	a	a	DET
njb-93	215	37	tertiary	tertiary	ADJ
njb-93	215	38	care	care	NOUN
njb-93	215	39	center	center	NOUN
njb-93	215	40	in	in	ADP
njb-93	215	41	nepal	nepal	NOUN
njb-93	215	42	.	.	PUNCT
njb-93	216	1	int	int	PROPN
njb-93	216	2	j	j	PROPN
njb-93	216	3	infect	infect	PROPN
njb-93	216	4	dis	dis	PROPN
njb-93	216	5	.	.	PROPN
njb-93	216	6	2012	2012	NUM
njb-93	216	7	.	.	PUNCT
njb-93	217	1	16:425	16:425	NUM
njb-93	217	2	.	.	PUNCT
njb-93	217	3	14	14	NUM
njb-93	217	4	.	.	PUNCT
njb-93	218	1	forbes	forbes	PROPN
njb-93	218	2	ba	ba	PROPN
njb-93	218	3	,	,	PUNCT
njb-93	218	4	sahm	sahm	VERB
njb-93	218	5	df	df	NOUN
njb-93	218	6	and	and	CCONJ
njb-93	218	7	weissfeld	weissfeld	PROPN
njb-93	218	8	as	as	ADP
njb-93	218	9	:	:	PUNCT
njb-93	218	10	bailey	bailey	PROPN
njb-93	218	11	and	and	CCONJ
njb-93	218	12	scott	scott	PROPN
njb-93	218	13	’s	’s	PART
njb-93	218	14	diagnostic	diagnostic	ADJ
njb-93	218	15	microbiology	microbiology	NOUN
njb-93	218	16	12th	12th	PROPN
njb-93	218	17	edition	edition	NOUN
njb-93	218	18	.	.	PUNCT
njb-93	219	1	mosby	mosby	PROPN
njb-93	219	2	elsevier	elsevi	ADJ
njb-93	219	3	publication	publication	PROPN
njb-93	219	4	,	,	PUNCT
njb-93	219	5	usa	usa	PROPN
njb-93	219	6	;	;	PUNCT
njb-93	219	7	2007	2007	NUM
njb-93	219	8	,	,	PUNCT
njb-93	219	9	350	350	NUM
njb-93	219	10	-	-	SYM
njb-93	219	11	362	362	NUM
njb-93	219	12	.	.	NOUN
njb-93	219	13	15	15	NUM
njb-93	219	14	.	.	PUNCT
njb-93	220	1	clsi	clsi	NOUN
njb-93	220	2	:	:	PUNCT
njb-93	220	3	performance	performance	NOUN
njb-93	220	4	standards	standard	NOUN
njb-93	220	5	for	for	ADP
njb-93	220	6	testing	testing	NOUN
njb-93	220	7	;	;	PUNCT
njb-93	220	8	twenty	twenty	NUM
njb-93	220	9	-	-	PUNCT
njb-93	220	10	first	first	ADJ
njb-93	220	11	informational	informational	ADJ
njb-93	220	12	supplement	supplement	NOUN
njb-93	220	13	.	.	PUNCT
njb-93	221	1	clsi	clsi	NOUN
njb-93	221	2	document	document	NOUN
njb-93	221	3	m100	m100	PROPN
njb-93	221	4	-	-	PUNCT
njb-93	221	5	s21	s21	NOUN
njb-93	221	6	.	.	PUNCT
njb-93	222	1	clinical	clinical	ADJ
njb-93	222	2	and	and	CCONJ
njb-93	222	3	laboratory	laboratory	PROPN
njb-93	222	4	standards	standards	PROPN
njb-93	222	5	institute	institute	PROPN
njb-93	222	6	,	,	PUNCT
njb-93	222	7	wayne	wayne	PROPN
njb-93	222	8	(	(	PUNCT
njb-93	222	9	pa	pa	PROPN
njb-93	222	10	)	)	PUNCT
njb-93	222	11	.	.	PUNCT
njb-93	223	1	2011	2011	NUM
njb-93	223	2	.	.	PUNCT
njb-93	224	1	16	16	NUM
njb-93	224	2	.	.	PUNCT
njb-93	225	1	clsi	clsi	PROPN
njb-93	225	2	:	:	PUNCT
njb-93	225	3	performance	performance	NOUN
njb-93	225	4	standards	standard	NOUN
njb-93	225	5	for	for	ADP
njb-93	225	6	antimicrobial	antimicrobial	ADJ
njb-93	225	7	susceptibility	susceptibility	NOUN
njb-93	225	8	testing	testing	NOUN
njb-93	225	9	;	;	PUNCT
njb-93	225	10	twenty	twenty	NUM
njb-93	225	11	-	-	PUNCT
njb-93	225	12	fourth	fourth	ADJ
njb-93	225	13	informational	informational	ADJ
njb-93	225	14	supplement	supplement	NOUN
njb-93	225	15	.	.	PUNCT
njb-93	226	1	m100	m100	PROPN
njb-93	226	2	s24	s24	NOUN
njb-93	226	3	.	.	PUNCT
njb-93	227	1	clinical	clinical	ADJ
njb-93	227	2	and	and	CCONJ
njb-93	227	3	laboratory	laboratory	PROPN
njb-93	227	4	standards	standards	PROPN
njb-93	227	5	institute	institute	PROPN
njb-93	227	6	,	,	PUNCT
njb-93	227	7	wayne	wayne	PROPN
njb-93	227	8	(	(	PUNCT
njb-93	227	9	pa	pa	PROPN
njb-93	227	10	)	)	PUNCT
njb-93	227	11	.	.	PUNCT
njb-93	228	1	2014	2014	NUM
njb-93	228	2	.	.	PUNCT
njb-93	229	1	17	17	NUM
njb-93	229	2	.	.	PUNCT
njb-93	230	1	bhandari	bhandari	PROPN
njb-93	230	2	p	p	PROPN
njb-93	230	3	:	:	PUNCT
njb-93	230	4	prevalence	prevalence	NOUN
njb-93	230	5	of	of	ADP
njb-93	230	6	esbl	esbl	PROPN
njb-93	230	7	produccing	produccing	NOUN
njb-93	230	8	escherichia	escherichia	NOUN
njb-93	230	9	coli	coli	NOUN
njb-93	230	10	from	from	ADP
njb-93	230	11	urine	urine	NOUN
njb-93	230	12	sample	sample	NOUN
njb-93	230	13	of	of	ADP
njb-93	230	14	the	the	DET
njb-93	230	15	patients	patient	NOUN
njb-93	230	16	visiting	visit	VERB
njb-93	230	17	venus	venus	PROPN
njb-93	230	18	internation	internation	NOUN
njb-93	230	19	hospital	hospital	NOUN
njb-93	230	20	,	,	PUNCT
njb-93	230	21	kathmandu	kathmandu	PROPN
njb-93	230	22	.	.	PUNCT
njb-93	231	1	msc	msc	PROPN
njb-93	231	2	thesis	thesis	NOUN
njb-93	231	3	.	.	PUNCT
njb-93	232	1	tribhuvan	tribhuvan	PROPN
njb-93	232	2	university	university	PROPN
njb-93	232	3	,	,	PUNCT
njb-93	232	4	submitted	submit	VERB
njb-93	232	5	to	to	ADP
njb-93	232	6	department	department	NOUN
njb-93	232	7	of	of	ADP
njb-93	232	8	microbiology	microbiology	PROPN
njb-93	232	9	,	,	PUNCT
njb-93	232	10	st	st	PROPN
njb-93	232	11	.	.	PROPN
njb-93	232	12	xaviers	xaviers	PROPN
njb-93	232	13	college	college	PROPN
njb-93	232	14	,	,	PUNCT
njb-93	232	15	2013	2013	NUM
njb-93	232	16	.	.	PUNCT
njb-93	232	17	18	18	NUM
njb-93	232	18	.	.	PUNCT
njb-93	233	1	niranjan	niranjan	PROPN
njb-93	233	2	v	v	PROPN
njb-93	233	3	,	,	PUNCT
njb-93	233	4	malini	malini	VERB
njb-93	233	5	a	a	DET
njb-93	233	6	:	:	PUNCT
njb-93	233	7	antimicrobial	antimicrobial	ADJ
njb-93	233	8	resistance	resistance	NOUN
njb-93	233	9	pattern	pattern	NOUN
njb-93	233	10	in	in	ADP
njb-93	233	11	escherichia	escherichia	NOUN
njb-93	233	12	coli	coli	NOUN
njb-93	233	13	causing	cause	VERB
njb-93	233	14	urinary	urinary	ADJ
njb-93	233	15	tract	tract	NOUN
njb-93	233	16	infection	infection	NOUN
njb-93	233	17	among	among	ADP
njb-93	233	18	inpatients	inpatient	NOUN
njb-93	233	19	.	.	PUNCT
njb-93	234	1	indian	indian	PROPN
njb-93	234	2	j	j	PROPN
njb-93	234	3	medical	medical	PROPN
njb-93	234	4	research	research	PROPN
njb-93	234	5	.	.	PUNCT
njb-93	235	1	2014	2014	NUM
njb-93	235	2	,	,	PUNCT
njb-93	235	3	139:945–8	139:945–8	PROPN
njb-93	235	4	.	.	PUNCT
njb-93	236	1	19	19	NUM
njb-93	236	2	.	.	PUNCT
njb-93	237	1	habte	habte	PROPN
njb-93	237	2	tm	tm	PROPN
njb-93	237	3	,	,	PUNCT
njb-93	237	4	dube	dube	PROPN
njb-93	237	5	s	s	PROPN
njb-93	237	6	,	,	PUNCT
njb-93	237	7	ismail	ismail	NOUN
njb-93	237	8	n	n	PROPN
njb-93	237	9	,	,	PUNCT
njb-93	237	10	hoosen	hoosen	PROPN
njb-93	237	11	aa	aa	PROPN
njb-93	237	12	:	:	PUNCT
njb-93	237	13	hospital	hospital	NOUN
njb-93	237	14	and	and	CCONJ
njb-93	237	15	community	community	NOUN
njb-93	237	16	isolates	isolate	NOUN
njb-93	237	17	of	of	ADP
njb-93	237	18	uropathogens	uropathogen	NOUN
njb-93	237	19	at	at	ADP
njb-93	237	20	a	a	DET
njb-93	237	21	tertiary	tertiary	ADJ
njb-93	237	22	hospital	hospital	NOUN
njb-93	237	23	in	in	ADP
njb-93	237	24	south	south	PROPN
njb-93	237	25	africa	africa	PROPN
njb-93	237	26	.	.	PUNCT
njb-93	238	1	south	south	PROPN
njb-93	238	2	africa	africa	PROPN
njb-93	238	3	medical	medical	PROPN
njb-93	238	4	j.	j.	PROPN
njb-93	238	5	2009	2009	NUM
njb-93	238	6	99:584–587	99:584–587	NUM
njb-93	238	7	.	.	PUNCT
njb-93	239	1	20	20	NUM
njb-93	239	2	.	.	PUNCT
njb-93	240	1	bhatta	bhatta	PROPN
njb-93	240	2	dr	dr	PROPN
njb-93	240	3	,	,	PUNCT
njb-93	240	4	shrestha	shrestha	PROPN
njb-93	240	5	j	j	PROPN
njb-93	240	6	,	,	PUNCT
njb-93	240	7	sharma	sharma	PROPN
njb-93	240	8	ar	ar	PROPN
njb-93	240	9	,	,	PUNCT
njb-93	240	10	banjara	banjara	PROPN
njb-93	240	11	mr	mr	PROPN
njb-93	240	12	:	:	PUNCT
njb-93	240	13	antimicrobial	antimicrobial	ADJ
njb-93	240	14	susceptibility	susceptibility	NOUN
njb-93	240	15	pattern	pattern	NOUN
njb-93	240	16	of	of	ADP
njb-93	240	17	escherichia	escherichia	NOUN
njb-93	240	18	coli	coli	NOUN
njb-93	240	19	isolated	isolate	VERB
njb-93	240	20	from	from	ADP
njb-93	240	21	urinary	urinary	ADJ
njb-93	240	22	tract	tract	NOUN
njb-93	240	23	infected	infect	VERB
njb-93	240	24	patients	patient	NOUN
njb-93	240	25	attending	attend	VERB
njb-93	240	26	bir	bir	PROPN
njb-93	240	27	hospital	hospital	PROPN
njb-93	240	28	.	.	PUNCT
njb-93	240	29	nepal	nepal	PROPN
njb-93	240	30	.	.	PUNCT
njb-93	241	1	j	j	PROPN
njb-93	241	2	science	science	PROPN
njb-93	241	3	and	and	CCONJ
njb-93	241	4	technology	technology	NOUN
njb-93	241	5	.	.	PUNCT
njb-93	242	1	2013	2013	NUM
njb-93	242	2	14(1	14(1	NUM
njb-93	242	3	):	):	PUNCT
njb-93	242	4	177	177	NUM
njb-93	242	5	-	-	SYM
njb-93	242	6	184	184	NUM
njb-93	242	7	.	.	PUNCT
njb-93	242	8	21	21	NUM
njb-93	242	9	.	.	PUNCT
njb-93	242	10	thakur	thakur	PROPN
njb-93	242	11	s	s	PROPN
njb-93	242	12	,	,	PUNCT
njb-93	242	13	pokhrel	pokhrel	PROPN
njb-93	242	14	n	n	NOUN
njb-93	242	15	and	and	CCONJ
njb-93	242	16	sharma	sharma	PROPN
njb-93	242	17	m	m	PROPN
njb-93	242	18	:	:	PUNCT
njb-93	242	19	prevalence	prevalence	NOUN
njb-93	242	20	of	of	ADP
njb-93	242	21	multidrug	multidrug	NOUN
njb-93	242	22	resistant	resistant	ADJ
njb-93	242	23	enterobacteriaceae	enterobacteriaceae	PROPN
njb-93	242	24	and	and	CCONJ
njb-93	242	25	extended	extend	VERB
njb-93	242	26	spectrum	spectrum	NOUN
njb-93	242	27	β	β	NOUN
njb-93	242	28	lactamase	lactamase	NOUN
njb-93	242	29	producing	produce	VERB
njb-93	242	30	escherichia	escherichia	NOUN
njb-93	242	31	coli	coli	NOUN
njb-93	242	32	in	in	ADP
njb-93	242	33	urinary	urinary	ADJ
njb-93	242	34	tract	tract	NOUN
njb-93	242	35	infection	infection	NOUN
njb-93	242	36	.	.	PUNCT
njb-93	243	1	research	research	PROPN
njb-93	243	2	j	j	PROPN
njb-93	243	3	pharmaceutical	pharmaceutical	PROPN
njb-93	243	4	,	,	PUNCT
njb-93	243	5	biological	biological	ADJ
njb-93	243	6	and	and	CCONJ
njb-93	243	7	chemical	chemical	ADJ
njb-93	243	8	sciences	science	NOUN
njb-93	243	9	.	.	PUNCT
njb-93	244	1	2013	2013	NUM
njb-93	244	2	4	4	NUM
njb-93	244	3	(	(	PUNCT
njb-93	244	4	2):1615	2):1615	NUM
njb-93	244	5	.	.	PUNCT
njb-93	244	6	22	22	NUM
njb-93	244	7	.	.	PUNCT
njb-93	245	1	baral	baral	ADJ
njb-93	245	2	p	p	PROPN
njb-93	245	3	,	,	PUNCT
njb-93	245	4	neupane	neupane	PROPN
njb-93	245	5	s	s	PROPN
njb-93	245	6	,	,	PUNCT
njb-93	245	7	marasini	marasini	PROPN
njb-93	245	8	bp	bp	PROPN
njb-93	245	9	,	,	PUNCT
njb-93	245	10	ghimire	ghimire	PROPN
njb-93	245	11	kr	kr	PROPN
njb-93	245	12	,	,	PUNCT
njb-93	245	13	lekhak	lekhak	PROPN
njb-93	245	14	b	b	PROPN
njb-93	245	15	,	,	PUNCT
njb-93	245	16	shrestha	shrestha	PROPN
njb-93	245	17	b	b	PROPN
njb-93	245	18	:	:	PUNCT
njb-93	245	19	high	high	ADJ
njb-93	245	20	prevalence	prevalence	NOUN
njb-93	245	21	of	of	ADP
njb-93	245	22	multidrug	multidrug	NOUN
njb-93	245	23	resistance	resistance	NOUN
njb-93	245	24	in	in	ADP
njb-93	245	25	bacterial	bacterial	ADJ
njb-93	245	26	uropathogens	uropathogen	NOUN
njb-93	245	27	from	from	ADP
njb-93	245	28	kathmandu	kathmandu	NOUN
njb-93	245	29	,	,	PUNCT
njb-93	245	30	nepal	nepal	ADJ
njb-93	245	31	.	.	PUNCT
njb-93	246	1	bmc	bmc	PROPN
njb-93	246	2	research	research	PROPN
njb-93	246	3	notes	note	NOUN
njb-93	246	4	.	.	PUNCT
njb-93	247	1	20125:38	20125:38	NUM
njb-93	247	2	.	.	PUNCT
njb-93	247	3	23	23	NUM
njb-93	247	4	.	.	PUNCT
njb-93	247	5	kot	kot	PROPN
njb-93	247	6	b	b	PROPN
njb-93	247	7	,	,	PUNCT
njb-93	247	8	wicha	wicha	PROPN
njb-93	247	9	j	j	PROPN
njb-93	247	10	,	,	PUNCT
njb-93	247	11	zak	zak	PROPN
njb-93	247	12	-	-	PUNCT
njb-93	247	13	palawska	palawska	PROPN
njb-93	247	14	z	z	NOUN
njb-93	247	15	:	:	PUNCT
njb-93	247	16	susceptibility	susceptibility	NOUN
njb-93	247	17	of	of	ADP
njb-93	247	18	escherichia	escherichia	NOUN
njb-93	247	19	coli	coli	NOUN
njb-93	247	20	strains	strain	NOUN
njb-93	247	21	isolated	isolate	VERB
njb-93	247	22	from	from	ADP
njb-93	247	23	persons	person	NOUN
njb-93	247	24	with	with	ADP
njb-93	247	25	urinary	urinary	ADJ
njb-93	247	26	tract	tract	NOUN
njb-93	247	27	infections	infection	NOUN
njb-93	247	28	in	in	ADP
njb-93	247	29	2007	2007	NUM
njb-93	247	30	-	-	SYM
njb-93	247	31	2008	2008	NUM
njb-93	247	32	to	to	ADP
njb-93	247	33	microbial	microbial	ADJ
njb-93	247	34	agents	agent	NOUN
njb-93	247	35	.	.	PUNCT
njb-93	248	1	przegl	przegl	PROPN
njb-93	248	2	epidemol	epidemol	PROPN
njb-93	248	3	.	.	PUNCT
njb-93	249	1	2010	2010	NUM
njb-93	249	2	64:307	64:307	NUM
njb-93	249	3	-	-	SYM
njb-93	249	4	312	312	NUM
njb-93	249	5	.	.	PROPN
njb-93	249	6	24	24	NUM
njb-93	249	7	.	.	PUNCT
njb-93	250	1	raza	raza	PROPN
njb-93	250	2	s	s	PROPN
njb-93	250	3	,	,	PUNCT
njb-93	250	4	pandey	pandey	PROPN
njb-93	250	5	s	s	PROPN
njb-93	250	6	,	,	PUNCT
njb-93	250	7	bhatt	bhatt	PROPN
njb-93	250	8	cp	cp	PROPN
njb-93	250	9	:	:	PUNCT
njb-93	250	10	microbiological	microbiological	ADJ
njb-93	250	11	analysis	analysis	NOUN
njb-93	250	12	of	of	ADP
njb-93	250	13	the	the	DET
njb-93	250	14	urine	urine	NOUN
njb-93	250	15	isolates	isolate	VERB
njb-93	250	16	in	in	ADP
njb-93	250	17	kathmandu	kathmandu	PROPN
njb-93	250	18	medical	medical	PROPN
njb-93	250	19	college	college	PROPN
njb-93	250	20	teaching	teaching	PROPN
njb-93	250	21	hospital	hospital	PROPN
njb-93	250	22	,	,	PUNCT
njb-93	250	23	kathmandu	kathmandu	PROPN
njb-93	250	24	,	,	PUNCT
njb-93	250	25	nepal	nepal	ADJ
njb-93	250	26	.	.	PUNCT
njb-93	251	1	kathmandu	kathmandu	PROPN
njb-93	251	2	univ	univ	PROPN
njb-93	251	3	med	me	VERB
njb-93	251	4	j.	j.	PROPN
njb-93	251	5	2011	2011	NUM
njb-93	251	6	36(4):295	36(4):295	PROPN
njb-93	251	7	-	-	SYM
njb-93	251	8	7	7	NUM
njb-93	251	9	.	.	NUM
njb-93	251	10	25	25	NUM
njb-93	251	11	.	.	PUNCT
njb-93	252	1	dahal	dahal	PROPN
njb-93	252	2	s	s	PROPN
njb-93	252	3	,	,	PUNCT
njb-93	252	4	singh	singh	PROPN
njb-93	252	5	a	a	PRON
njb-93	252	6	,	,	PUNCT
njb-93	252	7	sharma	sharma	PROPN
njb-93	252	8	s	s	PROPN
njb-93	252	9	,	,	PUNCT
njb-93	252	10	awal	awal	PROPN
njb-93	252	11	bk	bk	NOUN
njb-93	252	12	:	:	PUNCT
njb-93	252	13	extended	extended	ADJ
njb-93	252	14	spectrum	spectrum	NOUN
njb-93	252	15	b	b	PROPN
njb-93	252	16	lactamase	lactamase	NOUN
njb-93	252	17	producing	produce	VERB
njb-93	252	18	multidrug	multidrug	NOUN
njb-93	252	19	resistant	resistant	ADJ
njb-93	252	20	escherichia	escherichia	NOUN
njb-93	252	21	coli	coli	NOUN
njb-93	252	22	at	at	ADP
njb-93	252	23	community	community	NOUN
njb-93	252	24	hospital	hospital	NOUN
njb-93	252	25	of	of	ADP
njb-93	252	26	kathmandu	kathmandu	NOUN
njb-93	252	27	.	.	PUNCT
njb-93	253	1	tribhuvan	tribhuvan	PROPN
njb-93	253	2	university	university	PROPN
njb-93	253	3	j	j	PROPN
njb-93	253	4	microbiol	microbiol	PROPN
njb-93	253	5	.	.	PUNCT
njb-93	254	1	2016	2016	NUM
njb-93	254	2	3(1	3(1	X
njb-93	254	3	)	)	PUNCT
njb-93	254	4	55	55	NUM
njb-93	254	5	-	-	SYM
njb-93	254	6	60	60	NUM
njb-93	254	7	nepal	nepal	ADJ
njb-93	254	8	journal	journal	NOUN
njb-93	254	9	of	of	ADP
njb-93	254	10	biotechnology	biotechnology	NOUN
njb-93	254	11	.	.	PUNCT
njb-93	255	1	d	d	X
njb-93	255	2	e	e	PROPN
njb-93	255	3	c	c	PROPN
njb-93	255	4	.	.	PUNCT
njb-93	256	1	2	2	NUM
njb-93	256	2	0	0	NUM
njb-93	256	3	1	1	NUM
njb-93	256	4	7	7	NUM
njb-93	256	5	vol	vol	NOUN
njb-93	256	6	.	.	PROPN
njb-93	257	1	5	5	NUM
njb-93	257	2	,	,	PUNCT
njb-93	257	3	no	no	NOUN
njb-93	257	4	.	.	NOUN
njb-93	257	5	1	1	NUM
njb-93	257	6	:	:	SYM
njb-93	257	7	32	32	NUM
njb-93	257	8	-	-	SYM
njb-93	257	9	38	38	NUM
njb-93	257	10	rimal	rimal	NOUN
njb-93	257	11	et	et	PROPN
njb-93	257	12	al	al	PROPN
njb-93	257	13	.	.	PUNCT
njb-93	258	1	©	©	PROPN
njb-93	258	2	njb	njb	PROPN
njb-93	258	3	,	,	PUNCT
njb-93	258	4	biotechnology	biotechnology	NOUN
njb-93	258	5	society	society	NOUN
njb-93	258	6	of	of	ADP
njb-93	258	7	nepal	nepal	ADJ
njb-93	258	8	38	38	NUM
njb-93	258	9	nepjol.info/index.php/njb	nepjol.info/index.php/njb	PROPN
njb-93	258	10	26	26	NUM
njb-93	258	11	.	.	PUNCT
njb-93	259	1	sherchan	sherchan	PROPN
njb-93	259	2	jb	jb	PROPN
njb-93	259	3	,	,	PUNCT
njb-93	259	4	gurung	gurung	PROPN
njb-93	259	5	p	p	PROPN
njb-93	259	6	,	,	PUNCT
njb-93	259	7	bam	bam	PROPN
njb-93	259	8	ds	ds	PROPN
njb-93	259	9	:	:	PUNCT
njb-93	259	10	multi	multi	ADJ
njb-93	259	11	-	-	ADJ
njb-93	259	12	drug	drug	ADJ
njb-93	259	13	resistant	resistant	ADJ
njb-93	259	14	bacterial	bacterial	ADJ
njb-93	259	15	strains	strain	NOUN
njb-93	259	16	in	in	ADP
njb-93	259	17	lower	low	ADJ
njb-93	259	18	respiratory	respiratory	ADJ
njb-93	259	19	tract	tract	NOUN
njb-93	259	20	infections	infection	NOUN
njb-93	259	21	,	,	PUNCT
njb-93	259	22	antibiotic	antibiotic	ADJ
njb-93	259	23	sensitivity	sensitivity	NOUN
njb-93	259	24	patterns	pattern	NOUN
njb-93	259	25	and	and	CCONJ
njb-93	259	26	risk	risk	NOUN
njb-93	259	27	factor	factor	NOUN
njb-93	259	28	.	.	PUNCT
njb-93	260	1	nepal	nepal	PROPN
njb-93	260	2	j	j	PROPN
njb-93	260	3	science	science	PROPN
njb-93	260	4	and	and	CCONJ
njb-93	260	5	technology	technology	NOUN
njb-93	260	6	.	.	PUNCT
njb-93	261	1	2012	2012	NUM
njb-93	262	1	13(1):157	13(1):157	PROPN
njb-93	262	2	-	-	PUNCT
njb-93	262	3	163	163	NUM
njb-93	262	4	.	.	SYM
njb-93	262	5	27	27	NUM
njb-93	262	6	.	.	PUNCT
njb-93	263	1	mishra	mishra	PROPN
njb-93	263	2	mp	mp	PROPN
njb-93	263	3	,	,	PUNCT
njb-93	263	4	debata	debata	PROPN
njb-93	263	5	nk	nk	PROPN
njb-93	263	6	,	,	PUNCT
njb-93	263	7	padhy	padhy	PROPN
njb-93	263	8	rn	rn	NOUN
njb-93	263	9	:	:	PUNCT
njb-93	263	10	surveillance	surveillance	NOUN
njb-93	263	11	of	of	ADP
njb-93	263	12	multi	multi	ADJ
njb-93	263	13	-	-	ADJ
njb-93	263	14	drug	drug	ADJ
njb-93	263	15	resistant	resistant	ADJ
njb-93	263	16	uropathogenic	uropathogenic	ADJ
njb-93	263	17	bacteria	bacteria	NOUN
njb-93	263	18	in	in	ADP
njb-93	263	19	hospitalized	hospitalize	VERB
njb-93	263	20	patient	patient	NOUN
njb-93	263	21	in	in	ADP
njb-93	263	22	indian	indian	PROPN
njb-93	263	23	.	.	PUNCT
njb-93	264	1	asian	asian	PROPN
njb-93	264	2	pacific	pacific	PROPN
njb-93	264	3	j	j	PROPN
njb-93	264	4	tropical	tropical	PROPN
njb-93	264	5	biomedicine	biomedicine	NOUN
njb-93	264	6	.	.	PUNCT
njb-93	265	1	2013	2013	NUM
njb-93	265	2	3(4):315	3(4):315	NUM
njb-93	265	3	-	-	SYM
njb-93	265	4	324	324	NUM
njb-93	265	5	.	.	PUNCT
njb-93	265	6	28	28	NUM
njb-93	265	7	.	.	PUNCT
njb-93	266	1	randrianirina	randrianirina	PROPN
njb-93	266	2	f	f	PROPN
njb-93	266	3	,	,	PUNCT
njb-93	266	4	soares	soares	PROPN
njb-93	266	5	jl	jl	PROPN
njb-93	266	6	,	,	PUNCT
njb-93	266	7	carod	carod	PROPN
njb-93	266	8	jf	jf	PROPN
njb-93	266	9	,	,	PUNCT
njb-93	266	10	ratsima	ratsima	PROPN
njb-93	266	11	e	e	PROPN
njb-93	266	12	,	,	PUNCT
njb-93	266	13	thonnier	thonnier	PROPN
njb-93	266	14	v	v	NOUN
njb-93	266	15	,	,	PUNCT
njb-93	266	16	combe	combe	PROPN
njb-93	266	17	p	p	NOUN
njb-93	266	18	:	:	PUNCT
njb-93	266	19	antimicrobial	antimicrobial	ADJ
njb-93	266	20	resistance	resistance	NOUN
njb-93	266	21	among	among	ADP
njb-93	266	22	uropathogens	uropathogen	NOUN
njb-93	266	23	that	that	PRON
njb-93	266	24	cause	cause	VERB
njb-93	266	25	communityacquired	communityacquire	VERB
njb-93	266	26	urinary	urinary	ADJ
njb-93	266	27	tract	tract	NOUN
njb-93	266	28	infections	infection	NOUN
njb-93	266	29	in	in	ADP
njb-93	266	30	antananarivo	antananarivo	NOUN
njb-93	266	31	,	,	PUNCT
njb-93	266	32	madagascar	madagascar	NOUN
njb-93	266	33	.	.	PUNCT
njb-93	267	1	j	j	PROPN
njb-93	267	2	antimicrob	antimicrob	PROPN
njb-93	267	3	chemother	chemother	PROPN
njb-93	267	4	.	.	PUNCT
njb-93	268	1	2007	2007	NUM
njb-93	269	1	59:309–312	59:309–312	PROPN
njb-93	269	2	.	.	PROPN
njb-93	269	3	29	29	NUM
njb-93	269	4	.	.	PUNCT
njb-93	270	1	behrooozi	behrooozi	PROPN
njb-93	270	2	a	a	PROPN
njb-93	270	3	,	,	PUNCT
njb-93	270	4	rahbar	rahbar	NOUN
njb-93	270	5	m	m	PROPN
njb-93	270	6	,	,	PUNCT
njb-93	270	7	yousefi	yousefi	PROPN
njb-93	270	8	jv	jv	PROPN
njb-93	270	9	:	:	PUNCT
njb-93	270	10	frequency	frequency	NOUN
njb-93	270	11	of	of	ADP
njb-93	270	12	extended	extended	ADJ
njb-93	270	13	spectrum	spectrum	NOUN
njb-93	270	14	beta	beta	NOUN
njb-93	270	15	-	-	PUNCT
njb-93	270	16	lactamase	lactamase	NOUN
njb-93	270	17	(	(	PUNCT
njb-93	270	18	esbls	esbls	PROPN
njb-93	270	19	)	)	PUNCT
njb-93	270	20	producing	produce	VERB
njb-93	270	21	escherichia	escherichia	NOUN
njb-93	270	22	coli	coli	NOUN
njb-93	270	23	and	and	CCONJ
njb-93	270	24	klebsiella	klebsiella	PROPN
njb-93	270	25	pneumoniae	pneumoniae	NOUN
njb-93	270	26	isolated	isolate	VERB
njb-93	270	27	from	from	ADP
njb-93	270	28	urine	urine	NOUN
njb-93	270	29	in	in	ADP
njb-93	270	30	an	an	DET
njb-93	270	31	iranian	iranian	ADJ
njb-93	270	32	1000	1000	NUM
njb-93	270	33	-	-	PUNCT
njb-93	270	34	bed	bed	NOUN
njb-93	270	35	tertiary	tertiary	ADJ
njb-93	270	36	care	care	NOUN
njb-93	270	37	hospital	hospital	NOUN
njb-93	270	38	.	.	PUNCT
njb-93	271	1	african	african	PROPN
njb-93	271	2	j	j	PROPN
njb-93	271	3	microbiol	microbiol	PROPN
njb-93	271	4	research	research	PROPN
njb-93	271	5	.	.	PUNCT
njb-93	272	1	2010	2010	NUM
njb-93	272	2	4(9):881–884	4(9):881–884	NUM
njb-93	272	3	.	.	PUNCT
njb-93	273	1	30	30	NUM
njb-93	273	2	.	.	PUNCT
njb-93	274	1	bazzaz	bazzaz	PROPN
njb-93	274	2	bs	bs	PROPN
njb-93	274	3	,	,	PUNCT
njb-93	274	4	naderinasab	naderinasab	PROPN
njb-93	274	5	m	m	PROPN
njb-93	274	6	,	,	PUNCT
njb-93	274	7	mohamadpoor	mohamadpoor	NOUN
njb-93	274	8	ah	ah	INTJ
njb-93	274	9	,	,	PUNCT
njb-93	274	10	farshadzadeh	farshadzadeh	PROPN
njb-93	274	11	z	z	PROPN
njb-93	274	12	,	,	PUNCT
njb-93	274	13	ahmadi	ahmadi	PROPN
njb-93	274	14	s	s	PROPN
njb-93	274	15	,	,	PUNCT
njb-93	274	16	yousefi	yousefi	PROPN
njb-93	274	17	f	f	PROPN
njb-93	274	18	:	:	PUNCT
njb-93	274	19	the	the	DET
njb-93	274	20	prevalence	prevalence	NOUN
njb-93	274	21	of	of	ADP
njb-93	274	22	extended	extended	ADJ
njb-93	274	23	-	-	PUNCT
njb-93	274	24	spectrum	spectrum	NOUN
njb-93	274	25	beta	beta	NOUN
njb-93	274	26	-	-	PUNCT
njb-93	274	27	lactamaseproducing	lactamaseproduce	VERB
njb-93	274	28	escherichia	escherichia	NOUN
njb-93	274	29	coli	coli	NOUN
njb-93	274	30	and	and	CCONJ
njb-93	274	31	klebsiella	klebsiella	PROPN
njb-93	274	32	pneumoniae	pneumoniae	NOUN
njb-93	274	33	among	among	ADP
njb-93	274	34	clinical	clinical	ADJ
njb-93	274	35	isolates	isolate	NOUN
njb-93	274	36	from	from	ADP
njb-93	274	37	a	a	DET
njb-93	274	38	general	general	ADJ
njb-93	274	39	hospital	hospital	NOUN
njb-93	274	40	in	in	ADP
njb-93	274	41	iran	iran	PROPN
njb-93	274	42	.	.	PUNCT
njb-93	275	1	acta	acta	PROPN
njb-93	275	2	microbiol	microbiol	PROPN
njb-93	275	3	immunol	immunol	NOUN
njb-93	275	4	hung	hang	VERB
njb-93	275	5	.	.	PUNCT
njb-93	276	1	2009	2009	NUM
njb-93	276	2	56(1):89–99	56(1):89–99	NUM
njb-93	276	3	.	.	PUNCT
njb-93	276	4	31	31	NUM
njb-93	276	5	.	.	PUNCT
njb-93	276	6	jacoby	jacoby	PROPN
njb-93	276	7	ga	ga	PROPN
njb-93	276	8	:	:	PUNCT
njb-93	276	9	mechanism	mechanism	NOUN
njb-93	276	10	of	of	ADP
njb-93	276	11	resistance	resistance	NOUN
njb-93	276	12	to	to	ADP
njb-93	276	13	quinolones	quinolone	NOUN
njb-93	276	14	.	.	PUNCT
njb-93	277	1	clinical	clinical	ADJ
njb-93	277	2	infectious	infectious	ADJ
njb-93	277	3	disease	disease	NOUN
njb-93	277	4	.	.	PUNCT
njb-93	278	1	2005	2005	NUM
njb-93	278	2	,	,	PUNCT
njb-93	278	3	41:120–126	41:120–126	NUM
njb-93	278	4	.	.	PUNCT
njb-93	278	5	32	32	NUM
njb-93	278	6	.	.	PUNCT
njb-93	279	1	abdullah	abdullah	PROPN
njb-93	279	2	fe	fe	PROPN
njb-93	279	3	,	,	PUNCT
njb-93	279	4	mushtaq	mushtaq	PROPN
njb-93	279	5	a	a	DET
njb-93	279	6	,	,	PUNCT
njb-93	279	7	irshad	irshad	ADJ
njb-93	279	8	m	m	PROPN
njb-93	279	9	,	,	PUNCT
njb-93	279	10	rauf	rauf	PROPN
njb-93	279	11	h	h	PROPN
njb-93	279	12	,	,	PUNCT
njb-93	279	13	afzal	afzal	PROPN
njb-93	279	14	n	n	PROPN
njb-93	279	15	,	,	PUNCT
njb-93	279	16	rasheed	rashee	VERB
njb-93	279	17	a	a	DET
njb-93	279	18	:	:	PUNCT
njb-93	279	19	current	current	ADJ
njb-93	279	20	efficacy	efficacy	NOUN
njb-93	279	21	of	of	ADP
njb-93	279	22	antibiotics	antibiotic	NOUN
njb-93	279	23	against	against	ADP
njb-93	279	24	klebsiella	klebsiella	PROPN
njb-93	279	25	isolates	isolate	VERB
njb-93	279	26	from	from	ADP
njb-93	279	27	urine	urine	NOUN
njb-93	279	28	samples	sample	NOUN
njb-93	279	29	–	–	PUNCT
njb-93	279	30	a	a	DET
njb-93	279	31	multi	multi	ADJ
njb-93	279	32	-	-	ADJ
njb-93	279	33	centric	centric	ADJ
njb-93	279	34	experience	experience	NOUN
njb-93	279	35	in	in	ADP
njb-93	279	36	karachi	karachi	PROPN
njb-93	279	37	.	.	PUNCT
njb-93	280	1	pakistan	pakistan	PROPN
njb-93	280	2	j	j	PROPN
njb-93	280	3	pharmaceutical	pharmaceutical	PROPN
njb-93	280	4	sci	sci	PROPN
njb-93	280	5	.	.	PUNCT
njb-93	281	1	2013	2013	NUM
njb-93	281	2	26(1):11–15	26(1):11–15	NUM
njb-93	281	3	33	33	NUM
njb-93	281	4	.	.	PUNCT
njb-93	282	1	davis	davis	PROPN
njb-93	282	2	ma	ma	PROPN
njb-93	282	3	,	,	PUNCT
njb-93	282	4	baker	baker	PROPN
njb-93	282	5	kn	kn	PROPN
njb-93	282	6	,	,	PUNCT
njb-93	282	7	orfe	orfe	ADV
njb-93	282	8	lh	lh	PROPN
njb-93	282	9	,	,	PUNCT
njb-93	282	10	shah	shah	PROPN
njb-93	282	11	dh	dh	PROPN
njb-93	282	12	,	,	PUNCT
njb-93	282	13	besser	besser	PROPN
njb-93	282	14	te	te	PROPN
njb-93	282	15	,	,	PUNCT
njb-93	282	16	call	call	NOUN
njb-93	282	17	dr	dr	PROPN
njb-93	282	18	:	:	PUNCT
njb-93	282	19	discovery	discovery	NOUN
njb-93	282	20	of	of	ADP
njb-93	282	21	a	a	DET
njb-93	282	22	gene	gene	NOUN
njb-93	282	23	conferring	confer	VERB
njb-93	282	24	multiple	multiple	ADJ
njb-93	282	25	-	-	PUNCT
njb-93	282	26	aminoglycosides	aminoglycoside	NOUN
njb-93	282	27	resistance	resistance	NOUN
njb-93	282	28	in	in	ADP
njb-93	282	29	escherichia	escherichia	NOUN
njb-93	282	30	coli	coli	NOUN
njb-93	282	31	.	.	PUNCT
njb-93	283	1	antimicrobial	antimicrobial	ADJ
njb-93	283	2	agents	agents	PROPN
njb-93	283	3	chemother	chemother	PROPN
njb-93	283	4	.	.	PUNCT
njb-93	284	1	2010	2010	NUM
njb-93	284	2	54:266	54:266	NUM
njb-93	284	3	-	-	SYM
njb-93	284	4	2669	2669	NUM
njb-93	284	5	.	.	PUNCT
njb-93	285	1	34	34	NUM
njb-93	285	2	.	.	PUNCT
njb-93	285	3	ullah	ullah	PROPN
njb-93	285	4	f	f	PROPN
njb-93	285	5	,	,	PUNCT
njb-93	285	6	malik	malik	PROPN
njb-93	285	7	sa	sa	PROPN
njb-93	285	8	,	,	PUNCT
njb-93	285	9	ahmed	ahmed	PROPN
njb-93	285	10	j	j	PROPN
njb-93	285	11	:	:	PUNCT
njb-93	285	12	antibiotic	antibiotic	ADJ
njb-93	285	13	susceptibility	susceptibility	NOUN
njb-93	285	14	pattern	pattern	NOUN
njb-93	285	15	and	and	CCONJ
njb-93	285	16	esbl	esbl	NOUN
njb-93	285	17	prevalence	prevalence	NOUN
njb-93	285	18	in	in	ADP
njb-93	285	19	nosocomial	nosocomial	ADJ
njb-93	285	20	escherichia	escherichia	NOUN
njb-93	285	21	coli	coli	NOUN
njb-93	285	22	from	from	ADP
njb-93	285	23	urinary	urinary	ADJ
njb-93	285	24	tract	tract	NOUN
njb-93	285	25	infections	infection	NOUN
njb-93	285	26	in	in	ADP
njb-93	285	27	pakistan	pakistan	PROPN
njb-93	285	28	.	.	PUNCT
njb-93	286	1	african	african	PROPN
njb-93	286	2	j	j	PROPN
njb-93	286	3	biotechnology	biotechnology	PROPN
njb-93	286	4	.	.	PUNCT
njb-93	287	1	2009	2009	NUM
njb-93	287	2	8(16	8(16	NUM
njb-93	287	3	):	):	PUNCT
njb-93	287	4	3921	3921	NUM
njb-93	287	5	-	-	SYM
njb-93	287	6	3926	3926	NUM
njb-93	287	7	.	.	PUNCT
njb-93	288	1	35	35	NUM
njb-93	288	2	.	.	PUNCT
njb-93	288	3	nordmann	nordmann	PROPN
njb-93	288	4	p	p	PROPN
njb-93	288	5	,	,	PUNCT
njb-93	288	6	cuzon	cuzon	PROPN
njb-93	288	7	g	g	PROPN
njb-93	288	8	,	,	PUNCT
njb-93	288	9	naas	naas	PROPN
njb-93	288	10	t	t	PROPN
njb-93	288	11	:	:	PUNCT
njb-93	288	12	the	the	DET
njb-93	288	13	real	real	ADJ
njb-93	288	14	threat	threat	NOUN
njb-93	288	15	of	of	ADP
njb-93	288	16	klebsiella	klebsiella	PROPN
njb-93	288	17	pneumoniae	pneumoniae	NOUN
njb-93	288	18	carbapenemaseproducing	carbapenemaseproduce	VERB
njb-93	288	19	bacteria	bacteria	NOUN
njb-93	288	20	.	.	PUNCT
njb-93	289	1	lancet	lancet	PROPN
njb-93	289	2	infectious	infectious	ADJ
njb-93	289	3	disease	disease	NOUN
njb-93	289	4	.	.	PUNCT
njb-93	290	1	2009	2009	NUM
njb-93	290	2	9	9	NUM
njb-93	290	3	:	:	PUNCT
njb-93	290	4	228	228	NUM
njb-93	290	5	-	-	SYM
njb-93	290	6	236	236	NUM
njb-93	290	7	.	.	PROPN
njb-93	290	8	36	36	NUM
njb-93	290	9	.	.	PUNCT
njb-93	291	1	tuladhar	tuladhar	PROPN
njb-93	291	2	nr	nr	PROPN
njb-93	291	3	,	,	PUNCT
njb-93	291	4	banjade	banjade	PROPN
njb-93	291	5	n	n	PROPN
njb-93	291	6	,	,	PUNCT
njb-93	291	7	pokhrel	pokhrel	PROPN
njb-93	291	8	bm	bm	PROPN
njb-93	291	9	,	,	PUNCT
njb-93	291	10	rizal	rizal	PROPN
njb-93	291	11	b	b	PROPN
njb-93	291	12	,	,	PUNCT
njb-93	291	13	manandhar	manandhar	ADJ
njb-93	291	14	r	r	NOUN
njb-93	291	15	,	,	PUNCT
njb-93	291	16	shrestha	shrestha	PROPN
njb-93	291	17	s	s	PROPN
njb-93	291	18	,	,	PUNCT
njb-93	291	19	shah	shah	VERB
njb-93	291	20	a	a	PRON
njb-93	291	21	and	and	CCONJ
njb-93	291	22	chaurasia	chaurasia	PROPN
njb-93	291	23	s	s	NOUN
njb-93	291	24	:	:	PUNCT
njb-93	291	25	antimicrobial	antimicrobial	ADJ
njb-93	291	26	resistant	resistant	ADJ
njb-93	291	27	bacterial	bacterial	ADJ
njb-93	291	28	strains	strain	NOUN
njb-93	291	29	from	from	ADP
njb-93	291	30	inpatients	inpatient	NOUN
njb-93	291	31	of	of	ADP
njb-93	291	32	tribhuvan	tribhuvan	PROPN
njb-93	291	33	university	university	PROPN
njb-93	291	34	teaching	teaching	PROPN
njb-93	291	35	hospital	hospital	NOUN
njb-93	291	36	kathmandu	kathmandu	NOUN
njb-93	291	37	.	.	PUNCT
njb-93	292	1	j	j	PROPN
njb-93	292	2	inst	inst	ADP
njb-93	292	3	med	med	PROPN
njb-93	292	4	.	.	PROPN
njb-93	292	5	2003	2003	NUM
njb-93	292	6	25:19	25:19	NUM
njb-93	292	7	-	-	SYM
njb-93	292	8	26	26	NUM
njb-93	292	9	.	.	NUM
njb-93	292	10	37	37	NUM
njb-93	292	11	.	.	PUNCT
njb-93	293	1	upadhyay	upadhyay	PROPN
njb-93	293	2	g	g	PROPN
njb-93	293	3	,	,	PUNCT
njb-93	293	4	shakya	shakya	PROPN
njb-93	293	5	g	g	PROPN
njb-93	293	6	,	,	PUNCT
njb-93	293	7	upadhyaya	upadhyaya	PROPN
njb-93	293	8	bp	bp	PROPN
njb-93	293	9	,	,	PUNCT
njb-93	293	10	shrestha	shrestha	PROPN
njb-93	293	11	s	s	PROPN
njb-93	293	12	,	,	PUNCT
njb-93	293	13	ansari	ansari	PROPN
njb-93	293	14	s	s	PROPN
njb-93	293	15	,	,	PUNCT
njb-93	293	16	ghimire	ghimire	PROPN
njb-93	293	17	p	p	PROPN
njb-93	293	18	et	et	X
njb-93	293	19	al	al	PROPN
njb-93	293	20	:	:	PUNCT
njb-93	293	21	comparative	comparative	ADJ
njb-93	293	22	evaluation	evaluation	NOUN
njb-93	293	23	of	of	ADP
njb-93	293	24	urine	urine	NOUN
njb-93	293	25	isolates	isolate	VERB
njb-93	293	26	among	among	ADP
njb-93	293	27	kidney	kidney	NOUN
njb-93	293	28	transplanted	transplanted	PROPN
njb-93	293	29	and	and	CCONJ
njb-93	293	30	other	other	ADJ
njb-93	293	31	uti	uti	PROPN
njb-93	293	32	suspected	suspect	VERB
njb-93	293	33	patients	patient	NOUN
njb-93	293	34	visiting	visit	VERB
njb-93	293	35	national	national	ADJ
njb-93	293	36	public	public	PROPN
njb-93	293	37	health	health	PROPN
njb-93	293	38	laboratory	laboratory	PROPN
njb-93	293	39	,	,	PUNCT
njb-93	293	40	(	(	PUNCT
njb-93	293	41	nphl	nphl	PROPN
njb-93	293	42	)	)	PUNCT
njb-93	293	43	teku	teku	PROPN
njb-93	293	44	,	,	PUNCT
njb-93	293	45	nepal	nepal	ADJ
njb-93	293	46	.	.	PUNCT
njb-93	294	1	int	int	PROPN
njb-93	294	2	j	j	PROPN
njb-93	294	3	biomed	biome	VERB
njb-93	294	4	adv	adv	PROPN
njb-93	294	5	res	res	PROPN
njb-93	294	6	.	.	PUNCT
njb-93	295	1	2013	2013	NUM
njb-93	295	2	4(6):369	4(6):369	NUM
njb-93	295	3	-	-	SYM
njb-93	295	4	75	75	NUM
njb-93	295	5	.	.	NUM
njb-93	295	6	38	38	NUM
njb-93	295	7	.	.	PUNCT
njb-93	295	8	babypadmini	babypadmini	PROPN
njb-93	295	9	s	s	PROPN
njb-93	295	10	,	,	PUNCT
njb-93	295	11	appalaraju	appalaraju	PROPN
njb-93	295	12	b	b	PROPN
njb-93	295	13	:	:	PUNCT
njb-93	295	14	extended	extended	ADJ
njb-93	295	15	spectrum	spectrum	NOUN
njb-93	295	16	lactamase	lactamase	NOUN
njb-93	295	17	in	in	ADP
njb-93	295	18	urinary	urinary	ADJ
njb-93	295	19	isolates	isolate	NOUN
njb-93	295	20	of	of	ADP
njb-93	295	21	e.	e.	PROPN
njb-93	295	22	coli	coli	PROPN
njb-93	295	23	and	and	CCONJ
njb-93	295	24	klebsiella	klebsiella	PROPN
njb-93	295	25	pneumoniae	pneumoniae	PROPN
njb-93	295	26	prevalence	prevalence	NOUN
njb-93	295	27	and	and	CCONJ
njb-93	295	28	susceptibility	susceptibility	NOUN
njb-93	295	29	patterns	pattern	NOUN
njb-93	295	30	in	in	ADP
njb-93	295	31	a	a	DET
njb-93	295	32	tertiary	tertiary	ADJ
njb-93	295	33	care	care	NOUN
njb-93	295	34	hospital	hospital	NOUN
njb-93	295	35	.	.	PUNCT
njb-93	296	1	indian	indian	PROPN
njb-93	296	2	j	j	PROPN
njb-93	296	3	medical	medical	PROPN
njb-93	296	4	microbiol	microbiol	PROPN
njb-93	296	5	.	.	PUNCT
njb-93	297	1	2004	2004	NUM
njb-93	297	2	22:172	22:172	NUM
njb-93	297	3	–	–	PUNCT
njb-93	297	4	174	174	NUM
njb-93	297	5	.	.	X
njb-93	297	6	39	39	NUM
njb-93	297	7	.	.	PUNCT
njb-93	298	1	poudyal	poudyal	PROPN
njb-93	298	2	s	s	PROPN
njb-93	298	3	:	:	PUNCT
njb-93	299	1	prevalance	prevalance	NOUN
njb-93	299	2	of	of	ADP
njb-93	299	3	b	b	PROPN
njb-93	299	4	lactamase	lactamase	NOUN
njb-93	299	5	producing	produce	VERB
njb-93	299	6	multidrug	multidrug	NOUN
njb-93	299	7	resistant	resistant	ADJ
njb-93	299	8	bacterial	bacterial	ADJ
njb-93	299	9	pathogens	pathogen	NOUN
njb-93	299	10	isolated	isolate	VERB
njb-93	299	11	from	from	ADP
njb-93	299	12	different	different	ADJ
njb-93	299	13	clinical	clinical	ADJ
njb-93	299	14	samples	sample	NOUN
njb-93	299	15	at	at	ADP
njb-93	299	16	national	national	ADJ
njb-93	299	17	public	public	PROPN
njb-93	299	18	health	health	PROPN
njb-93	299	19	laboratory	laboratory	PROPN
njb-93	299	20	,	,	PUNCT
njb-93	299	21	nepal	nepal	ADJ
njb-93	299	22	.	.	PUNCT
njb-93	300	1	msc	msc	PROPN
njb-93	300	2	thesis	thesis	NOUN
njb-93	300	3	.	.	PUNCT
njb-93	301	1	tribhuvan	tribhuvan	PROPN
njb-93	301	2	university	university	PROPN
njb-93	301	3	,	,	PUNCT
njb-93	301	4	submitted	submit	VERB
njb-93	301	5	to	to	ADP
njb-93	301	6	central	central	ADJ
njb-93	301	7	department	department	NOUN
njb-93	301	8	of	of	ADP
njb-93	301	9	microbiology	microbiology	NOUN
njb-93	301	10	.	.	PUNCT
njb-93	302	1	2010	2010	NUM
njb-93	302	2	40	40	NUM
njb-93	302	3	.	.	PUNCT
njb-93	303	1	logan	logan	PROPN
njb-93	303	2	lk	lk	PROPN
njb-93	303	3	,	,	PUNCT
njb-93	303	4	braykov	braykov	PROPN
njb-93	303	5	np	np	PROPN
njb-93	303	6	,	,	PUNCT
njb-93	303	7	weinstein	weinstein	PROPN
njb-93	303	8	ra	ra	PROPN
njb-93	303	9	,	,	PUNCT
njb-93	303	10	laxminarayan	laxminarayan	PROPN
njb-93	303	11	r.	r.	PROPN
njb-93	303	12	extended	extend	VERB
njb-93	303	13	-	-	PUNCT
njb-93	303	14	spectrum	spectrum	NOUN
njb-93	303	15	betalactamase	betalactamase	NOUN
njb-93	303	16	-	-	PUNCT
njb-93	303	17	producing	produce	VERB
njb-93	303	18	and	and	CCONJ
njb-93	303	19	third	third	ADJ
njb-93	303	20	-	-	PUNCT
njb-93	303	21	generation	generation	NOUN
njb-93	303	22	cephalosporin	cephalosporin	NOUN
njb-93	303	23	-	-	PUNCT
njb-93	303	24	resistant	resistant	ADJ
njb-93	303	25	enterobacteriaceae	enterobacteriaceae	PROPN
njb-93	303	26	in	in	ADP
njb-93	303	27	children	child	NOUN
njb-93	303	28	:	:	PUNCT
njb-93	303	29	trends	trend	NOUN
njb-93	303	30	in	in	ADP
njb-93	303	31	the	the	DET
njb-93	303	32	united	united	PROPN
njb-93	303	33	states	states	PROPN
njb-93	303	34	,	,	PUNCT
njb-93	303	35	1999–2011	1999–2011	NUM
njb-93	303	36	.	.	PUNCT
njb-93	304	1	j	j	PROPN
njb-93	304	2	pediatr	pediatr	PROPN
njb-93	304	3	infect	infect	VERB
njb-93	304	4	dis	dis	PROPN
njb-93	304	5	soc	soc	PROPN
njb-93	304	6	.	.	PUNCT
njb-93	305	1	2014	2014	NUM
njb-93	305	2	3:320–8	3:320–8	NUM
njb-93	305	3	.	.	PUNCT
njb-93	306	1	41	41	NUM
njb-93	306	2	.	.	PUNCT
njb-93	306	3	chander	chander	VERB
njb-93	306	4	a	a	PRON
njb-93	306	5	,	,	PUNCT
njb-93	306	6	shrestha	shrestha	PROPN
njb-93	306	7	cd	cd	PROPN
njb-93	306	8	:	:	PUNCT
njb-93	306	9	prevalence	prevalence	NOUN
njb-93	306	10	of	of	ADP
njb-93	306	11	extended	extend	VERB
njb-93	306	12	spectrum	spectrum	NOUN
njb-93	306	13	beta	beta	NOUN
njb-93	306	14	-	-	PUNCT
njb-93	306	15	lactamase	lactamase	NOUN
njb-93	306	16	producing	produce	VERB
njb-93	306	17	escherichia	escherichia	NOUN
njb-93	306	18	coli	coli	NOUN
njb-93	306	19	and	and	CCONJ
njb-93	306	20	klebsiella	klebsiella	PROPN
njb-93	306	21	pneumoniae	pneumoniae	PROPN
njb-93	306	22	urinary	urinary	ADJ
njb-93	306	23	isolates	isolate	NOUN
njb-93	306	24	in	in	ADP
njb-93	306	25	tertiary	tertiary	ADJ
njb-93	306	26	care	care	NOUN
njb-93	306	27	hospital	hospital	NOUN
njb-93	306	28	in	in	ADP
njb-93	306	29	kathmandu	kathmandu	NOUN
njb-93	306	30	,	,	PUNCT
njb-93	306	31	nepal	nepal	ADJ
njb-93	306	32	.	.	PUNCT
njb-93	307	1	bmc	bmc	PROPN
njb-93	307	2	research	research	PROPN
njb-93	307	3	notes	note	NOUN
njb-93	307	4	.	.	PUNCT
njb-93	308	1	2013	2013	NUM
njb-93	308	2	6(1):487	6(1):487	NUM
njb-93	308	3	42	42	NUM
njb-93	308	4	.	.	PUNCT
njb-93	309	1	chudhary	chudhary	ADJ
njb-93	309	2	u	u	PROPN
njb-93	309	3	and	and	CCONJ
njb-93	309	4	aggarwal	aggarwal	PROPN
njb-93	309	5	r	r	NOUN
njb-93	309	6	:	:	PUNCT
njb-93	309	7	extended	extended	ADJ
njb-93	309	8	spectrum	spectrum	NOUN
njb-93	309	9	b	b	PROPN
njb-93	309	10	lactamase	lactamase	NOUN
njb-93	309	11	(	(	PUNCT
njb-93	309	12	esbl)an	esbl)an	ADV
njb-93	309	13	emerging	emerge	VERB
njb-93	309	14	threat	threat	NOUN
njb-93	309	15	to	to	ADP
njb-93	309	16	clinical	clinical	ADJ
njb-93	309	17	therapeutics	therapeutic	NOUN
njb-93	309	18	.	.	PUNCT
njb-93	310	1	indian	indian	PROPN
njb-93	310	2	j	j	PROPN
njb-93	310	3	med	med	PROPN
njb-93	310	4	microbiol	microbiol	PROPN
njb-93	310	5	rev	rev	PROPN
njb-93	310	6	.	.	PROPN
njb-93	310	7	2004	2004	NUM
njb-93	310	8	22	22	NUM
njb-93	310	9	:	:	PUNCT
njb-93	310	10	75	75	NUM
njb-93	310	11	-	-	SYM
njb-93	310	12	80	80	NUM